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RESUMO	  
Compreender	   como	   famílias	   de	   proteínas	   interagem	   para	   coordernar	   o	  
desenvolvimento	  e	  função	  do	  sistema	  nervoso	  central	  (SNC)	  é	  crítico	  para	  entender	  
o	  funcionamento	  desta	  região	  em	  situações	  normais	  bem	  como	  em	  caso	  de	  doença.	  
O	  tráfego	  de	  proteínas	  para	  compartimentos	  intracelulares	  alternativos	  pode	  levar	  a	  
respostas	   biológicas	   completamente	   distintas.	   A	   família	   de	   neurotrofinas,	  
constituída	  por	  três	  receptors	  (TrkA,	  TrkB	  e	  TrkC)	  e	  quatro	  ligandos	  (NGF,	  BDNF,	  NT3	  
e	   NT4)	   é	   um	   grupo	   de	   proteínas	   muito	   importante	   para	   o	   desenvolvimento	   e	  
manutenção	   do	   sistema	   nervoso.	   O	   receptor	   TrkA	   e	   respectivo	   ligando,	   NGF,	   são	  
expressos	   predominantemente	   no	   sistema	   nervoso	   periférico.	   Por	   outro	   lado,	   no	  
SNC	  encontram-­‐se	  níveis	  mais	  elevados	  do	  receptor	  TrkB	  e	  os	  dois	  ligandos	  BDNF	  e	  
NT4.	  O	  receptor	  TrkC	  e	  o	  ligando	  NT3	  são	  expressos	  em	  ambos	  os	  sistemas.	  O	  nosso	  
conhecimento	   do	   funcionamento	   molecular	   das	   neurotrofinas	   é	   baseado	  
principalmente	   em	   estudos	   feitos	   com	   neurónios	   do	   sistema	   periférico	   e	   com	   o	  
receptor	   TrkA	   e	   NGF.	   Por	   outro	   lado,	   é	   ainda	   um	  mistério	   por	   que	  motivo	   o	   SNC	  
expressa	  dois	   ligandos	   (BDNF	  e	  NT4)	   com	  a	  mesma	  afinidade	  para	  um	  só	   receptor	  
(TrkB),	  os	  quais	  parecem	  modular	  funções	  diferentes.	  Levantámos	  então	  a	  hipótese	  
de	  que	  estas	   diferentes	   funções,	  mediadas	  pelo	  mesmo	   receptor,	   são	   conseguidas	  
por	  via	  de	  um	  controlo	  diferente	  do	  tráfego	  endocítico	  do	  TrkB	  iniciado	  por	  cada	  um	  
dos	   ligandos.	   Os	   estudos	   que	   efectuámos	   demonstram	   que	   a	   activação	   inicial	   to	  
receptor	   TrkB	   com	   BDNF	   ou	   NT4	   é	   semelhante;	   porém,	   o	   BDNF	   induz	   uma	  
ubiquitinação	   mais	   eficiente	   do	   receptor	   TrkB	   do	   que	   o	   NT4.	   Como	   resultado,	  
verificámos	   que	   tratando	   os	   neurónios	   do	   córtex	   com	   BDNF,	   o	   tráfego	   para	   o	  
lisosoma	   e	   degradação	   foi	   mais	   eficiente.	   Por	   outro	   lado,	   e	   considerando	   que	  
tratando	  os	  neurónios	  com	  NT4	  não	  houve	   tanta	  degradação	  de	  TrkB,	  observámos	  
que	   este	   ligando	   leva	   a	   uma	   activação	   mais	   eficiente	   de	   proteínas	   sinal	   ajusante	  
(nomeadamente	   Akt	   e	   MAPK).	   Assim	   sendo,	   estes	   resultados	   providenciam	   a	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primeira	   explicação	   molecular	   para	   os	   efeitos	   distintos	   observados	   em	   estudos	  
comparando	  as	  funções	  de	  BDNF	  e	  NT4.	  
Outra	   família	   de	   proteínas	   que	   foi	   identidicada	   recentemente	   como	   sendo	  
crítica	   para	   o	   desenvolvimento	   do	   SNC	   é	   a	   família	   Slitrk.	   Os	   Slitrks	   têm	   algumas	  
semelhanças	   estruturais	   com	   os	   Trks	   uma	   vez	   que	   também	   formam	   proteínas	  
membranares	   tipo	   I,	   têm	   domínios	   repetidos	   de	   leucina	   na	   região	   extra-­‐celular,	  
contêm	   várias	   tirosinas	   com	   potencial	   para	   serem	   fosforiladas	   na	   região	   intra-­‐
celular,	  e	  também	  são	  expresses	  em	  níveis	  elevados	  no	  SNC.	  Apesar	  disso,	  ainda	  se	  
sabe	   muito	   pouco	   sobre	   a	   função	   molecular	   destas	   proteínas.	   O	   Slitrk1,	   um	   dos	  
membros	   dos	   Slitrks,	   está	   implicado	   em	   doenças	   psiquiátricas,	   nomeadamente	  
síndrome	  de	  Tourrette	  e	  tricotilomania.	  O	  Slitrk6	  é	  o	  membro	  cuja	  expressão	  é	  mais	  
restricta,	  estando	  presente	  em	  níveis	  elevados	  no	  ouvido.	  A	  remoção	  do	  gene	  Slitrk6	  
no	   ratinho,	   levou	   a	   um	   desenvolvimento	   deficiente	   do	   ouvido,	   caracterizado	   por	  
uma	  elevada	  morte	  neuronal	  neste	  orgão	  bem	  como	  um	  crescimento	  deficiente	  de	  
axónios	   e	   dendrites.	   Para	   compreender	   melhor	   a	   função	   destas	   proteínas	  
escolhemos	   o	   membro	   da	   família	   que	   é	   expresso	   em	   níveis	   mais	   elevados	   no	  
cérebro:	  o	   Slitrk5.	  Nesse	   sentido,	   gerámos	  um	   ratinho	  do	  qual	   removemos	  o	   gene	  
Slitrk5	  (Slitrk5-­‐/-­‐).	  Estudos	  feitos	  com	  este	  ratinho	  revelaram	  um	  comportamento	  que	  
tem	  sido	  descrito	  na	  literatura	  como	  obsessivo	  compulsivo	  (OCD),	  que	  se	  reflecte	  em	  
movimentos	   repetidos,	   bem	   como,	   ansiedade.	   Para	   melhor	   compreender	   este	  
fenótipo,	   tratámos	   os	   ratinhos	   com	   um	   inibidor	   de	   transporte	   de	   serotonina	  
selectivo,	  que	  é	  o	   fármaco	  mais	  utilizado	  para	   tratar	  humanos	  com	  esta	  doença,	  e	  
verificámos	  que	  o	  tratamento	  levou	  a	  uma	  redução	  dos	  movimentos	  repetitivos.	  Por	  
outro	   lado	   também	   verificámos	   que	   os	   ratinhos	   Slitrk5-­‐/-­‐	   possuem	   deficiências	   em	  
zonas	  do	  cérebro	  que	  têm	  sido	  descritas	  como	  estando	  afectadas	  em	  pacientes	  com	  
OCD.	  Nomeadamente,	  estudos	  de	  electrofisiologia	   revelaram	  que	  a	   ligação	  entre	  o	  
córtex	   e	   estriado	   estava	   afectada.	   Também	   observámos	   que	   os	   neurónios	   do	  
estriado	   estavam	   subdesenvolvidos.	   A	   nível	   celular,	   observámos	   que	   o	   Slitrk5	   está	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localizado	  em	  dendrites	  e	  sinapses	  e	   regula	  o	   tráfego	  dos	  receptores	  de	  glutamato	  
AMPA,	  reduzindo	  os	  níveis	  membranares	  da	  subunidade	  GluA2.	  Estudos	  feitos	  com	  
ratinhos	   Slitrk5-­‐/-­‐	   novos	   revelaram	  que	   a	   aprendizagem	  e	  memória	   dependente	  do	  
hipocampo	   estava	   afectada.	   Por	   outro	   lado,	   também	   observámos	   que	   o	   Slitrk5	  
modula	   a	   degradação	   do	   receptor	   TrkB	   e	   de	   proteínas	   sinal	   ajusante.	   Estes	  
resultados	  sugerem	  que	  o	  Slitrk5	  é	  uma	  proteína	  que	  desempenha	  múltiplas	  funções	  
no	  cérebro	  e	  consequentemente,	  a	  eliminação	  deste	  gene	  no	  ratinho	   leva	  a	  graves	  
fenótipos	   neurológicos.	   Mais	   estudos	   serão	   necessários	   para	   a	   compreendermos	  
completamente	   a	   relevância	   desta	   proteína	   em	   estados	   fisiológicos	   normais	   bem	  
como	   em	   doença	   (incluíndo	   OCD).	   No	   entanto,	   os	   resultados	   aqui	   apresentados	  
claramente	   favorecem	  uma	  papel	  activo	  do	  Slitrk5	  para	  a	   função	  normal	  do	  SNC	  e	  
que	  o	  nosso	  conhecimento	  sobre	  a	  função	  deste	  sistema	  é	  ainda	  limitado.	  
Em	  suma,	  com	  estes	  estudos	  providenciamos	  uma	  explicação	  molecular	  para	  
as	   funções	   distintas	   mediadas	   por	   BDNF	   e	   NT4.	   Por	   outro	   lado,	   descobrimos	   um	  
candidato	  novo	  que	  pode	  agora	  ser	  estudado	  em	  pacientes	  com	  OCD	  e	  criámos	  um	  
modelo	   animal	   novo	   onde	   esta	   doença	   pode	   mais	   facimente	   ser	   estudada	   e	  
manipulada.	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ABSTRACT	  
Understanding	  how	  protein	  families	  interact	  to	  coordinate	  the	  development	  
and	  function	  of	  the	  central	  nervous	  system	  (CNS)	  is	  critical	  for	  the	  understanding	  of	  
this	   structure	   in	   normal	   conditions	   as	   well	   as	   in	   disease.	   Endocytic	   trafficking	   of	  
membrane	  proteins	  to	  alternate	  intracellular	  targets	  can	  have	  significantly	  different	  
biological	   outcomes.	   The	   neurotrophin	   family	   of	   proteins,	   composed	   of	   three	  
receptors	   (TrkA,	  TrkB	  and	  TrkC)	  and	   four	   ligands	   (BDNF,	  NGF,	  NT3	  and	  NT4),	  has	  a	  
well-­‐established	   role	   in	   the	  development	   and	  maintenance	  of	   the	  nervous	   system.	  
TrkA	   receptor	   and	   its	   ligand	   NGF,	   are	   expressed	  mostly	   in	   the	   peripheral	   nervous	  
system.	  In	  the	  CNS,	  TrkB	  and	  its	  two	  ligands,	  BDNF	  and	  NT4,	  are	  dominant,	  whereas	  
TrkC	   and	   NT3	   are	   expressed	   in	   both	   systems.	   Our	   current	   knowledge	   on	   the	  
mechanisms	   of	   receptor	   activation,	   internalization	   and	   downstream	   targeting	   and	  
signaling	  are	  mostly	  based	  on	  studies	  performed	  with	  sensory	  neurons	  relying	  on	  the	  
TrkA/NGF	  system.	  On	  the	  other	  hand,	   it	   is	  still	  puzzling	  that	   in	  the	  CNS	  two	  ligands	  
(BDNF	  and	  NT4)	  with	  similar	  affinity	  to	  the	  same	  receptor	  (TrkB)	  are	  expressed	  but	  
seem	  to	  fulfill	  distinct	  biological	  responses.	  We	  hypothesized	  that	  these	  differences	  
could	  be	  due	   to	  differential	   regulation	  of	   the	  endocytic	   trafficking	  pathway.	   In	   fact	  
we	   observed	   that,	   even	   though	  NT4	   and	   BDNF	   can	   equally	   activate	   TrkB	   receptor	  
and	   its	  downstream	  signaling,	  BDNF	  promoted	  more	  efficient	  ubiquitination	  of	   the	  
receptor	   than	   NT4.	   As	   a	   consequence,	   BDNF	   led	   to	   more	   efficient	   lysosomal	  
degradation.	  On	  the	  other	  hand,	  even	  after	  long	  continuous	  treatment,	  NT4	  did	  not	  
induce	   efficient	   downregulation	   of	   TrkB.	   Consequently,	   NT4-­‐induced	   activation	   of	  
TrkB	  signaling	  was	  efficiently	   sustained,	  as	   seen	  by	  prolonged	  activation	  of	   the	  Akt	  
and	   MAPK	   pathways.	   This	   data	   provides	   a	   new	   mechanism	   that	   can	   potentially	  
explain	   the	   differential	   functions	   reported	   for	   these	   two	   ligands	   and	   adds	   to	   the	  
current	  understanding	  of	  neurotrophin	  regulation	  and	  function	  in	  the	  CNS.	  
Another	  protein	  family	  that	  has	  emerged	  as	  being	  key	  for	  CNS	  development	  
and	  function	  is	  the	  Slitrk	  family,	  which	  is	  composed	  of	  six	  members.	  The	  Slitrks	  share	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some	   structural	   characteristics	   with	   Trks	   in	   that	   they	   form	   type	   one	   membrane	  
proteins	   with	   extracellular	   leucine-­‐rich	   repeat	   domains	   and	   intracellular	   phospho-­‐
tyrosines,	  and	  they	  are	  primarily	  expressed	   in	   the	  CNS.	  Despite	   this,	   little	   is	  known	  
about	   Slitrks	   function	   in	   the	   brain.	   Slitrk1	   has	   been	   associated	   with	   psychiatric	  
disorders.	  Slitrk6,	  which	  is	  the	  member	  with	  the	  most	  restrictive	  expression,	  is	  highly	  
expressed	   in	   the	   inner	   ear.	   Knocking	   out	   Slitrk6	   in	   the	   mouse	   leads	   to	   reduced	  
neuronal	   innervation	   and	   death	   in	   this	   organ.	   In	   order	   to	   better	   understand	   the	  
function	  of	  this	  protein	  family	  we	  generated	  a	  mouse	  knockout	  for	  Slitrk5,	  which	  is	  
the	  member	  with	  highest	  and	  broadest	  expression	  in	  the	  brain.	  We	  discovered	  that	  
loss	  of	   this	  protein	   led	   to	  obsessive-­‐compulsive-­‐like	  behaviors	   in	   the	  mouse,	  which	  
manifested	  in	  excessive	  self	  over-­‐grooming	  as	  well	  as	  anxiety.	  To	  further	  delineate	  if	  
this	   behavior	   represented	   OCD,	   we	   treated	   the	   mice	   with	   a	   selective	   serotonin	  
reuptake	   inhibitor	   (fluoxetine),	   the	  most	   common	  drug	  used	   to	   treat	  humans	  with	  
OCD.	   We	   observed	   that	   indeed	   fluoxetine	   ameliorated	   the	   over-­‐grooming	  
symptoms.	   Consistently	   with	   our	   knowledge	   of	   the	   pathophysiology	   of	   OCD	   in	  
humans,	   we	   observed	   that	   the	   Slitrk5-­‐/-­‐	  mice	   have	   selective	   over-­‐activation	   of	   the	  
orbitofrontal	   cortex,	   impaired	   cortico-­‐striatal	   transmission	   and	   morphological	  
defects	  in	  the	  medium	  spiny	  neurons,	  namely	  reduced	  dendritic	  complexity.	  We	  also	  
found	  that,	  at	  a	  cellular	  level,	  Slitrk5	  localizes	  to	  synapses	  and	  modulates	  trafficking	  
of	   AMPARs	   by	   reducing	   the	   surface	   expression	   of	   the	   subunit	   GluA2.	   Analysis	   of	  
young	   Slitrk5-­‐/-­‐	   mice	   revealed	   impairment	   in	   hippocampal-­‐dependent	   learning	   and	  
memory	   tasks.	   Interestingly	   we	   also	   found	   that	   Slitrk5	   delays	   BDNF-­‐induced	  
degradation	   of	   TrkB	   receptor	   and	  modulates	   its	   downstream	   signaling.	   These	   data	  
suggests	  that	  Slitrk5	  is	  a	  protein	  with	  multiple	  functions	  in	  the	  brain.	  In	  aggrement,	  
lack	  of	  Slitrk5	  in	  the	  mouse	  leads	  to	  severe	  neurological	  phenotypes.	  Further	  studies	  
will	  be	  required	  for	  its	  full	  characterization,	  as	  well	  as	  to	  understand	  the	  relevance	  of	  
this	   protein	   in	   normal	   human	   physiology	   and	   disease	   states	   (including	   OCD).	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Nevertheless,	   our	   pioneer	   work	   clearly	   supports	   an	   active	   role	   of	   Slitrk5	   for	   CNS	  
function	  and	  that	  this	  system	  is	  still	  poorly	  understood.	  	  
Thus,	  with	  these	  studies	  we	  uncovered	  the	  mechanisms	  mediated	  by	  BDNF	  
and	   NT4	   modulation	   of	   TrkB	   endocytic	   trafficking	   and	   we	   also	   discovered	   a	   new	  
candidate	   molecule	   for	   obsessive-­‐compulsive	   disorder,	   and	   provide	   a	   new	   mouse	  





































	   	  
	  
	  
Chapter	  1	  –	  General	  Introduction	  
	   	  
Chapter	  1	  –	  General	  Introduction	  
	   21	  
GENERAL	  INTRODUCTION	  
The	   human	   brain	   is	   composed	   of	   approximately	   100	   billion	   neurons	  
connected	  by	  up	  to	  10	  000	  synaptic	  sites	  [1].	  Understanding	  how	  neuronal	  numbers	  
are	   controlled	   and	   how	   the	   connections	   between	   different	   brain	   structures	   are	  
established	  are	  key	  questions	  in	  the	  field	  of	  neuroscience.	  
Secreted	   proteins	   play	   essential	   roles	   in	   the	   modulation	   of	   neuronal	  
quantities,	   migration,	   morphology	   and	   function.	   The	   discovery	   of	   protein	   families	  
that	  modulate	  these	  processes	  is	  critical	  for	  a	  basic	  understanding	  of	  nervous	  system	  
function,	  as	  well	  as	  to	  identify	  molecular	  factors	  in	  disease.	  Several	  protein	  families	  
have	  been	  described	  to	  play	  critical	  roles	  during	  brain	  development	  as	  well	  as	  adult	  
nervous	   system	   maintenance.	   Among	   these,	   neurotrophins	   are	   one	   of	   the	   best	  
characterized	   protein	   families	   known	   to	   regulate	   both	   these	   functions	   [2].	   Initial	  
studies	   in	   developmental	   neurobiology	   showed	   that	   targets	   of	   nerve	   innervation	  
secrete	   limiting	   quantities	   of	   survival	   signals	   that	   ensure	   a	   balance	   between	  
innervation	   and	   target	   tissue	   size.	   Nerve	   growth	   factor	   (NGF),	   a	   member	   of	   the	  
neurotrophin	  family,	  was	  the	  first	  secreted	  polypeptide	  discovered	  to	  play	  this	  role	  
[3].	   It	  was	  later	  shown	  that	  NGF	  could	  be	  internalized	  and	  travels	  retrogradely	  long	  
distances	   along	   the	   axon	   to	   reach	   the	   soma,	   where	   it	   regulates	   transcription	   of	  
genes	  critical	  for	  neuronal	  development.	  In	  addition,	  NGF	  can	  also	  modulate	  neuron	  
survival	   and	   differentiation.	   NGF	   remained	   an	   orphan	   ligand	   until	   the	   early	   1990s	  
(almost	  30	  years),	  when	  binding	  to	  two	  distinct	  classes	  of	  transmembrane	  receptors	  
was	   identified:	   the	   p75	   receptor	   and	   the	   tropomyosin	   related	   kinase	   (Trks)	  
receptors,	  named	  after	  the	  protoncogene	  that	  resulted	  in	  its	  identification	  [4,5,6,7].	  
The	   discovery	   of	   a	   complete	   set	   of	   ligand-­‐receptor	   signaling	   complex	   had	   a	  major	  
impact	  in	  the	  field	  and	  provided	  the	  right	  tools	  to	  further	  delineate	  the	  downstream	  
cascades	  involved.	  We	  now	  have	  a	  fairly	  good	  understanding	  of	  how	  neurotrophins	  
function	  in	  the	  peripheral	  nervous	  system	  (PNS).	  However,	  neutrophin	  actions	  in	  the	  
central	  nervous	  system	  (CNS)	  are	  less	  clear.	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The	   continuous	   search	   for	   factors	   regulating	   central	   nervous	   system	  
development	   led	   to	   the	   discovery	   of	   a	   new	  protein	   family	   named	  Slitrk	   [8].	   Slitrks	  
were	  discovered	  in	  a	  screen	  for	  molecules	  that	  were	  differentially	  expressed	  in	  mice	  
with	  neural	   tube	  defects.	  Slitrks	  are	   tansmembrane	  proteins	  primarily	  expressed	   in	  
the	   brain	   of	   both	   mice	   and	   humans.	   They	   can	   modulate	   neurite	   outgrowth	   and	  
synapse	   formation.	   Interestingly,	   it	  was	   found	  that	  mutations	   in	   the	  Slitrk1	  gene,	  a	  
member	   of	   the	   Slitrk	   family,	   are	   associated	  with	   psychiatric	   disorders.	   Similarly	   to	  
neurotrophins,	   it	   seems	   that	   this	   protein	   family	   can	   play	   important	   roles	   not	   only	  
during	  CNS	  development	  but	  also	  for	  adult	  CNS	  maintenance	  [9].	  We	  are	  still	  at	  early	  
stages	   in	   terms	   of	   understanding	   the	   main	   functions	   of	   this	   protein	   family.	   It	   is	  
plausible	   to	   speculate	   that,	   as	   opposed	   to	   neurotrophins,	   a	   set	   of	   receptors	   was	  
identified	   before	   their	   ligands.	   Discovery	   of	   Slitrk’s	   binding	   partners,	   such	   as	   a	  
secreted	   ligand,	   other	   transmembrane	   protein,	   or	   even	   cytoplasmic	   partners,	   will	  
provide	  invaluable	  tools	  to	  explore	  this	  family	  and	  extend	  our	  understanding	  of	  CNS	  
development	  and	  function.	  
The	  goal	  of	  this	  thesis	  work	  was	  to	  contribute	  to	  a	  better	  understanding	  of	  
the	  mechanisms	  of	  action	  of	  polypeptides	  critical	  for	  CNS	  function.	  On	  the	  one	  hand	  
I	   was	   interested	   in	   consolidating	   our	   knowledge	   of	   neurotrophin’s	   downstream	  
signaling	   pathways	   in	   the	   CNS.	   On	   the	   other,	   we	   aimed	   to	   explore	   the	   newly	  
identified	  Slitrk	  protein	  family,	  which	  is	  highly	  enriched	  in	  the	  brain.	  
	  
1. NEUROTROHPHIN	  FAMILY	  
Neurotrophins	   are	   secreted	   polypeptides	   that	   were	   initially	   identified	   as	  
survival	   factors	   for	   sensory	   and	   sympathetic	   neurons,	   and	  were	   later	   shown	   to	   be	  
critical	   for	   nervous	   system	   development	   and	   function	   [10,11].	   These	   peptides	  
regulate	  processes	  such	  as	  cell	  survival,	  proliferation,	  differentiation	  and	  death.	  They	  
also	  play	  critical	  roles	  in	  high	  order	  cognitive	  processes	  such	  as	  learning	  and	  memory	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[12,13].	   Altered	   neurotrophin	   levels	   have	   been	   implicated	   in	   the	   development	   of	  
several	   neurodegenerative	   disorders	   including	   Alzheimer’s	   and	   Hungtington’s	  
disease,	  as	  well	  as	  in	  psychiatric	  disorders,	  such	  as	  depression	  [14].	  
	  	  
1.1	  Neurotrophin	  family	  and	  receptors	  
The	   neurotrophin	   family	   is	   composed	   of	   four	   polypeptides:	   NGF,	   brain-­‐
derived	  neurotrophic	  factor	  (BDNF),	  neurotrophin	  3	  (NT3)	  and	  neurotrophin	  4	  (NT4).	  
Even	  though	  NGF	  was	  the	  first	  neurotrophin	  to	  be	  identified,	  very	  few	  neurons	  in	  the	  
CNS	  require	  NGF	  for	  survival.	  The	  search	  for	  a	   functional	  analog	  to	  NGF	   in	  the	  CNS	  
led	  to	  the	  discovery	  BDNF	  [11,15].	  	  
The	   p75	   receptor	   belongs	   to	   the	   tumor	   necrosis	   factor	   (TNF)	   receptor	  
superfamily	   and,	  neurotrophin	  binding	   to	   this	   receptor	  has	  been	   shown	   to	   lead	   to	  
apoptosis	   [16].	   P75	   receptor	   expression	   is	   downregulated	   during	   postnatal	  
development	   in	   the	   CNS	   but	   is	   rapidly	   induced	   after	   seizure	   or	   neuronal	   lesion.	  
Although	   p75-­‐mediated	   signaling	   has	   been	   shown	   to	   be	   important	   for	   nervous	  
system	  development	  the	  discussion	  of	  the	  mechanisms	  involved	  in	  these	  pathways	  is	  
outside	  the	  scope	  of	  this	  thesis.	  For	  detailed	   information	  about	  this	  subject,	  please	  
refer	  to	  the	  following	  reviews	  [17,18,19].	  	  
Three	  trk	  genes	  have	  been	  identified	  in	  vertebrates	  coding	  for	  three	  protein	  
receptors:	   TrkA,	   TrkB	   and	   TrkC	   that	   differ	   in	   their	   expression	   profile	   and	  
neurotrophin	  affinity.	  NGF	  binds	  to	  TrkA;	  NT4	  and	  BDNF	  bind	  to	  TrkB,	  and	  NT3	  binds	  
TrkC.	   In	   addition,	   NT3	   can	   bind	   TrkA	   and	   TrkB	   in	   certain	   cellular	   contexts,	   even	  
though	  with	  a	  100x	  fold	  reduced	  affinity	  [2,20].	  Expression	  of	  a	  specific	  Trk	  receptor	  
confers	   responsiveness	   to	   the	   neurotrophin	   it	   binds;	   however	   the	   binding	   affinity	  
can	  be	  regulated	  by	  p75	  interaction	  with	  Trks.	  P75	  modulates	  the	  binding	  affinity	  of	  
NGF	   and	  BDNF,	   increasing	   their	   affinities	   to	   TrkA	   and	   TrkB	   respectively,	   as	  well	   as	  
decreasing	  the	  affinities	  of	  NT3	  and	  NT4	  for	  the	  same	  receptors	  [4,21].	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Different	  splice	  variants	  have	  been	  described	  for	  all	  Trk	  receptors	  that	  differ	  
in	   neurotrophin	   affinity	   and	   function.	   A	   TrkB	   splice	   variant	   lacking	   exon9	   in	   the	  
extracellular	   domain	   that	   has	   reduced	   affinity	   for	   NT4	   and	  NT3	   but	   not	   for	   BDNF,	  
was	  found	  in	  the	  developing	  nervous	  system	  of	  the	  chick	  [22].	  A	  TrkB	  splice	  variant	  
lacking	  exon9	  in	  the	  extracellular	  domain	  that	  has	  reduced	  affinity	  for	  NT4	  and	  NT3	  
but	   not	   for	   BDNF,	   was	   found	   in	   the	   developing	   nervous	   system	   of	   the	   chick	   [23].	  
Moreover,	   splice	   variants	   of	   TrkC,	   and	   especially	   TrkB,	   lacking	   the	   catalytic	   kinase	  
domain,	  are	  highly	  expressed	  in	  the	  mature	  CNS	  [24].	  This	  truncated	  TrkB	  variant	  is	  
thought	   to	   act	   as	   a	   dominant	   negative	   since	   it	   can	   bind	   and	   internalize	   BDNF	   and	  
possibly	  restrict	  its	  availability	  [25].	  	  
	  
1.2	  Neurotrophin	  expression	  and	  functions	  
Target-­‐derived	  NGF	  plays	  critical	  roles	  for	  cell	  survival	  and	  differentiation	  of	  
peripheral	   neurons.	  NGF	  expression	   in	   the	  CNS	   is	  more	   restricted	   and	   it	   promotes	  
survival	  of	  cholinergic	  neurons	  in	  the	  basal	  forebrain.	  BDNF	  and	  NT4	  are	  more	  widely	  
expressed	   in	   the	   CNS	   with	   particular	   high	   levels	   in	   the	   cortex	   and	   hippocampus	  
[2,26].	   Their	   expression	   is	   developmentally	   regulated	   increasing	   during	   the	   first	  
postnatal	   weeks	   [27,28,29].	   NT3	   is	   broadly	   expressed	   throughout	   the	   nervous	  
system.	  In	  the	  periphery,	  it	  acts	  in	  coordination	  with	  NGF	  to	  support	  the	  survival	  of	  
sympathetic	  neurons,	  being	  expressed	  in	  intermediate	  targets	  at	  high	  levels	  [30].	  
Trks	   are	   expressed	   in	   the	   nervous	   system	   in	   a	   temporal	   and	   selective	  
manner.	   TrkA	   is	   more	   predominantly	   expressed	   in	   the	   PNS.	   It	   can	   be	   found	   in	  
trigeminal	   ganglia,	   sympathetic	   neurons	   and	   in	   dorsal	   root	   ganglia.	   Neurotrophins	  
are	  highly	  expressed	  in	  the	  target	  areas	  innervated	  by	  responsive	  PNS	  axons.	  On	  the	  
other	  hand,	  TrkA	  expression	  in	  the	  CNS	  is	  less	  abundant,	  being	  restricted	  to	  the	  basal	  
forebrain	   cholinergic	   neurons.	   TrkB	   is	   primarily	   expressed	   in	   the	   CNS	   and	   TrkC	   is	  
broadly	  expressed	  in	  the	  nervous	  system,	  with	  high	  expression	  early	  in	  development	  
[31].	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The	  best-­‐studied	  system	  showing	  neurotrophin-­‐dependance	  for	  survival	  and	  
development	  has	  been	   the	  PNS.	  All	  peripheral	   sensory	  neurons	  express	  one	  of	   the	  
Trk	   receptors	   at	   some	   point	   in	   development	   and,	   presence	   or	   absence	   of	  
corresponding	   neurotrophins	   at	   their	   innervated	   targets,	   determines	   survival	   or	  
death.	  	  Ablation	  of	  individual	  Trk	  receptors	  leads	  to	  elimination	  of	  specific	  neuronal	  
subpopulations.	  For	  example,	  NGF/TrkA	  ablation	  in	  mice	  leads	  to	  a	  complete	  loss	  of	  
nociceptive	   neurons,	   whereas,	   null	   mutations	   of	   NT3/TrkC,	   leads	   to	   a	   lack	   of	  
propioceptive	  neurons	  [31].	  Moreover	  it	  was	  shown	  that	  mice	  null	  for	  both	  TrkB	  and	  
TrkC	  have	  decreased	  synaptic	  density	  and	  lower	  numbers	  of	  pre-­‐synaptic	  vesicles	  in	  
the	  hippocampus	  [32].	  
An	  increasing	  body	  of	  data	  has	  suggested	  that	  unlike	  the	  PNS,	  neurotrophins	  
are	  not	  necessary	  for	  survival	  of	  neurons	  in	  the	  CNS,	  but	  rather	  play	  critical	  roles	  in	  
cell	  morphology	  and	  plasticity.	  Although	  initial	  studies	  using	  BDNF	  or	  TrkB	  null	  mice	  
have	   reported	   brain	   neuronal	   loss,	   mainly	   using	   TUNEL	   staining,	   they	   were	  
confounded	  by	  the	  early	  and	  severe	  PNS	  abnormalities	  [32,33].	  Subsequent	  studies	  
in	  BDNF-­‐	  and	  TrkB-­‐null	  mice	  have	  shown	  that	  despite	  developmental	  abnormalities,	  
the	  neuronal	  numbers	  in	  the	  hippocampus	  and	  cortex	  are	  normal	  [26].	  Accordingly,	  
postnatal	  ablation	  of	  TrkB	  in	  the	  forebrain	  revealed	  a	  decrease	  in	  cortical	  size,	  likely	  
as	   a	   result	   of	   reduced	   dendritic	   complexity,	   but	   normal	   neuronal	   numbers.	   These	  
mice	  were,	  however,	   impaired	   in	   spatial	   reference	  memory	   tasks	  and	  had	   reduced	  
long	   term	   potentiation	   (LTP)	   at	   CA1	   hippocampal	   synapses	   [34].	   The	   double	  
BDNF/NT4	  mutant	   shows	   no	   changes	   in	   spinal	   cord	   motor	   neuron	   numbers	   or	   in	  
ganglion	  cells	  from	  the	  retina,	  but	  shows	  sensory	  neuronal	   loss	  [35,36].	  Similarly	  to	  
the	   TrkB	   null,	   the	   BDNF-­‐deficient	   mice	   have	   decreased	   dendritic	   arborization	   and	  
impairments	  in	  long	  term	  potentiation	  (LTP)	  at	  CA1	  synapses	  [37,38].	  Recently	  a	  new	  
mouse	   line	  was	  generated	   in	  which	   the	  BDNF	  gene	  was	  conditionally	  ablated	   from	  
post-­‐mitotic	   neurons	   of	   the	   CNS.	   Surprisingly	   the	   overall	  morphology	   of	   the	   brain	  
was	   normal	   with	   no	   major	   morphological	   defects	   and	   no	   change	   in	   neuronal	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numbers.	  It	  did	  however	  have	  defects	  in	  dendritic	  arborization	  specifically	  in	  striatal	  
neurons,	   suggesting	   that	   BDNF	   is	   negligible	   for	   mature	   hippocampal	   maintenance	  
[27].	  
	  
1.3	  Neurotrophin-­‐mediated	  signaling	  
Trks	   form	   single	   pass	   transmembrane	   proteins	   containing	   3	   leucine-­‐rich	  
repeats	   (LRR)	   flanked	   by	   cysteine-­‐rich	   domains,	   and	   two	   immunoglobulin-­‐like	  
domains	  involved	  in	  ligand	  binding.	  Non-­‐covalent	  homodimers	  of	  neurotrophins	  bind	  
to	   Trks	   inducing	   receptor	   dimerization	   and	   activation.	   Dimeric	   Trks	   phosphorylate	  
each	   other	   in	   the	   cytoplasmic	   auto-­‐regulatory	   loop	   of	   the	   kinase	   domain	   and	   in	  
other	  cytoplasmic	  tyrosines,	  further	  strengthening	  the	  catalytic	  activity	  of	  the	  kinase.	  
Trks	   are	   highly	   homologous	   in	   their	   intracellular	   domain	   which	   is	   73%	   conserved.	  
Most	  research	  on	  Trk-­‐mediated	  signaling	  has	  focused	  mainly	  on	  two	  phosphorylated	  
tyrosines:	  Y496	  in	  human	  TrkA	  (homologous	  to	  Y516	  in	  TrkB)	  that	  is	  localized	  in	  the	  
juxtamembrane	   domain	   within	   the	   NPxY	   motif	   and	   tyrosine	   Y791	   in	   human	   TrkA	  
(Y817	  in	  TrkB),	  that	  is	  located	  at	  the	  carboxy-­‐terminal	  (C-­‐terminal).	  Phosphorylation	  
of	   these	   tyrosines	   creates	   docking	   sites	   for	   adaptor	   proteins	   that	   couple	   to	  
downstream	  signaling	   cascades	   including	   the	  Ras/mitogen	  activated	  protein	   kinase	  
(a	   MAPK	   also	   known	   as	   extracellular	   signal	   regulated	   kinase	   -­‐	   Erk)	   pathway,	  
phosphatidyl	   inositol-­‐3	   kinase	   (PI3K)/Akt	   kinase	   pathway	   and	   the	   PLC-­‐γ/cAMP	  
response	   element	   binding	   protein	   (CREB)	   pathways	   [2,19,39].	   For	   a	   summary	   of	  
neurotrophin	  mediated	  signaling	  see	  figure	  1.	  
Upon	   phosphorylation,	   the	   NPxY	  motif	   of	   Trks	   serves	   as	   a	   binding	   site	   for	  
adaptor	   proteins	   containing	   the	   Src	   homology	   domain	   (SH2),	   or	   phosphotyrosine	  
binding	  domain	  (PBD),	  such	  as	  the	  Src	  homologous	  and	  collagen-­‐like	  adaptor	  protein	  
(Shc),	  and	  the	   fibroblast	  growth	   factor	   receptor	  substrate	  2	   (Frs2)	   [40,41,42].	  Most	  
research	   has	   focused	   on	   signaling	   mediated	   by	   these	   two	   interactors.	  
Phosphorylated	   Shc	   recruits	   adaptor	   molecules	   such	   as	   Grb2	   and	   the	   guanine	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nucleotide	   exchange	   factor	   Son	   of	   Sevenless	   (SOS)	   that	   converts	   Ras	   into	   its	   GTP	  
bound	   form.	   This	   active	   form	   of	   Ras	   activates	   the	   PI3K,	   the	   p38,	  MAPK	   and	   c-­‐Raf	  
pathways	   [43].	  One	   of	   the	   targets	   of	  MAPK	   is	   the	   ribosomal	   protein	   kinase	   2	   that	  
phosphorylates	  CRE-­‐binding	  proteins	  modulating	  transcription	  of	  critical	  genes.	  	  
Trk	   receptor	   mediated	   activation	   of	   Ras	   through	   Grb2	   and	   Shc	   promotes	  
MAPK	   signaling	   in	   a	   transient	   rather	   than	   sustained	   fashion	   [39].	   Prolonged	  MAPK	  
activation	  depends	  on	  the	  recruitment	  of	  Frs2	  to	  Y490.	  Frs2	  phosphorylation	  in	  turn	  
provides	   binding	   sites	   for	   several	   other	   signaling	   players	   including	   the	   protein	  
tyrosine	  phosphatase	  2	   (Shp2),	  Grb2	  and	  the	  adaptor	  protein	  Crk.	  Association	  with	  
Crk	   results	   in	   activation	   of	   the	   small	   GTPase	   Rap1	   that	   that	   initiates	   the	   MAPK	  
cascade.	   Recruitment	   of	   Grb2	   provides	   an	   independent	   mechanism	   for	   Ras	  
activation.	   Signaling	   through	   Y490	   leads	   to	   survival	   and	   differentiation	   of	   cells	  
[39,41,42,44,45,46].	   Shp2	   is	   a	   rare	   protein	   phosphatase	   implicated	   in	   signaling	  
amplification.	  It	  acts	  as	  an	  adaptor	  protein	  recruiting	  Grb2/SOS	  complex,	  and	  it	  also	  
mediates	   dephosphorylation	   of	   Sprouty,	   reversing	   its	   general	   receptor	   tyrosine	  
kinase	  (RTK)	  inhibitory	  effects	  [47].	  
Phosphorylation	   of	   Y791	   in	   human	   TrkA	   recruits	   and	   activates	   PLC-­‐γ	   that	  
triggers	   hydrolysis	   of	   phosphatidyl-­‐inositol	   (4,5)	   2	   phostate	   (PIP2)	   to	   generated	  
inositol	   (1,4,5)	   triphosphate	   (IP3)	   and	   diacylglycerol	   (DAG).	   IP3	  mobilizes	   Ca2+	   from	  
cytoplasmic	  stores,	  leading	  to	  the	  activation	  of	  Ca2+-­‐regulated	  protein	  kinases	  as	  well	  
as	  Ca2+-­‐calmoduling	  regulated	  proteins.	  DAG	  activates	  protein	  kinase	  C	  (PKC)	  that	  is	  
required	   for	   NGF	   induced	   neurite	   outgrowth	   [39].	   The	   function	   of	   the	   signaling	  
elicited	   by	   the	   PLC-­‐γ	   pathway	   was	   studied	   in	   detail	   in	   mice	   with	   a	   homozygous	  
mutation	   of	   Y816	   in	   TrkB	   receptor.	   BDNF	   induced	   phosphorylation	   of	   Ca2+	   -­‐
calmodulin	   protein	   kinase	   and	   CREB	   was	   blocked.	   Consistent	   with	   the	   role	   these	  
proteins	   play	   in	   synaptic	   plasticity,	   hippocampal	   long-­‐term	   potentiation	   (LTP)	   was	  
impaired	   in	   these	   mice.	   BDNF-­‐dependent	   activation	   of	   the	   MAPK	   pathway	   that	  
occurs	  through	  the	  Shc	  site	  was	  intact	  [48].	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Figure	   1:	   Summary	   of	   neurotrophin	   signaling.	   Neurotrophin	   binding	   to	   Trk	  
receptors	   triggers	   dimmerization	   and	   activation	   of	   different	   signaling	   pathways.	   Depicted	  
here	   is	   human	   TrkB	   receptor	   and	   recruitment	   of	   adaptor	   proteins	   to	   the	   two	   main	  
phosphorylated	   tyrosines.	   Phosphorylation	   of	   the	   tyrosine	   residue	   located	   in	   the	  
juxtamembrane	   region	   of	   Trk	   receptor	   recruits	   two	   complexes	   of	   adapter	   proteins	   the	  
Shc/Grb2/SOS	   and	   the	   FRS2/Shp2/Grb2/SOS	   complexes.	   Activation	   of	   Ras	   triggers	   the	  
MAPK/Erk	   signaling	   pathway,	   which	   stimulates	   neuronal	   differentiation	   including	   neurite	  
outgrowth.	   Activation	   of	   PI3K	   through	   Ras/Gab1	   promotes	   cell	   survival	   and	   growth.	  
Phosphorylation	   of	   the	   c-­‐terminal	   tyrosine	   recruits	   PLC-­‐γ	   that	   results	   in	   increase	   in	  
intracellular	  Ca2+	  and	  modulation	  of	  synaptic	  plasticity.	  
	  
1.4	  Regulation	  of	  signal	  specificity	  
A	   question	   that	   arises	   from	   studies	   of	   RTK-­‐mediated	   signaling	   is	   how	  
specificity	  is	  achieved.	  The	  overall	  topology	  of	  RTKs,	  such	  as	  epidermal	  growth	  factor	  
receptor	   (EGFR),	   fibroblast	   growth	   factor	   receptor	   (FGFR)	   or	   Insulin	   receptor,	   is	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similar:	   all	   contain	   a	   ligand-­‐binding	   domain	   in	   the	   extracellular	   region,	   a	   single	  
transmembrane	  domain	  and	  a	  cytoplasmic	  domain	  that	  contains	  the	  tyrosine	  kinase	  
plus	   regulatory	   sequences	   at	   the	   juxtamembrane	   region	   and	   the	   C-­‐terminus.	   The	  
signaling	   cascades	   previously	   described	   (RAS/MAPK	   and	   MAPK)	   are	   the	   canonical	  
pathways	  that	  can	  be	  activated	  by	  virtually	  all	  RTKs	  [49],	  thus	  raising	  the	  question	  of	  
how	   Trk-­‐induced	   signaling	   is	   different	   from	   other	   RTKs	   and	   within	   the	   Trk	   family.	  
Differential	  temporal	  and	  spatial	  distribution	  of	  signaling	  partners	  amongst	  different	  
cell	   types	   provides	   one	   level	   of	   specificity.	   Specific	   neuronal	   populations	   express	  
particular	   types	  of	   adaptors,	   and	  different	   Trks	   are	  expressed	  at	  different	   levels	   in	  
the	  same	  cell	  type	  which	  can	  lead	  to	  diverse	  outcomes.	  A	  recent	  study	  reported	  that	  
expression	   of	   TrkA	   or	   TrkC	   in	   mouse	   embryonic	   stem	   cells	   which	   were	   later	  
differentiated	   into	   glutamatergic	   neurons,	   leads	   to	   neuronal	   death,	   whereas	   TrkB	  
does	  not	  [50].	  This	  suggests	  that	  even	  in	  similar	  contexts,	  different	  Trks	  are	  capable	  
of	  engaging	  alternative	  signaling	  networks.	  	  
	  Differential	   sorting	   of	   adaptor	   proteins	   within	   intracellular	   membrane	  
compartments	   also	   contribute	   to	   signal	   specificity	   and	   regulation.	   Recently,	   it	  was	  
shown	  that	  transport	  of	  BDNF-­‐activated	  TrkB	  to	  lipid	  rafts,	  through	  Fyn,	  was	  critical	  
for	  efficient	  PLC-­‐γ	  activation.	  In	  Fyn	  knockout	  mice,	  BDNF	  was	  unable	  to	  direct	  TrkB	  
to	   intracellular	   lipid	   raft	  compartments	  and	  phopshorylation	  of	  PLC-­‐γ	  was	   reduced.	  
On	   the	   other	   hand,	   Akt	   and	   MAPK	   were	   excluded	   from	   lipid	   rafts	   and	  
phosphorylation	  of	  these	  proteins	  occurred	  outside	  these	  domains	  [51].	  	  
Membrane	  trafficking	  controls	  both	  localization	  and	  accessibility	  of	  signaling	  
players,	   providing	   some	   degree	   of	   specificity.	   RTK	   endocytosis	   is	   a	   critical	   step	   to	  
regulate	  receptor	  activation	  of	  downstream	  cascades,	  signaling	  amplification	  as	  well	  
as	  attenuation.	  Ligand	  binding	  to	  RTKs	   leads	  to	  receptor	  dimerization,	  activation	  of	  
intrinsic	  kinase	  activity	  and	  tyrosine	  phosphorylation,	  triggering	  protein	  recruitment	  
and	   activation	   of	   downstream	   signaling	   cascades.	   Ligand	   binding	   also	   triggers	  
receptor	   internalization	   via	   clathrin-­‐coated	   pits	   (CCP)	   that	   contain	   several	   adaptor	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proteins	   such	   as	   AP2.	   CCP	   fuse	   with	   a	   specialized	   intracellular	   organelle	   the	   early	  
endosome,	   also	   named	   sorting	   endosome.	   This	   process	   is	   regulated	   by	   Rab5	   and	  
early	  endosome	  antigen	  1	   (EEA1).	  The	  early	  endosome	   is	   characterized	  by	  a	  mildly	  
acidic	   pH	   that	   leads	   to	   the	   uncoupling	   or	   receptor-­‐ligand	   complex.	   Membrane	  
proteins	   rapidly	   exit	   the	   early	   endosome	  and	   can	   follow	   two	  opposing	   routes	   that	  
result	   in	   different	   signaling	   outcomes:	   recycling	   to	   the	   plasma	   membrane	   or	  
degradation	   through	   the	   lysosome	   [52,53,54,55].	   Phosphorylation,	   mono-­‐
ubiquitination	   and	   receptor-­‐ligand	   uncoupling	   are	   key	   mechanisms	   modulating	  
endocytic	   sorting.	   Transferrin	   receptor	   (TfnR)	   is	   the	   canonical	   constitutive	   recycled	  
receptor.	   From	   the	   early	   endosome	   TfnR	   can	   either	   recycle	   directly	   to	   the	  
membrane	   (rapid	   recycling)	   or	   it	   can	   be	   targeted	   to	   the	   recycling	   endosome	   and	  
then	  to	  the	  membrane	  (slow	  recycling).	  EGFR	   is	  the	  best	  described	  RTK	  to	  undergo	  
ligand-­‐induced	  degradation	  through	  the	   lysosome.	  From	  the	  early	  endosome,	  EGFR	  
is	  sorted	  to	  a	  late	  endosome,	  also	  known	  as	  multivesicular	  body,	  and	  subsequently,	  
to	   the	   hydrolytic	   interior	   of	   the	   lysosome,	   where	   proteins	   are	   degraded	  
[56,57,58,59,60,61].	  	  
Trks	  are	  multimonoubiquitinated	  upon	  ligand	  binding,	  via	  specific	  E3	  ligases.	  
The	   E3	   ligase	   for	   TrkA	   has	   been	   identified	   as	  Nedd4-­‐2.	  On	   the	   other	   hand,	   the	   E3	  
ligases	  for	  TrkB	  and	  TrkC	  are	  still	  unknown.	  Ligand-­‐dependent	  ubiquitination	  of	  TrkA	  
and	  TrkB	   is	   critical	   for	   lysosomal	   targeting	  of	  Trk	   receptors	  and	   this	   leads	   to	   signal	  
attenuation;	  however,	  these	  receptors	  differ	  in	  their	  recycling	  and	  degradative	  rates	  
[62].	  Upon	  BDNF	  treatment	  Flag-­‐tagged	  TrkB	  receptor	  is	  predominantly	  sorted	  to	  the	  
degradative	   pathway,	   whereas,	   NGF	   leads	   to	   Flag-­‐tagged	   TrkA	   recycling,	   both	   in	  
PC12	   cells	   as	   well	   as	   in	   cultured	   cortical	   neurons.	   The	   difference	   lies	   in	   a	   small	  
stretch	   of	   amino	   acids	   in	   the	   juxtamembrane	   domain	   and	   transplantation	   of	   this	  
domain	   into	  TrkB	  receptor	   reroutes	  TrkB	  to	   the	  recycling	  pathway.	  The	  contrasting	  
endocytic	   sorting	   leads	   to	   different	   biological	   outcomes.	   Upon	   prolonged	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neurotrophin	   treatment	   TrkA	   promotes	   sustained	   Akt	   phosphorylation	   as	   well	   as	  
survival	  responses	  whereas	  TrkB	  does	  not	  [63].	  	  
In	  PC12	  cells	  it	  has	  been	  shown	  that	  blocking	  NGF-­‐dependent	  endocytosis	  of	  
TrkA	   disrupts	   differentiation,	   even	   though	   survival	   was	   unaffected.	   Since	   Frs2	  
signaling	   is	   required	   for	   sustained	  MAPK	   activation	   and	   differentiation,	   this	   study	  
suggests	   that	   efficient	   Frs2	   activation	   requires	   endocytosis	   of	   the	   neurotrophin-­‐
receptor	  complex	  [64].	  Endocytosis	  also	  seems	  to	  facilitate	  activation	  of	  the	  small	  G	  
and	   attenuates	   Ras.	   On	   the	   other	   hand,	   PI3K	   activation	   occurs	   independently	   of	  
endocytosis	  and	  this	  mechanism	  appears	  to	  attenuate	  this	  signaling	  pathway	  [65].	  
Accumulation	   of	   signaling	   partners	   at	   specialized	   structures	   contributes	   to	  
more	  efficient	  signaling.	  In	  the	  PNS,	  binding	  of	  target-­‐derived	  neurotrophins	  to	  pre-­‐
synaptic	   axons	   leads	   to	   Trk	   activation	   and	   endocytosis	   to	   early	   endosomes.	   A	  
fraction	  of	  these	  endosomes	  evolves	  to	  specialized	  signaling	  endosomes	  that	  contain	  
the	  ligand-­‐receptor	  complex	  and	  signaling	  adaptors,	  which	  may	  trigger	  qualitatively	  
different	   signals	   than	   those	   from	   receptors	   located	   at	   the	   plasma	  membrane.	   The	  
signaling	   endosomes	   are	   retrogradely	   transported	   leading	   to	   signaling	  propagation	  
throughout	  the	  axon	  and	  transcriptional	  regulation	  when	  they	  reach	  the	  soma.	  This	  
transport	   is	   critical	   for	   cell	   survival,	   differentiation,	   innervation	   and	   synaptic	  
plasticity	   [65,66,67].	   Studies	   that	   used	   compartmentalized	   cultures	   of	   sensory	  
neurons	   showed	   that	   neurotrophin	   stimulation	   directly	   in	   the	   cell	   body	   leads	   to	  
activation	   of	   two	   pathways:	   the	   Erk1/Erk2	   and	   Erk5,	   whereas	   neurotrophin	  
treatment	  of	  distal	  axons	  leads	  to	  Erk5	  activation	  in	  the	  soma	  but	  not	  Erk1/Erk2	  [68].	  
These	  data	  suggest	  that	  activation	  of	  neurotrophin	  receptors	  within	  different	  cellular	  
compartments	  leads	  to	  diverse	  functional	  outcomes.	  A	  new	  protein	  interacting	  with	  
Trk	   receptors	   that	   localizes	   to	   signaling	   endosomes	   (named	   neurotrophic	   factor	  
receptor	   associated	  protein	   -­‐	  NTRAP)	   has	   been	   shown	   to	  be	   critical	   for	   retrograde	  
activation	   of	   the	   transcription	   factor	   CREB	   in	   compartmentalized	   sensory	   neurons	  
[69].	  Another	  aspect	   to	   consider	   is	   that	   research	   studies	  usually	  employ	   saturating	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amounts	   of	   ligands	   to	   study	   downstream	   signaling	   effects.	  However,	   this	   probably	  
does	   not	   mimic	   endogenous	   contexts	   in	   which	   limiting	   amounts	   of	   ligands	   might	  
induce	  specific	  signaling	  pathways.	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2.	  SLITRK	  FAMILY	  OF	  PROTEINS	  AND	  FUNCTION	  
The	   advances	   in	   gene	   sequencing	   and	   cloning	   techniques	   of	   the	   past	  
decades	   have	   contributed	   to	   the	   discovery	   of	   several	   protein	   families	   key	   for	   the	  
development	  and	  function	  of	  the	  CNS.	  An	  example	  of	  this	  is	  the	  neurotrophin	  family	  
that	  was	   covered	   in	   the	   previous	   section.	   However,	   our	   current	   knowledge	   of	   the	  
molecular	   players	   involved	   in	   these	   processes	   is	   still	   limited	   and	   not	   sufficient	   to	  
explain	   the	   complexity	   and	   diversity	   of	   this	   system.	  On	   the	   one	   hand,	  many	   open	  
questions	   remain	   regarding	   the	  pathways	  and	  mechanisms	  of	   actions	  mediated	  by	  
known	   protein	   families.	   On	   the	   other,	   the	   discovery	   and	   characterization	   of	   new	  
molecular	   players	   is	   still	   necessary.	   This	   knowledge	   will	   allow	   us	   not	   only	   to	  
understand	  the	  function	  of	  the	  normal	  nervous	  system,	  but	  also	  what	  fails	  in	  disease	  
conditions.	  
Understanding	   the	   molecular	   mechanisms	   underlying	   pathological	  
conditions	  are	  key	  question	   in	  neuroscience,	  being	  critical	   for	  the	  discovery	  of	  new	  
molecular	   targets	   for	   pharmacological	   treatments.	   In	   this	   context,	   we	   were	  
interested	   in	   studying	   new	   protein	   families	   that	   play	   critical	   roles	   for	   CNS	  
maintenance	   and	   function.	   Slitrks	   are	   a	   recently	   discovered	   family	   of	   proteins	  
primarily	   expressed	   in	   the	   brain	   that	  were	   discovered	   in	   a	   screen	   for	   proteins	   de-­‐
regulated	   in	   mice	   with	   neural	   tube	   defects	   [8].	   So	   far,	   the	   few	   research	   studies	  
addressing	   the	   function	   of	   these	   proteins	   in	   the	   CNS	   suggest	   that	   Slitrks	   mediate	  
basic	  functions	  in	  neuronal	  development	  and	  also	  that	  they	  might	  be	  associated	  with	  
psychiatric	   disorders	   ranging	   from	   obsessive-­‐compulsive	   spectrum	   disorders	   to	  
schizophrenia.	  Reminiscent	  of	  the	  neurotrophin	  family,	  it	  seems	  that	  the	  Slitrk	  family	  
is	  key	  not	  only	  for	  the	  elaboration	  and	  development	  of	  the	  CNS	  but	  also	   in	  disease	  
conditions.	  
Little	  is	  known	  about	  the	  main	  function	  that	  these	  proteins	  play	  in	  the	  brain.	  
In	  order	  to	  contribute	  to	  a	  better	  understanding	  of	  this	  protein	  family,	  we	  recently	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generated	   a	   Slitrk5	   knockout	  mouse	   line	   and	   found	   that	   this	   protein	   plays	   critical	  
roles	  for	  CNS	  function	  (see	  chapter	  3).	  	  
	  
2.1	  Slitrk	  gene	  family	  
Slitrks	   are	   composed	   of	   six	   members,	   Slitrk1	   through	   Slitrk6.	   They	   were	  
initially	   identified	   in	   a	   screen	   for	   genes	   that	   were	   differentially	   expressed	   in	  mice	  
with	   neural	   tube	   defects	   [8].	   Slitrk5	   had	   been	   previously	   discovered	   as	   a	   gene	  
expressed	  in	  early	  hematopoietic	  progenitors	  but	  not	  in	  mature	  hematopoietic	  cells	  
[70].	  All	  Slitrks	  form	  single	  pass	  (type	  I)	  transmembrane	  proteins	  with	  an	  intracellular	  
domain	   that	   varies	   in	   length	   [8]	   (Figure	   2).	   At	   the	   extracellular	   domain,	   Slitrks	  
contain	  two	  leucine-­‐rich	  repeat	  (LRR)	  domains,	  which	  are	  each	  composed	  of	  6	  LRRs,	  
flanked	   by	   cysteine	   rich	   capping	   domains	   [8].	   Sequence	   analysis	   has	   revealed	   that	  
the	   extracellular	   LRR	   domains	   of	   Slitrks	   resembled	   Slit	   proteins,	   and	   a	   conserved	  
region	   in	   their	   intracellular	   carboxyl	   terminus	   (C-­‐terminus)	   has	   a	   high	   degree	   of	  
consensus	  with	  the	  last	  16	  amino	  acids	  of	  the	  neurotrophin	  receptor	  (Trk)	  [8].	  Based	  
on	  their	  similarity	  with	  Slits	  and	  Trks,	  these	  proteins	  were	  named	  Slitrks	  [8].	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Figure	   2:	   Schematic	   representation	   of	   the	   Slitrk	   protein	   family.	   Slitrks	   are	  
composed	   of	   six	  members,	   Slitrk1	   through	   Slitrk6.	   All	   contain	   extracellular	   LRR	  motifs	   that	  
vary	   in	   numbers,	   flanked	   by	   cysteine-­‐rich	   motifs,	   followed	   by	   a	   single	   transmembrane	  
domain	   and	   an	   intracellular	   domain.	   All	   but	   Slitrk1	   contain	   long	   intracellular	   domains	   that	  
share	   some	   homology	   with	   Trk	   receptors	   at	   a	   C-­‐terminus	   tyrosine.	   Phosphorylation	   of	  
intracellular	  residues	  has	  been	  showed	  for	  Slitrk2,	  Slitrk5	  and	  Slitrk6,	  however,	  the	  function	  is	  
still	  unknown.	  
	  
Slit	   is	   one	   of	   the	  most	  well-­‐known	   LRR-­‐containing	   proteins.	   These	   proteins	   have	   a	  
tandem	  of	  four	  LRR	  domains	  at	  the	  N-­‐terminus	  (D1-­‐D4),	  each	  containing	  an	  array	  of	  
five	   to	   seven	   LRRs	   [71].	   Slit	   was	   originally	   discovered	   in	   Drosophila	   as	   a	   protein	  
secreted	  by	  midline	  glia	  of	  the	  developing	  CNS	  [72,73].	  Three	  Slit	  homologues	  (Slit1-­‐
3)	  have	  been	  discovered	  in	  mammals	  [74].	  Later	  it	  was	  shown	  that	  Slit	  is	  a	  ligand	  for	  
Robo	  receptors	  [75].	  Slit-­‐Robo	  signaling	  is	  involved	  in	  a	  variety	  of	  processes,	  key	  for	  
proper	  nervous	   system	  development,	   such	  as	   repulsion	  of	  axons	   from	   the	  midline,	  
axon	  guidance	  and	  repulsion,	  orchestrating	  tangential	  neuronal	  migration,	  regulating	  
cytoskeletal	  dynamics	  and	  modifying	  cell	  adhesion	  properties	  [76,77].	  
LRR	   domains	   are	   composed	   of	   tandem	   repeats	   of	   LRR	   motifs	   and	   have	  
curved	   solenoid	   structures	   that	   are	   suitable	   for	   mediating	   protein-­‐protein	  
interactions	   [78,79,80].	   The	   LRR	   is	   a	   widespread	   structural	   motif	   of	   20-­‐30	   amino	  
acids	  with	  a	  defining	  sequence	  LxxLxLxxN/GxL	  (x	  being	  any	  amino	  acid).	  Given	  their	  
extracellular	   LRR	  domains,	   Slitrks	   are	   considered	  part	   of	   the	   LRR	   superfamily.	   LRR-­‐
containing	  proteins	   are	   emerging	   as	   key	   regulators	  of	   the	  CNS	   functions,	   including	  
neurite	  outgrowth,	  neuronal	  survival,	  myelin-­‐based	  axon	  growth	  inhibition,	  synapse	  
formation,	  dendritic	  morphogenesis,	  etc	  [81,82,83].	  Given	  below	  is	  a	  brief	  summary	  
of	  some	  LRR	  protein	  families	  and	  their	  main	  roles	  in	  CNS,	  including	  those	  in	  synapse	  
formation.	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2.2	  LRR	  protein	  families	  and	  their	  function	  in	  the	  CNS	  
Several	  LRR	  proteins	  act	  as	  synaptic	  cell	  adhesion	  molecules	   (CAMs).	  These	  
molecules	   play	   important	   roles	   in	   the	   establishment,	   maintenance	   and	   activity-­‐
dependent	  changes	  of	  synapses.	  For	  a	  protein	  to	  be	  classified	  as	  a	  synaptic	  CAM,	  it	  
should	  be	  able	   to	  mediate	  cell	   adhesion	   through	   interacting	  with	  other	  proteins	   in	  
trans;	   and	   it	   should	   interact	   in	   cis	   with	   scaffolding	   proteins	   that	   recruit	   synaptic	  
proteins	  to	  the	  synapse.	  Many	  LRR-­‐containing	  proteins	  meet	  these	  criteria	  and	  have	  
been	  shown	  to	  regulate	  synapse	  formation	  and	  maturation.	  	  
The	  Amphoterin-­‐induced	  gene	  and	  ORF	  (Amigo)	  family	  is	  composed	  of	  three	  
members	   that	   are	   almost	   exclusively	   expressed	   in	   the	   CNS	   [81].	   They	   contain	   six	  
LRRs	  at	  the	  extracellular	  domain	  and	  an	  immunoglobulin-­‐like	  domain	  located	  next	  to	  
the	   transmembrane	  segment	   [84].	  When	  the	  ectodomain	  of	  Amigo	   is	  expressed	  as	  
an	   Fc	   fusion	   protein	   and	   substratum-­‐attached,	   it	   promotes	   prominent	   neurite	  
extension	   of	   cultured	   hippocampal	   neurons	   [84].	  Moreover	   Amigo2	   has	   also	   been	  
implicated	  in	  activity-­‐dependent	  survival	  of	  cerebellar	  neurons	  [85].	  	  
Synaptic	   adhesion-­‐like	  molecules	   (SALMs)	   are	   a	   recently	   identified	   class	   of	  
adhesion	   proteins	   primarily	   expressed	   in	   the	   brain	   [86,87].	   The	   SALM	   family	   is	  
composed	   of	   five	  members	   and	   all	   contain	   extracellular	   LRRs,	   an	   immunoglobulin	  
C2-­‐like	   (IgC2)	   domain,	   a	   fibronectin	   type	   III	   (FNIII)	   domain,	   a	   transmembrane	  
domain,	   and	   a	   cytoplasmic	   C-­‐terminal	   tail	   [86,87].	   All	   SALMs	   have	   been	   shown	   to	  
promote	  neurite	   outgrowth	   in	   cultured	  neurons,	   being	   the	  C-­‐terminal	   PDZ	  binding	  
domain	   crucial	   for	   this	   function	   [86,88].	   SALMs	   interact	  with	  N-­‐methyl	  D-­‐aspartate	  
receptors	   (NMDAR)	   and	   post-­‐synaptic	   density	   protein	   95	   (PSD-­‐95).	   Moreover,	  
SALM2,	   3	   and	  5	   are	   also	   involved	   in	   synapse	   formation	   [87,89].	  Overexpression	  of	  
SALM2	   increases	   the	   number	   of	   excitatory	   synapses	   and	   dendritic	   spines,	   while	   a	  
knockdown	   has	   the	   opposite	   effect,	   in	   addition	   to	   decreasing	   the	   frequency	   of	  
miniature	  excitatory	  postsynaptic	  currents	  (mESPCs)	  [87].	  Overexpression	  of	  SALM3	  
and	   SALM5	   in	   non-­‐neuronal	   cells	   induces	   presynaptic	   differentiation	   of	   both	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excitatory	  and	  inhibitory	  synapses	  in	  contacting	  axons	  [89].	  The	  ligands	  for	  the	  SALM	  
proteins	  are	  still	  unknown.	  
The	   netrin-­‐G	   ligand	   (NGL)	   family	   form	   type	   one	   membrane	   proteins	   with	  
nine	   LRRs	   at	   the	   extracellular	   domain,	   flanked	   by	   cysteine	   rich	   capping	   domains	  
(LRRCT	  and	  LRRNT)	  and	  a	  C2	   imunoglobulin	  domain	   [90].	  NGLs	  are	   synaptic	  CAMs,	  
primarily	   localized	   to	   the	   postsynaptic	   compartment	   of	   excitatory	   synapses.	   There	  
are	  three	  known	  members:	  NGL-­‐1,	  NGL-­‐2	  and	  NGL-­‐3	  and	  they	  interact	  with	  the	  pre-­‐
synaptic	   ligands,	   netrin-­‐G1,	   netrin-­‐G2	   and	   LAR,	   respectively	   [81,90,91,92].	   NGLs	  
associate	   with	   main	   components	   of	   the	   synapse	   such	   as	   PSD-­‐95	   and	   NMDA	  
receptors	   [86,93].	   NGL-­‐1	   is	   highly	   expressed	   in	   the	   hippocampus,	   striatum	   and	  
cerebral	  cortex	  and	  it	  promotes	  outgrowth	  of	  thalamocortical	  axons	  [94].	  Both	  NGL-­‐
2	   and	  NGL-­‐3	   induce	  pre-­‐synaptic	   differentiation	   in	   a	   co-­‐culture	   assay,	   increase	   the	  
excitatory	   synapse	   density	   when	   over-­‐expressed	   in	   cultured	   neurons	   and,	   when	  
directly	   aggregated	   on	   dendrites,	   they	   recruit	   PSD-­‐95	   post-­‐synaptically	   [93,95].	  
Disruption	  of	  NGL-­‐2	  or	  NGL-­‐3	  expression	  in	  cultured	  hippocampal	  neurons	  decreases	  
the	  number	  and	  function	  of	  excitatory	  synapses	  [93,95].	  	  	  
The	  Leucine-­‐rich	  repeat	  transmembrane	  (LRRTM)	  protein	   family,	  composed	  
of	  four	  members,	  was	  initially	  described	  as	  a	  new	  family	  of	  transmembrane	  proteins	  
expressed	   primarily	   and	   differentially	   in	   the	   central	   nervous	   system	   [96].	   LRRTM1	  
and	  2	  are	  strong	  inducers	  of	  pre-­‐synaptic	  differentiation	  in	  coculture	  assays	  and	  they	  
localize	   to	   excitatory	   post-­‐synaptic	   sites	   in	   neurons	   [83].	   The	   LRRMT1	   knockout	  
mouse	   has	   been	   developed,	   and	   it	   was	   shown	   to	   have	   mild	   defects	   in	   excitatory	  
synapse	  formation	  with	  just	  a	  modest	  increase	  in	  VGlut1	  puncta	  size	  in	  the	  CA1,	  but	  
not	  CA3,	  and	  no	  changes	   in	  puncta	   intensity	  or	  density.	  These	  data	  suggest	   that	   in	  
this	   mouse	   model,	   possible	   compensatory	   mechanisms	   from	   LRRTM2	   may	   be	  
occurring	   [83].	   LRRTM2	   was	   recently	   identified	   as	   a	   post-­‐synaptic	   ligand	   for	  
Neurexin1	   and	   this	   interaction	   was	   shown	   to	   be	   critical	   for	   synapse	   induction	  
[97,98].	   Knockdown	   of	   LRRTM2	   decreases	   excitatory	   synapses	   in	   vitro	   and	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attenuates	  the	  strength	  of	  evoked	  excitatory	  synaptic	  currents	  in	  vivo.	  LRRTM2	  also	  
interacts	  with	  PSD-­‐95	  and	  regulates	  surface	  expression	  of	  AMPA	  receptors	  [97,98].	  
In	   summary,	   LRR	   domains	   are	   involved	   in	   protein-­‐protein	   interactions	   and	  
LRR-­‐containing	  proteins	  mediate	  a	  myriad	  of	  functions	  key	  for	  CNS	  development	  and	  
function.	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Table	  1:	  Summary	  of	  LRR-­‐containing	  proteins	  and	  their	  functions	  





Amigo	  2	  is	  
ubiquitous	  
-­‐ TM	  protein	  that	  promotes	  prominent	  neurite	  extension	  in	  cultured	  
hippocampal	  neurons	  
-­‐ Exhibits	  homophilic	  and	  heterophilic	  binding	  activity	  
-­‐ Modulates	  depolarization	  and	  NMDA-­‐dependent	  survival	  of	  cerebellar	  
granule	  neurons	  
[81,84]	  
FLRT3	   Ubiquitous	   -­‐ TM	  protein	  identified	  in	  a	  screen	  for	  genes	  upregulated	  after	  nerve	  injury	  
-­‐ Promotes	  neurite	  outgrowth	  in	  cultured	  DRG	  neurons	  
[99]	  
	  
Lingo-­‐1	   CNS	   -­‐ TM	  protein	  that	  acts	  as	  co-­‐receptor	  for	  Nogo	  receptor	  
-­‐ Over-­‐expression	  enhances	  responsiveness	  to	  myelin-­‐associated	  inhibitors	  	  
-­‐ Dominant	  negative	  form	  protects	  midbrain	  dopaminergic	  neurons	  against	  
degeneration	  
-­‐ Pathologically	  upregulated	  in	  SN	  of	  PD	  patients	  
-­‐ Also	  interacts	  with	  EGFR	  and	  decreases	  its	  protein	  levels	  
[100,101,1
02,103]	  
Linx	   DRG	  
neurons	  
-­‐ TM	  protein	  that	  interacts	  with	  Trk	  and	  Ret	  receptors	  and	  augments	  
neurotrophin	  and	  GDNF/Ret	  signaling	  
-­‐ Knocking	  out	  Linx	  partially	  photocopies	  axonal	  projection	  defects	  in	  mice	  
lacking	  NGF,	  TrkA,	  or	  Ret	  
[104]	  
Lrig1	   Ubiquitous;	  	   -­‐ TM	  protein	  that	  interacts	  with	  ErbB	  receptor	  family	  members	  (EGFR,	  ErbB2-­‐
4)	  and	  recruits	  cytoplasmic	  E3	  ubiquitin	  ligases	  
-­‐ Attenuates	  GDNF/Ret	  signaling	  in	  neuronal	  cells	  through	  its	  physical	  
interaction	  with	  Ret	  
[105,106,1
07,108]	  
Lrig3	   Ubiquitous	   -­‐ TM	  protein	  that	  interacts	  with	  Xenopus	  FGFR	  through	  extracellular	  domain	  
-­‐ Inhibits	  FGF-­‐dependent	  MAPK	  phosphorylation	  
-­‐ Negatively	  regulates	  FGF	  expression	  levels	  
[109]	  
LRRTM2	   CNS,	  post-­‐
synaptic	  
-­‐ TM	  post-­‐synaptic	  partner	  for	  α	  and	  β	  Neurexins	  
-­‐ Promotes	  excitatory	  synapse	  formation	  
-­‐ Interacts	  with	  PSD-­‐95	  and	  regulates	  surface	  expression	  of	  AMPARs	  
[83,96,97,9
8]	  
NGL-­‐1	   CNS:	  ST,	  CT,	  
TCA,	  
dendritic	  
-­‐ TM	  protein	  that	  binds	  netrin	  G-­‐1	  through	  LRRs	  
-­‐ Stimulates	  outgrowth	  of	  embryonic	  thalamic	  axons	  
[94,110]	  
NGL-­‐	   CNS,	  HC,	  CT,	  
post-­‐
synaptic	  
-­‐ TM	  protein	  that	  induces	  presynaptic	  differentiation	  and	  clustering	  of	  
postsynaptic	  proteins	  
-­‐ Increases	  the	  number	  of	  excitatory	  synapses	  
[93,95,110]	  
NGL-­‐3	   Brain	   -­‐ TM	  protein	  that	  binds	  LAR	  through	  LRRs	  	  
-­‐ Induces	  presynaptic	  differentiation	  	  
-­‐ Promotes	  excitatory	  synapse	  formation	  
[95]	  
Omgp	  	   CNS	   -­‐ GPI-­‐anchored	  protein	  that	  is	  expressed	  by	  neurons	  and	  oligodendrocytes	  




CNS	   -­‐ TM	  proteins	  that	  form	  homo	  and	  heteromeric	  complexes	  
-­‐ Promotes	  neurite	  outgrowth	  in	  young	  neurons	  (DIV	  4-­‐6)	  but	  not	  in	  older	  
neurons	  (DIV	  14-­‐16)	  
-­‐ SALM1-­‐3	  contain	  a	  PDZ-­‐binding	  motif	  	  
-­‐ SALM1	  induces	  the	  dendritic	  clustering	  of	  NMDA	  receptors	  
-­‐ SALM2	  increases	  the	  number	  of	  excitatory	  synapses	  and	  dendritic	  spines	  
-­‐ SALM3	  &	  5	  induces	  excitatory	  and	  inhibitory	  pre-­‐synaptic	  differentiation	  	  
[86,88,89,1
12]	  
Trks	   CNS	   -­‐ TM	  receptors	  that	  bind	  the	  neurotrophin	  family	  of	  growth	  factors	  
-­‐ Influences	  the	  proliferation,	  differentiation,	  plasticity	  and	  survival	  of	  neurons	  	  
[2,19]	  
	  
Abbreviations:	   Amigo,	   amphoterin-­‐induced	   protein;	   FLRT3,	   fibronectin	   leucine	   rich	   transmembrane	  
protein	  3;	   Lingo-­‐1,	   leucine	   rich	   repeat	   and	   Ig	  domain	   containing	  1;	   Linx,	   immunoglobulin	   superfamily	  
containing	   leucine-­‐rich	   repeat	   2;	   Lrig,	   leucine-­‐rich	   repeats	   and	   immunoglobulin-­‐like	   domains;	   NGL,	  
Netrin	  G	   ligand;	   	  Omgp,	  oligodendrocyte	  myelin	  glycoprotein;	  SALM,	  Synaptic	  adhesion	   like	  molecule;	  
Chapter	  1	  –	  General	  Introduction	  
	   40	  
TCA,	   thalamocortical	   axons;	   ST,	   striatum;	   CT,	   Cortex;	   PD,	   Parkinson’s	   disease;	   DA,	   dopamine;	   TM,	  
transmembrane;	   DRG,	   dorsal	   root	   ganglia;	   GDNF,	   glial	   cell	   line-­‐derived	   neurotrophic	   factor;	   SN,	  
substantia	   nigra;	   TM,	   transmembrane;	   HC,	   hippocampus,	   AMPAR,	   α-­‐amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐
isoxazolepropionic	   acid	   receptor;	   FGF,	   fibroblast	   growth	   factor;	   ErbB/EGFR,	   epidermal	   growth	   factor	  
receptor;	  LAR,	   leukocyte	  antigen-­‐related;	  GPI,	  glycosylphosphatidylinisotol;	  DIV,	  developmental	  day	   in	  
vitro;	  PSD-­‐95,	  synapse	  associated	  protein	  95	  kDa	  
	  
2.3	  Slitrks	  and	  their	  functions	  in	  the	  CNS	  
The	  Slitrk	  gene	   family	  has	  been	   implicated	   in	  psychiatric	  disorders,	   such	  as	  
Tourrete	   Syndrome	   (TS),	   trichotillomania	   (TTM),	   obsessive-­‐compulsive	   disorder	  
(OCD)	   and	   schizophrenia	   [113,114,115,116].	   Mechanistically,	   Slitrks	   can	   modulate	  
neurite	   outgrowth,	   dendritic	   complexity,	   neuronal	   survival,	   and	   synapse	   formation	  
[83,113,116,117].	  Slitrks	  are	  highly	  expressed	  in	  the	  CNS,	  with	  its	  expression	  starting	  
prenatally	  both	  in	  the	  mouse	  and	  humans	  [8,118,119].	  	  
Initial	   studies	   performed	   by	   over-­‐expressing	   each	   of	   the	   Slitrk	  members	   in	  
PC12	   cells	   revealed	   that	   treatment	   of	   the	   transfected	   cells	  with	  NGF	   resulted	   in	   a	  
decreased	  number	  of	  neurites	  per	  cell	  [8].	  Neurite	  length	  was	  also	  decreased	  except	  
for	   SLitrk1	   and	   Slitrk4	   [8].	   Subsequently,	   the	   neurite	   outgrowth	   function	   of	   Slitrk1	  
has	   been	   analyzed	   in	  mouse	   cortical	   neurons	   [113,120].	   Cortical	   neurons	   cultured	  
from	  mouse	   embryos	   previously	   electroporated	  with	   human	   Slitrk1	   cDNA	   showed	  
increased	   dendritic	   length	   [113],	   suggesting	   that	   this	   Slitrk	   member	   plays	   an	  
important	   role	   in	   promoting	   neurite	   outgrowth.	   More	   recently,	   it	   has	   been	  
demonstrated	  that	  phosphorylation	  of	  Slitrk1	  on	  Ser695	  by	  casein	  kinase	  II	  is	  critical	  
for	   the	   interaction	   of	   Slitrk1	   with	   14-­‐3-­‐3	   proteins	   [120],	   which	   are	   ubiquitously	  
expressed	   phosphorylation-­‐binding	   proteins	   that	   regulate	   a	   number	   of	   important	  
cellular	   processes	   including	   cell	   proliferation,	   neuronal	   migration	   and	   membrane	  
excitability	  [120,121].	  Mutation	  of	  this	  serine	  residue	  to	  an	  alanine	  residue	  abolished	  
the	   interaction	   of	   Slitrk1	   with	   14-­‐3-­‐3	   proteins	   as	   well	   as	   the	   induction	   of	   neurite	  
outgrowth	  in	  cultured	  mouse	  cortical	  neurons	  [120].	  	  
Considering	   the	   more	   restricted	   distribution	   of	   Slitrk6	   in	   the	   brain,	   with	  
selectively	   high	   expression	   in	   the	   inner	   ear,	   a	   recent	   study	   performed	   a	   detailed	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analysis	   of	   this	   organ	   in	   a	  mouse	  model	   that	   ubiquitously	   lacks	   Slitrk6	   expression	  
[117].	  Results	   from	  this	   study	  demonstrated	   that	  Slitrk6	  promotes	   the	  survival	  and	  
neurite	   outgrowth	   of	   sensory	   neurons	   of	   the	   inner	   ear	   [117].	   Histological	  
examinations	   revealed	   that	   vestibular	   innervation	   was	   markedly	   decreased	   and	  
sometimes	   misguided	   in	   the	   Slitrk6	   null	   mice.	   The	   mutant	   mice	   also	   showed	  
significant	   cell	   death	   in	   the	   spiral	   and	   vestibular	   ganglia.	   Furthermore,	   cochlear	  
sensory	   epithelia	   taken	   from	   these	   mice	   and	   co-­‐cultured	   with	   wild-­‐type	   spiral	  
ganglion	   neurons	  were	   less	   effective	   in	   promoting	   neurite	   outgrowth	   of	   the	   spiral	  
ganglion	  neurons	   compared	   to	   co-­‐cultures	   in	  which	  both	   types	  of	   cells	  were	   taken	  
from	   wild-­‐type	   mice	   [117].	   Evidence	   for	   a	   trophic	   role	   of	   Slitrk6	   was	   further	  
strengthened	  by	   the	  observation	   that	   both	  BDNF	  and	  neurotrophin	  3	   (NT3)	  mRNA	  
levels,	   as	   well	   as	   their	   corresponding	   receptor	   protein	   levels,	   TrkB	   and	   TrkC	  
respectively,	  were	  down-­‐regulated	  in	  the	  inner	  ear	  of	  Slitrk6	  null	  mice.	  Interestingly,	  
this	  was	  observed	  at	  an	  early	  developmental	  stage	  of	  the	  cochlea,	  when	  cell	  death	  
had	  not	  occurred	   [117].	  This	   study	  suggests	   that,	  at	   least	   in	  part,	  Slitrk6	  may	  exert	  
trophic	   actions	   by	   modulation	   of	   the	   neurotrophin	   system.Several	   LRR	   containing	  
proteins	   have	   been	   shown	   to	   interact	   and	   modulate	   RTKs.	   For	   example	   Linx,	   a	  
leucine-­‐rich	   repeat	   and	   immunoglobulin	   (LIG)	   family	   protein,	   physically	   interacts	  
with	   both	   Trk	   and	   Ret	   receptors,	   resulting	   in	   increased	   neurotrophin	   and	   GDNF	  
signaling,	  respectively	  [104].	  Besides	  Slitrk6,	   it	  would	  be	  interesting	  to	  investigate	  if	  
other	  Slitrks	  could	  also	  modulate	  Trk	  receptor	  signaling.	  
Taken	  together,	  the	  results	  obtained	  with	  Slitrk1	  overexpression	  in	  neurons	  
[113,120]	   and	   the	   analyses	   the	   Slitrk6	   null	  mouse	   [116,117],	   suggest	   that	  multiple	  
Slitrk	   members	   play	   key	   roles	   in	   promoting	   neurite	   outgrowth.	   Even	   though	   the	  
initial	   description	   of	   Slitrks	   indicated	   that	   they	   play	   a	   negative	   role	   on	   neurite	  
outgrowth	   when	   over-­‐expressed	   in	   PC12	   cells	   [8],	   it	   remains	   unclear	   if	   this	   is	   of	  
physiological	   relevance	   in	   vivo.	   It	   is	   likely	   that	   crucial	   binding	   partners	   involved	   in	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neurite	  outgrowth	  that	  are	  endogenously	  expressed	   in	  neurons	  are	   lacking	   in	  PC12	  
cells.	  
Slitrks	   have	   also	   been	   implicated	   in	   synapse	   formation.	   A	   recent	   study	  
performing	  an	  expression	  screen	  for	  synaptogenic	  proteins	  revealed	  the	  abundance	  
of	   LRR	   containing	  proteins	   capable	  of	   inducing	   synapse	   formation	   [83].	   Slitrk2	  was	  
one	   of	   the	   LRR	   proteins	   identified	   in	   this	   screen,	   and	   it	   was	   shown	   to	   induce	  
excitatory	   pre-­‐synaptic	   neuronal	   differentiation	   in	   a	   cellular	   co-­‐culture	   system,	  
suggesting	  that	  it	  could	  be	  a	  postsynaptic	  protein	  [28].	  	  It	  is	  possible	  that	  Slitrks	  could	  
interact	  with	  a	  pre-­‐synaptic	  partner	  such	  as	  the	  Neurolgin-­‐Neurexin	  system,	  via	  their	  
extracellular	   LRR	   domains	   and	   could	   recruit	   intracellular	   post-­‐synaptic	   proteins.	  
Identifying	  the	  intracellular	  binding	  partners	  for	  Slitrks	  would	  contribute	  significantly	  
to	  understanding	  the	  molecular	  basis	  of	  Slitrk	  functions	  in	  the	  nervous	  system.	  
	  
2.4	  Slitrk1	  and	  OCD-­‐spectrum	  disorders	  
TS	   is	   characterized	   by	   persistent	   involuntary	   vocal	   and	  motor	   tics	   and	   it	   is	  
believed	   to	   belong	   to	   the	   OCD-­‐spectrum	   [122,123].	   Patients	   with	   OCD	   are	  
characterized	   by	   having	   intrusive	   and	   persistent	   thoughts	   (obsessions)	   that	   cause	  
anxiety	   and	   also	   by	   repetitive	   and	   ritualistic	   behaviors	   (compulsions)	   that	   they	  
engage	   in	   order	   to	   reduce	   the	   anxiety	   caused	   by	   the	   obsessions	   [124,125,126].	  
Family	  studies	  have	  suggested	  that	  genetic	  factors	  are	  involved	  in	  the	  manifestation	  
of	  OCD-­‐spectrum	  disorders;	  however,	  finding	  susceptible	  genes	  for	  this	  disorder	  has	  
been	   a	   daunting	   task	   [123,127].	  OCD	   is	   present	   in	   2-­‐3%	  of	   the	   general	   population	  
worldwide	  and	  epidemiological	  studies	  have	  shown	  that	  at	   least	  50%	  of	  the	  people	  
with	  OCD	  also	   suffer	   from	  other	   psychological	   disorders	   such	   as	   anxiety	   (including	  
TS)	  or	  mood	  related	  disorders.	  Moreover,	  it	  is	  estimated	  that	  90%	  of	  TS	  patients	  also	  
suffer	  from	  OCD.	  It	  is	  this	  co-­‐occurrence	  and	  the	  phenomenological	  similarities	  that	  
motivated	   the	   hypothesis	   that	   these	   disorders	   might	   share	   common	   genetic	   and	  
pathophysiological	   factors.	   Other	   so	   called	   OCD-­‐spectrum	   disorders	   include	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trichotillomania	   (TTM),	   that	   is	   characterized	   by	   a	   compulsive	   hair	   pulling	   behavior	  
that	   leads	   to	   visible	   patches,	   and	   body	   dysmorphic	   disorder,	   characterized	   by	  
obsession	   and	   extreme	   body	   image	   dissatisfaction	   and	   engaging	   in	   repetitive	  
behaviors	  in	  order	  to	  change	  owns	  appearance,	  [125,128,129,130].	  
Studies	  performed	  on	   subjects	   that	   suffered	   from	  OCD	  as	   a	   result	   of	   brain	  
lesions,	   as	  well	   as	   functional	   imaging	  analysis,	  have	  provided	  valuable	   insights	   into	  
the	   pathophysiology	   of	   OCD.	   The	   cortico-­‐striatal-­‐thalamocortical	   circuit	   (CSTC)	   is	  
known	  to	  play	  important	  roles	  in	  movement	  control	  and	  to	  facilitate	  adaptive	  motor	  
actions	  and	  suppress	  others.	  These	  brain	  circuits,	  and	  mainly	  the	  basal	  ganglia,	  have	  
been	   implicated	   in	   movement	   disorders	   including	   OCD,	   in	   which	   repetitive	  
movements	  are	  core	  symptom	  [126,131].	  The	  CSTC	  circuit	  is	  composed	  of	  two	  main	  
parallel	  loops:	  the	  direct	  and	  indirect	  pathway,	  having	  opposing	  results	  in	  activating	  
the	  orbitofrontal-­‐cortex	  (Figure	  3).	  In	  the	  direct	  pathway,	  neurons	  from	  orbitofrontal	  
cortex	  project	  to	  medium	  spiny	  neurons	  in	  the	  striatum,	  expressing	  the	  D1	  dopamine	  
receptor.	   These	   neurons	   make	   connections	   with	   the	   globus	   pallidus	   interna-­‐
substantia	   nigra	   pars	   reticulata	   (GPi/SNr)	   complex,	   which	   then	   projects	   to	   the	  
thalamus	  that	   in	  turn	  has	  reciprocal,	  excitatory	  projections	  to	  and	  from	  the	  cortical	  
site	  of	  origin.	  The	  indirect	  pathway	  also	  originates	  in	  the	  frontal	  cortex	  and	  projects	  
to	  medium	   spiny	   neurons	   expressing	   D2	   dopamine	   receptor	   in	   the	   striatum,	   then	  
projects	  to	  the	  globus	  pallidus	  externa	  (GPe),	  then	  to	  the	  subthalamic	  nucleus,	  then	  
back	  to	  GPi/SNr,	  before	  returning	  to	  the	  thalamus	  and	  finally	  back	  to	  frontal	  cortex.	  
The	  direct	  pathway	  contains	  two	  excitatory	  and	  two	  inhibitory	  connections,	  resulting	  
in	  a	  net	  positive	  circuit	  back	  to	  the	  cortex.	  The	  indirect	  pathway	  has	  three	  inhibitory	  
connections	   resulting	   in	   a	   net	   negative	   feedback	   loop	   to	   the	   cortex.	   Studies	   have	  
suggested	   that	   OCD	   is	   associated	   with	   an	   over-­‐activation	   of	   the	   direct	   pathway	  
relative	  to	  the	  indirect	  pathway	  [124,129,132,133].	  The	  origin	  of	  the	  over-­‐activation	  
observed	   is	   still	   being	   debated;	   however,	   evidence	   has	  mounting	   to	   implicate	   the	  
glutamatergic	  system	  and	  the	  orbitofrontal	  cortex	  as	  the	  main	  players.	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Figure	  3.	  Schematic	   representation	  of	   the	  direct	  and	   indirect	  pathway,	  which	  are	  
two	  opposing	  circuit	  loops	  in	  the	  basal	  ganglia.	  The	  direct	  pathway	  originates	  in	  the	  frontal	  
cortex	   and	   projects	   to	   the	   striatum.	  Medium	   spiny	   neurons	   in	   the	   striatum,	   expressing	  D1	  
dopamine	   receptor,	   project	   to	   the	   globus	   pallidus	   interna/substantia	   nigra	   pars	   reticulata	  
(GPi/SNr)	   complex,	   which	   projects	   to	   the	   thalamus	   that	   in	   turn	   has	   reciprocal,	   excitatory	  
projections	  to	  and	  from	  the	  cortical	  site	  of	  origin.	  The	  indirect	  pathway	  also	  originates	  in	  the	  
frontal	  cortex	  and	  projects	  to	  medium	  spiny	  neurons	  expressing	  D2	  dopamine	  receptor	  in	  the	  
striatum,	  then	  projects	  to	  the	  globus	  pallidus	  externa	  (GPe),	  then	  to	  the	  subthalamic	  nucleus,	  
then	  back	  to	  GPi/SNr,	  before	  returning	  to	  the	  thalamus	  and	  finally	  back	  to	  frontal	  cortex.	  The	  
direct	   pathway	   contains	   two	   excitatory	   and	   two	   inhibitory	   connections,	   resulting	   in	   a	   net	  
positive	   circuit	   back	   to	   the	   cortex.	   The	   indirect	   pathway	   has	   three	   inhibitory	   connections	  
resulting	  in	  a	  net	  negative	  feedback	  loop	  to	  the	  cortex.	  
	  
The	  Slitrk1	  gene	  was	  first	  implicated	  in	  TS	  in	  a	  rare	  variant	  study	  where	  two	  
mutations	  were	  identified	  in	  three	  unrelated	  individuals	  with	  TS	  [113].	  When	  looking	  
for	   candidate	   genes	   that	   could	   be	   associated	   with	   TS,	   this	   group	   focused	   their	  
attention	   in	  a	  particular	  subset	  of	  TS	  patients	   that	  had	  chromosomal	  abnormalities	  
and	   no	   family	   history	   of	   TS.	   Fine	   mapping	   of	   the	   affected	   region	   led	   to	   the	  
identification	   of	   several	   genes,	   including	   Slitrk1	   that	   mapped	   350Kb	   from	   the	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breakpoint.	   Subsequent	   sequencing	   of	   Slitrk1	   gene	   in	   a	   cohort	   of	   174	   individuals	  
with	  TS,	  identified	  one	  proband	  (diagnosed	  with	  TS	  and	  attention-­‐deficit	  hyperactive	  
disorder)	  with	  a	  single	  base	  deletion,	  that	  led	  to	  a	  frame-­‐shift	  and	  the	  expression	  of	  a	  
truncated	   protein	   (named	   varCDf).	   The	   same	   mutation	   was	   also	   found	   in	   the	  
patient’s	  mother	  that	  suffered	  from	  TTM	  but	  not	  in	  unaffected	  relatives.	  Functional	  
analysis	   showed	   that	   truncated	   Slitrk1	   was	   ineffective	   in	   inducing	   dendritic	  
outgrowth	  of	  cultured	  mouse	  cortical	  neurons	  as	  compared	  with	  wild	  type	  Slitrk1.	  An	  
additional	   non-­‐coding	   sequence	   variant	   (var321)	   in	   the	   3’UTR	   was	   found	   in	   two	  
unrelated	  individuals.	  This	  variant	  altered	  binding	  to	  the	  microRNA	  hsa-­‐miR-­‐189	  and	  
it	   negatively	  modulated	   Slitrk1	  mRNA	  expression.	   These	  mutations	  were	   absent	   in	  
over	  3600	  control	  samples,	  indicating	  that	  they	  are	  rare	  variants	  [113].	  	  
Subsequent	   studies	   were	   unable	   to	   find	   associations	   between	   these	   two	  
reported	  variants	   in	   larger	  TS	  populations	   [134,135,136,137,138],	  arguing	  against	  a	  
segregation	   of	   Slitrk1	   and	   TS.	   Furthermore,	   it	  was	   reported	   that	   var321	  was	   over-­‐
represented	  in	  the	  Ashkenazi	  Jew	  population,	  raising	  the	  possibility	  that	  population	  
stratification	  might	  have	   led	   to	  a	   false	  positive	   result	   [136,137].	  The	   largest	   screen	  
for	  Slitrk1	  and	  TS	  performed	  so	   far,	  which	   involved	  sequencing	  1048	  samples	   from	  
the	   Tourette	   Syndrome	  Association	   International	   Consortium	   for	  Genetics,	   did	   not	  
find	  association	  between	  var321	  and	  TS	  [137].	  Only	  two	  individuals	  were	  found	  who	  
carried	  var321:	  one	  was	  diagnosed	  with	  TS,	  OCD	  and	  TTM,	  and	  the	  other	  with	  OCD	  
but	  not	  TS.	  None	  transmitted	  the	  mutation	  to	  their	  affected	  offspring	  [137].	  VarCDf	  
was	   not	   analyzed.	   Additional	   studies	   provided	   more	   information	   regarding	   the	  
ethnicity	  of	  the	  initially	  reported	  cases,	  and	  five	  additional	  subjects	  carrying	  var321	  
were	  reported	  [139].	  Fine	  mapping	  of	  all	  seven	  carriers	  of	  the	  Slitrk1	  region	  argued	  
against	  population	  stratification	  confounding	  the	  original	  data	  [139].	  	  	  
In	   addition	   to	   these	   two	   variants,	   a	   recent	   study	   testing	   for	   association	   of	  
common	  tag	  SNP’s	  spanning	  SIitrk1	  and	  TS	   identified	  an	  association	  to	  one	  specific	  
tag	  SNP	  (rs959383)	  as	  well	  as	  two	  three-­‐marker	  haplotypes,	  suggesting	  there	  may	  be	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a	   common	  TS	   risk	   factor	   of	   low	  penetrance	   in	   linkage	  disequilibrium	   (LD)	  with	   the	  
associated	   marker/haplotypes	   [140].	   Furthermore,	   novel	   mutations	   in	   the	   Slitrk1	  
gene	  have	  been	  found	  to	  co-­‐segregate	  with	  OCD-­‐spectrum	  disorders	  [114,140,141].	  
Two	  non-­‐synonymous	  mutations	   in	   the	  Slitrk1	  extracellular	   region	  were	  discovered	  
in	   two	   independent	   individuals	   of	   European	   descent,	   in	   a	   set	   of	   44	   families	   with	  
TTM,	  and	  were	  absent	   in	  a	  group	  of	  almost	  3000	  healthy	  controls	   [114].	  TTM	  is	  an	  
OCD-­‐spectrum	   disorder	   thought	   to	   be	   genetically	   associated	   with	   TS	   [130,142].	  
Moreover,	   a	   mutation	   in	   the	   3’UTR	   of	   Slitrk1	   gene	   was	   found	   in	   a	   group	   of	   92	  
Austrian	   patients,	   that	   segregated	   in	   two	   additional	   family	   members	   with	   tic	  
disorders,	  and	  which	  was	  absent	  in	  192	  control	  subjects	  [141].	  
Slitrk1	   null	  mice	   have	   been	   generated	   and	   studied	  with	   the	   aim	   of	   better	  
clarifying	  the	  potential	  role	  that	  Slitrk1	  may	  play	  in	  neuropsychiatric	  disorders	  [143].	  
It	   has	   been	   demonstrated	   that	   these	   mutant	   mice	   display	   increased	   anxiety-­‐like	  
behavior	   (as	   measured	   by	   the	   elevated	   plus	   maze	   test)	   as	   well	   as	   depressive-­‐like	  
behaviors	  (as	  assessed	  in	  a	  forced	  swim	  task).	  Neurochemical	  analysis	  revealed	  that	  
Slitrk1	   null	   mice	   had	   increased	   levels	   of	   norepinephrine	   in	   the	   prefrontal	   cortex,	  
striatum,	  and	  nucleus	  accumbens	  [143].	  This	  is	  consistent	  with	  the	  pathophysiology	  
of	   TS	   since	   patients	   with	   this	   disorder	   have	   been	   reported	   to	   have	   high	  
concentrations	  of	  norepinephrine	   in	   their	  cerebrospinal	   fluid	   [144].	  Although	  these	  
mice	   did	   not	   recapitulate	   the	   hallmark	  motor	   characteristics	   of	   human	   TS,	   anxiety	  
and	  depressive	  disorders	  are	  highly	  comorbid	  with	  TS	  [122,145],	  and	  administration	  
of	   clonidine	   (an	   α2-­‐adrenergic	   agonist	   commonly	   used	   to	   treat	   TS	   patients	  
[146,147,148])	  was	  able	  to	  rescue	  the	  anxiety-­‐like	  behavior	  of	  Slitrk1	  null	  mice	  [143].	  
These	   findings	   add	   support	   to	   a	   likely	   role	   of	   Slitrk1	   in	   neuropsychiatric	   disorders.	  
The	   generation	   of	   future	   mouse	   models	   for	   Slitrk1,	   especially	   those	   which	  
conditionally	  knock-­‐down	  the	  gene	  in	  a	  spatially	  and/or	  temporally-­‐specific	  manner,	  
will	  help	  to	  further	  delineate	  the	  exact	  roles	  that	  this	  protein	  plays,	  and	  will	  help	  to	  
avoid	  potential	  developmental	  compensation	  from	  other	  Slitrk	  family	  members	  that	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may	   occur	   with	   traditional	   knockout	   mouse	   models.	   Furthermore,	   it	   would	   be	  
interesting	   to	   determine	   the	   consequences	   of	   the	   introduction	   of	   human	   Slitrk1	  
variants	   (eg.	   var321	   or	   varCDfs)	   in	   future	   knock-­‐in	   mouse	   models,	   and	   to	   assess	  
these	  mice	  for	  their	  subsequent	  neuroanatomical	  and	  behavioral	  phenotypes.	  Such	  
studies	  will	  help	  to	  directly	  evaluate	  the	  in	  vivo	  consequences	  of	  specific	  mutants	  in	  
the	   Slitrk1	   gene,	   and	   they	   would	   avoid	   possible	   compensatory	   mechanisms	   from	  
other	  Slitrk	  members	  that	  could	  have	  occurred	  in	  the	  Slitrk1	  mouse	  leading	  to	  a	  fairly	  
modest	  phenotype	  and	  no	  tics.	  
	  
2.5	  Glutamate	  receptors	  implicated	  in	  psychiatric	  disorders	  
Glutamate	  is	  the	  major	  excitatory	  neurotransmitter	  in	  the	  CNS	  and	  as	  much	  
as	   half	   of	   the	   entirety	   of	   brain	   synapses	   releases	   this	   agent.	   Glutamate	  
neurotransmission	  is	  mainly	  mediated	  by	  two	  ionotropic	  reptors,	  the	  NMDA	  and	  α-­‐
amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazole	   propionic	   acid	   (AMPA)	   receptors	   [149].	   It	   is	  
then	   not	   surprising	   that	   modulation	   of	   the	   glutamatergic	   system	   is	   key	   for	   the	  
regulation	  of	  a	  myriad	  of	  CNS	  properties	  ranging	  from	  high	  cognitive	  processes	  such	  
as	  learning	  and	  memory,	  to	  disease	  [150,151].	  Recent	  data	  has	  suggested	  a	  role	  for	  
the	   glutamatergic	   system	   in	  OCD.	   Analysis	   of	   cerebral	   spinal	   fluid	   of	   patients	  with	  
OCD,	   not	   undergoing	   pharmacological	   treatment,	   showed	   that	   glutamate	   levels	  
were	  significantly	  elevated	  as	  compared	  to	  age-­‐matched	  controls	  [152].	  Correlation	  
studies	   have	   suggested	   an	   association	   between	   the	   gene	   GRIN2B	   (coding	   for	   the	  
NMDA	  receptor	  subunit	  2B	  protein)	  and	  OCD	  [153].	  Moreover,	  a	  gene	  encoding	  the	  
neuronal	  glutamate	  transporter	  protein,	  SLC1A1	  gene,	  has	  also	  been	  associated	  with	  
OCD	  [154].	  Even	  though	  in	  small	  number	  and	  requiring	  larger	  sampling	  confirmation,	  
these	   studies	   emphasize	   the	   importance	   of	   the	   glutamatergic	   system	   in	   OCD.	  
Therefore,	   understanding	   the	   mechanisms	   of	   glutamate	   receptor	   expression	   and	  
modulation	  is	  critical	  for	  the	  understanding	  of	  these	  disorders.	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The	   synthesis,	   transport,	   stabilization	   and	   degradation	   of	   AMPA	   receptors	  
are	   tightly	   controlled	   by	   a	   complex	   set	   of	   transmembrane	   and	   cytoplasmatic	  
proteins	  [155,156].	  Stargazin	  was	  the	  first	  transmembrane	  protein	  found	  to	  act	  as	  an	  
auxiliary	  subunit	  to	  AMPA	  receptors	  [157].	  Discovery	  of	  stargazin	  resulted	  from	  the	  
characterization	   of	   a	   spontaneous	   mutation	   in	   inbred	   mice,	   distinguished	   by	   its	  
striking	  behavior	  phenotype	  that	  includes	  absence	  epilepsy,	  cerebellar	  ataxia,	  and	  an	  
abnormal	  motor	  syndrome	  [158].	  Detailed	  analysis	  of	  the	  protein	  coded	  by	  stargazer	  
mutation	  revealed	  that	  the	  protein	  stargazin	  belongs	  to	  a	  family	  of	  six	  members	  that	  
are	   collectively	   called	   transmembrane	  AMPA	   receptor	   regulatory	   proteins	   (TARPs).	  
TARPs	  are	  brain	   specific	   tetraspanning	  proteins	   that	   avidly	   and	   specifically	   interact	  
with	   oligomeric	   AMPAR	   [159].	   TARPs	   promote	   surface	   expression	   of	   AMPARs	   and	  
also	  target	  AMPARs	  to	  the	  synapse	  through	  interactions	  with	  the	  synaptic	  scaffolding	  
proteins	  PSD-­‐95	  and	  MAGUK.	  The	  stargazer	  mutant	  mouse	  exhibits	  a	  striking	  lack	  of	  
surface	   AMPARs	   in	   cerebellar	   granule	   cells,	   confirming	   the	   critical	   role	   that	   these	  
proteins	   play	   in	   correct	   targeting	   of	   AMPARs.	   TARPs	   are	   also	   key	   regulators	   of	  
channel	  gating	  and	  pharmacology,	  and	  generally	  tend	  to	  enhance	  AMPAR	  mediated	  
currents	  [160,161].	  
A	   recent	   study	   employing	   functional	   proteomic	   analysis	   of	   affinity	   purified	  
native	  AMPARs	  from	  rat	  brain	  membrane	  fragments	  identified	  new	  binding	  partners	  
for	   these	   receptors.	   The	   immunoprecipitation	   of	   the	   previously	   described	   TARPS	  
validated	  this	  approach	  as	  an	  efficient	  screening	  method.	  In	  addition	  to	  TARPS,	  mass	  
spectrometry	   analysis	   consistently	   identified	   homologs	   of	   a	   protein	   family	   named	  
Cornichon,	   co-­‐purifying	  with	   all	   AMPARs	   subunits	   analyzed	   (GluA1,	   2	   and	  3)	   [162].	  
Cornichons	   form	   three-­‐pass	   transmembrane	   proteins	   that	   promote	   forward	  
trafficking	   of	   AMPARs	   from	   the	   ER,	   enhancing	   surface	   expression	   and	  modulating	  
AMPARs	   channel	   properties	   by	   slowing	   deactivation	   and	   desensitization	   of	   the	  
receptor.	   Interestingly	  this	  study	  revealed	  that	  the	  majority	  of	  AMPARs	  coassemble	  
with	   cornichon	   homologs	   2	   and	   3	   (CNIH-­‐2,	   CNIH-­‐3)	   rather	   than	  with	   TARPS	   [162].	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Subsequent	   studies	   raised	   questions	   regarding	   the	   mechanisms	   by	   which	   these	  
proteins	   regulate	   AMPAR	   currents	   and	   location.	   Over-­‐expression	   of	   CNIH2	   in	  
cerebellar	  granule	  neurons	  of	  the	  stargazer	  mouse	  failed	  to	  rescue	  synaptic	  currents,	  
suggesting	   that	   CNIH2	   is	   not	   associated	   with	   surface	   AMPARs.	   Moreover,	   in	   this	  
study	  Flag-­‐tagged	  CNIH2	  was	  found	  associated	  with	  a	  Golgi	  marker	  and	  absent	  from	  
the	  surface	  in	  cultured	  hippocampal	  neurons	  [163].	  In	  contrast,	  parallel	  studies	  were	  
able	   to	   find	  surface	  CNIH2	  that	  co-­‐localized	  with	  GluA1	  [164].	  The	  results	   from	  the	  
first	  study	  suggest	  that	  cornichons	  may	  act	  as	  ER	  chaperones	  required	  to	  modulate	  
AMPARs	   to	   acquire	   an	   appropriate	   conformational	   structure,	   therefore	   allowing	  
efficient	   receptor	   currents.	   On	   the	   other	   hand,	   TARPS	   act	   as	   integral	   subunits	   of	  
surface	  AMPARs	  critical	   to	  modulate	   receptor	   currents.	  An	  alternative	  possibility	   is	  
that	  AMPARs	  may	  normally	  be	  associated	  with	  both	  CNIH-­‐2	  and	  stargazing	  (member	  
γ-­‐8).	  
Another	   recent	   proteomic	   approach	   identified	   CKAMP44	   (cysteine-­‐knot	  
AMPAR	  modulating	  protein)	  as	  a	   type	   I	   transmembrane	  protein	   that	   interacts	  with	  
TARP	   containing	   AMPARs.	   CKAMP44	   is	   robustly	   and	   specifically	   expressed	   in	   the	  
hippocampal	  dentate	  gyrus	  and,	   in	   contrast	  with	  TARPs	  and	   cornichons,	   it	   reduces	  
glutamate-­‐evoked	  currents	  [165].	  
Lastly,	   microarray	   analysis	   of	   mice	   with	   neuronal	   differentiation	   defects	  
identified	   SynDIG1	   as	   another	   type	   I	   transmembrane	   protein	   that	   interacts	   and	  
modulates	  synaptic	  targeting	  of	  AMPARs.	  Knocking	  down	  SynDIG1	  expression	   leads	  
to	  a	  decrease	   in	   synaptic	  puncta	   size	  and	  AMPAR	  mEPSC	   frequency	  and	  amplitude	  
[166].	  
Identification	  of	  glutamate	  receptor	  binding	  proteins	  and	  characterization	  of	  
their	  mechanisms	  will	  contribute	  to	  a	  better	  understanding	  of	  this	  protein	  family	  and	  
facilitate	  the	  discovery	  of	  potential	  molecular	  targets	  in	  a	  context	  of	  disease.	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3.	  RESEARCH	  QUESTION	  AND	  GOAL	  OF	  THE	  THESIS	  
Understanding	   the	  molecular	  mechanism	  underlying	  CNS	  development	  and	  
function	   is	   critical	   to	   comprehend	   the	   failure	   of	   these	   systems	   in	   disease.	   I	   was	  
interested	   in	   further	   extend	   our	   knowledge	   of	   a	   known	   protein	   family,	   the	  
neurotrophin,	  while	   at	   the	   same	   time	  exploring	   a	  new	  protein	   family	   that	  has	   just	  
recently	  been	  described	  to	  be	  present	  in	  the	  brain.	  
Our	  understanding	  of	  the	  molecular	  mechanisms	  of	  neurotrophin	  dependent	  
signaling	   is	   mainly	   based	   on	   studies	   performed	   in	   the	   PNS,	   whereas	   their	  
characterization	   in	   the	   CNS	   is	   more	   limited.	   Amongst	   all	   Trk	   receptors,	   TrkB	   has	  
some	  distinct	   characteristics,	   as	   it	  was	   found	   to	  be	  expressed	  primarily	   in	   the	  CNS	  
and	   serve	   as	   a	   high	   affinity	   receptor	   to	  more	   than	  one	  neurotrophin.	   In	   fact,	   TrkB	  
binds	   with	   equal	   affinity	   to	   BDNF	   and	   NT4,	   which	   are	   similarly	   distributed	  
throughout	  the	  brain.	  It	  is	  an	  interesting	  question	  why	  nature	  evolved	  to	  express	  two	  
ligands	  for	  the	  same	  receptor	  that	  apparently	  fulfill	  a	  similar	  role.	  NT4	  was	  the	  latest	  
neurotrophin	  to	  appear	   in	  evolution	  and	   it	   is	  not	  present	   in	   fish,	  suggesting	  that	   in	  
the	   CNS	   an	   extra	   level	   of	   variability	   was	   necessary	   to	   achieve	   more	   complex	  
functions.	   Despite	   binding	   the	   same	   receptor,	   studies	   have	   shown,	   however,	   that	  
knocking	  down	  each	  of	   these	  neurotrophins	   can	   lead	   to	  different	  outcomes.	   I	  was	  
interested	   in	   understanding	   how	   BDNF	   and	   NT4	   differentially	   modulate	   the	   TrkB	  
receptor	   in	   order	   to	   achieve	   distinct	   functions.	   Considering	   the	   prominent	   role	   of	  
endocytic	  protein	   trafficking	   in	   regulating	  RTK	   signaling,	   I	  decided	   to	  approach	   this	  
question	  by	  investigating	  the	  downstream	  targeting	  of	  TrkB	  receptor	  upon	  activation	  
by	  BDNF	  or	  NT4.	  
Comprehensive	   analyses	   of	   the	   molecular	   players	   involved	   in	   CNS	  
development	   and	   function	   have	   shown	   us	   that	   our	   knowledge	   is	   still	   limited	   to	  
explain	   the	   complexity	   and	   diversity	   of	   this	   system.	   In	   addition	   to	   expansion	   of	  
existing	  protein	  families,	  such	  as	  the	  appearance	  of	  NT4	  in	  the	  neurotrophic	  family,	  
evolution	   has	   constantly	   brought	   us	   new	  molecules	   to	   allow	   the	   viability	   of	  more	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complex	   organisms.	   I	   became	   interested	   in	   a	   newly	   identify	   protein	   family,	   Slitrk,	  
given	   their	   structural	   similarities	   with	   Trk	   receptors,	   their	   high	   expression	   in	   the	  
brain	   and	   the	   little	   information	   we	   had	   on	   their	   molecular	   functions.	   Proteins	  
containing	  LLR	  domains	  are	  emerging	  as	  major	  determinants	  of	  brain	  development	  
and	  wiring.	  The	  few	  studies	  performed	  to	  date	  on	  the	  Slitrk	  family	  have	  highlighted	  
their	   potential	   association	   with	   psychiatric	   disorders,	   raising	   the	   significance	   of	  
delineating	   the	   function	   of	   this	   family.	   Thus,	  we	  were	   interested	   in	   understanding	  
the	   molecular	   mechanisms	   regulated	   by	   these	   proteins.	   We	   also	   would	   like	   to	  
identify	  new	  pathways	  altered	   in	  psychiatric	  disorders	  and	  eventually	  contribute	  to	  
the	   discovery	   of	   new	   therapeutic	   targets	   for	   intervention	   in	   patients	   affected	   by	  
these	  conditions.	   I	   accomplished	   this	  by	   studying	   the	   function	  of	  one	  of	   the	  highly	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INTRODUCTION	  
Neurotrophins	   are	   secreted	   polypeptides	   known	   to	   play	   critical	   roles	   for	  
nervous	   system	   development	   and	   function.	   There	   are	   two	   types	   of	   neurotrophin	  
receptors:	  the	  p75	  and	  Trk	  receptors.	  Trks	  are	  a	  family	  of	  three	  members	  TrkA,	  TrkB	  
and	  TrkC.	  TrkB	  being	  the	  most	  highly	  expressed	  in	  the	  brain.	  TrkB	  receptor	  is	  mainly	  
activated	   by	   BDNF	   and	  NT4,	   although	   it	   can	   also	   bind	  NT3	   to	   a	   lesser	   extent	   [39].	  
Comparative	   analysis	   of	   BDNF	   and	   NT4	   expression	   has	   shown	   that	   these	  
neurotrophins	  are	  widely	  expressed	  in	  the	  brain;	  however,	  NT4	  is	  expressed	  at	  much	  
lower	   levels	   that	   escape	   histological	   detection.	   Studies	   using	   sensitive	   RNAse	  
protection	   assays	   with	   total	   rat	   brain	   showed	   that	   NT4	   expression	   is	   maximal	   at	  
embryonic	   day	   13	   (E13)	   followed	   by	   a	   decline	   at	   around	   birth,	   after	   which	   it	  
increases	  again	  [29].	  The	  levels	  of	  BDNF	  also	  increase	  during	  postnatal	  rodent	  brain	  
development	   peaking	   at	   P20.	   This	   developmental	   regulation	   of	   BDNF	   and	   NT4	  
expression	  was	  observed	  in	  the	  cortex,	  hippocampus	  and	  cerebellum	  [28,29].	  	  
Recent	  structural	  analysis	  revealed	  that	  the	  neurotrophin–binding	  domain	  in	  
Trk	   receptors	   is	   the	   second	   immunoglobulin	   like	   domain	   (Ig2)	   [167,168].	  
Neurotrophin	   homodimers	   form	   a	   bridge	   between	   two	   Ig2	   homodimer	   molecules	  
stabilizing	   this	   complex	   [167].	   The	  binding	   affinity	  of	  BDNF	  and	  NT4	   to	  purified	   Ig2	  
domains	   has	   been	   determined	   using	   surface	   plasmon	   resonance.	   NT4	   shows	   a	  
slightly	  higher	  affinity	  for	  TrkB	  Ig2	  (KD	  of	  260	  pM)	  as	  compared	  BDNF	  (KD	  of	  790	  pM),	  
while	  NGF	  did	  not	  bind,	  as	  expected	  [168].	  The	  association	  constant	   for	  BDNF	  with	  
Ig2	  was	  consistent	  with	  the	  previously	  reported	  affinity	  to	  the	  full	  length	  receptor	  (of	  
990	  pM)	  [168].	  Interestingly,	  after	  acidic	  ligand	  washing,	  NT4	  appeared	  to	  dissociate	  
faster	   than	   BDNF	   from	   TrkB	   receptor	   [168].	   Consistent	   with	   a	   similar	   binding	  
mechanism,	  it	  has	  been	  shown	  that	  BDNF	  and	  NT4	  lead	  to	  comparable	  activation	  of	  
TrkB	  receptor	  and	  its	  downstream	  signaling	  molecules	  (such	  as	  PLC-­‐γ,	  Shc	  and	  MAPK)	  
in	  heterologous	  cells	  [169].	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Despite	  the	  similarities	  in	  receptor	  binding	  and	  activation,	  BDNF	  and	  NT4	  can	  
mediate	   different	   cellular	   mechanisms.	   BDNF	   has	   been	   established	   as	   a	   major	  
regulator	  of	  synaptic	  transmission	  and	  plasticity.	   It	  can	  modulate	  processes	  such	  as	  
ion	  channel	  activity,	  neurotransmitter	  release,	  LTP,	  transcriptional	  activation	  during	  
LTP	  and	  it	  is	  also	  involved	  in	  higher	  order	  cognitive	  tasks,	  ranging	  from	  learning	  and	  
memory	   to	   psychiatric	   disorders	   [13,14,170,171,172,173].	   The	   role	   of	   NT4	   for	  
synaptic	   transmission	   is	   less	   pronounced,	   however,	   a	   recent	   study	   highlighted	   the	  
ability	  of	  NT4	  to	  rescue	  deficits	  in	  LTP	  in	  the	  Schaffer	  collateral-­‐CA1	  area,	  induced	  by	  
amyloid	   β	   peptide	   treatment,	   in	   a	   CaMKII	   (Ca2+	   Calmodulin	   dependent	   kinase	   II)-­‐
dependent	  manner	  [174].	  Studies	  comparing	  the	  effects	  of	  exogenous	  application	  of	  
BDNF	  and	  NT4	   in	   the	  development	  of	   retinal	   ganglion	  cells	  have	   shown	   that	  BDNF	  
promotes	   cell	   polarization	   and	   extension	  of	   a	   single	   neurite,	  whereas	  NT4	   induces	  
the	  formation	  of	  highly	  branched	  symmetrical	  arbors	  with	  short	  neurites	  [175].	  The	  
BDNF	   and	   NT4	   knockout	   mice	   (BDNF-­‐/-­‐	   or	   NT4-­‐/-­‐)	   also	   show	   strikingly	   different	  
phenotypes.	   Complete	   BDNF-­‐/-­‐	   mice	   have	   severe	   cardiac	   and	   breathing	   defects	  
leading	   to	   early	   post-­‐natal	   lethality	   [176,177,178].	   Therefore,	   approaches	   such	   as	  
utilization	  of	  BDNF+/-­‐	   (heterozygous)	  mice,	  generation	  of	   region	  specific	   conditional	  
deletions	  and	  local	  delivery	  of	  gene	  knockdown	  agents	  have	  been	  employed.	  These	  
studies	   have	   strengthened	   the	   impact	   of	   BDNF	   for	   proper	   CNS	   development	   and	  
function	  [27,179,180].	  In	  contrast	  to	  BDNF-­‐deficient	  mice,	  the	  NT4-­‐/-­‐	  mouse	  has	  been	  
studied	   to	   a	   much	   lesser	   extent.	   NT4-­‐/-­‐	   mice	   are	   viable	   and	   do	   not	   exhibit	   major	  
developmental	  defects,	  allowing	  for	  behavioral	  and	  physiological	  studies	  to	  be	  easily	  
performed	   [181].	   These	   mice	   have	   defects	   in	   long-­‐term	   memory	   in	   a	   cue	   and	  
contextual	   fear	   conditioning	   task,	   but	   short	   term	   memory	   is	   intact.	   Hippocampal	  
slices	  show	  normal	  basal	  synaptic	  transmission,	  in	  contrast	  to	  the	  BDNF-­‐/-­‐;	  however,	  
they	   have	   a	   selective	   defect	   in	   long	   lasting	   LTP	   in	   the	   Schaffer	   collateral	   –	   CA1	  
synapses,	  that	  correlated	  with	  a	  selective	  defect	   in	   long	  versus	  short	  term	  memory	  
[181].	   In	  the	  periphery,	  mice	  lacking	  NT4	  exhibit	  a	  selective	  loss	  of	  nodose-­‐petrosal	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and	  geniculate	  ganglia	  neurons	  [36].	  This	  neuronal	  population	  was	  also	  shown	  to	  be	  
dependent	  on	  BDNF,	  however,	  whereas	   two	  BDNF	  alleles	  are	  necessary	   to	  support	  
the	  survival	  of	  these	  neurons,	  a	  single	  NT4	  allele	  is	  sufficient	  [176].	  
The	  differences	  observed	   in	   the	  modulation	  of	   synaptic	  plasticity	  mediated	  
by	  these	  two	  neurotrophins	  might	  be	  explained	  by	  the	  fact	  that	  BDNF	  is	  released	  in	  
an	   activity-­‐dependent	  manner,	  whereas	  NT4	   is	   processed	   through	   the	   constitutive	  
secretory	  pathway	  [182].	  Regarding	  the	  phenotype	  of	  the	  null	  mice,	  it	  is	  plausible	  to	  
speculate	  that	  endogenous	  expression	  of	  high	  levels	  of	  BDNF	  are	  sufficient	  to	  rescue	  
major	   defects	   in	   the	   NT4-­‐/-­‐	   mice.	   In	   contrast,	   the	   endogenous	   expression	   of	   NT4	  
might	   not	   be	   enough	   to	   rescue	   the	   lack	   of	   BDNF.	   In	   this	   line	   of	   thought,	   a	   very	  
interesting	   study	   in	   which	   the	   BDNF	   gene	   was	   replaced	   by	   NT4,	   maintaining	   the	  
BDNF	   promoter	   intact,	   showed	   that	   not	   only	  NT4	   was	   able	   to	   rescue	   the	   BDNF-­‐/-­‐	  
phenotype	   (these	   mice	   are	   viable),	   it	   was	   also	   more	   potent	   at	   inducing	   synaptic	  
maturation	   and	   sensory	   neuron	   survival.	   NT4	   levels	   in	   the	   knock-­‐in	   mouse	   were	  
comparable	  to	  BDNF	  in	  wild	  type	  mice	  [183].	  In	  fact,	  some	  studies	  that	  compared	  the	  
biological	   actions	   of	   BDNF	   and	  NT4	   in	   parallel	   have	   suggested	   that	   NT4	   is	   a	  more	  
potent	   neurotrophin	   in	   certain	   contexts.	   One	   study	   that	   analyzed	   the	   ability	   of	  
different	   neurotrophins	   to	   counteract	   monocular	   deprivation	   in	   rats	   showed	   that	  
infusion	   of	   NT4	   in	   the	   visual	   cortex	  was	  more	   potent	   than	   BDNF	   in	   counteracting	  
monocular	  deprivation.	  However,	  as	  shown	  in	  other	  studies,	  it	  did	  not	  enhance	  basal	  
nor	   evoked	   neuronal	   activity	   [184].	   NT4	   is	   more	   effective	   than	   BDNF	   at	   inducing	  
axonal	  outgrowth	  of	  peripheral	  neurons	  of	  the	  mouse	  nodose	  ganglia	  in	  organotypic	  
cultures	   [185].	   Neuropeptide	   Y	   (NPY)	   is	   synthesized	   by	   neurons	   of	   CNS	   and	  
peripheral	  nervous	  system	  (PNS)	  and	  is	  implicated	  in	  regulating	  appetite	  and	  energy	  
homeostasis.	   Explants	   of	   thalamocortical	   cocultures	   that	   were	   transfected	   with	  
either	  BDNF	  or	  NT4	   showed	   that	   transfection	  with	  NT4	  evoked	   substantially	   larger	  
numbers	  of	  NPY-­‐positive	  neurons	  and	  mRNA	  per	  neuron;	  however,	  in	  contrast	  with	  
BDNF	   this	  was	   independent	  of	   calcium	   influx.	  Both	  effects	  could	  be	  abolished	  by	  a	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TrkB	   inhibitor	   [186].	   Finally,	   analysis	   of	   neurotrophin	   induced	   dendritic	   growth,	  
arborization	  and	  spine	  formation	  of	  the	  ferret	  visual	  cortex	  showed	  that	  NT4	  is	  more	  
potent	  than	  BDNF	  at	  inducing	  dendritic	  density	  and	  spines	  in	  the	  layer	  5	  and	  layer	  6,	  
of	   both	   apical	   and	   basal	   dendrites.	   	   In	   basal	   dendrites	   of	   the	   layer	   4,	   BDNF	   had	   a	  
more	  prominent	  role	  [187].	  
The	  above	   studies	   suggest	   that	   even	   though	  BDNF	  and	  NT4	   signal	   through	  
the	  same	  receptor	  they	  can	  mediate	  distinct	  cellular	  outcomes.	  Interestingly,	  TrkB	  is	  
the	   only	   Trk	   receptor	   similarly	   activated	   by	   two	   neurotrophins	   and	   the	   most	  
expressed	  in	  the	  brain.	  NT4	  was	  the	  last	  neurotrophin	  to	  be	  discovered	  owing	  to	  its	  
divergent	  sequence,	  however	  it	  has	  a	  similar	  structure	  as	  BDNF	  and	  binds	  TrkB	  in	  the	  
same	  regions	  [188,189,190].	   It	  remains	  an	  open	  question	  why	  would	  nature	  evolve	  
to	   generate	   two	  different	   ligands	   that	   activate	   the	   same	   receptor,	   apparently	   to	   a	  
similar	  extend,	  and	  have	  a	  similar	  spatial	  distribution	  [29].	  	  
The	   duration,	   specificity	   and	   intensity	   of	   signaling	   through	   RTKs	   can	   be	  
modulated	  by	   ligand-­‐mediated	  endocytosis	   and	  post-­‐endocytic	   sorting	  of	   activated	  
receptors.	   Internalization	   of	   activated	   RTKs	   and	   consequent	   targeting	   to	   the	  
lysosome	  results	   in	  downregulation	  of	  the	  activated	  signaling	  receptor	   [53].	  On	  the	  
other	  hand,	  post-­‐endocytic	   recycling	  of	  RTK	  contributes	  to	  sustained	  signaling	   [54].	  
We	  asked	   the	  question	   if	   the	  distinct	  biological	  outcomes	  achieved	  with	  BDNF	  and	  
NT4	   could	   be	   due	   to	   differential	   sorting	   of	   TrkB	   receptor	   to	   distinct	   endocytic	  
trafficking	  routes.	  We	  found	  that	  NT4	  leads	  to	  efficient	  TrkB	  activation,	  endocytosis	  
and	   downstream	   signaling	   at	   early	   time	   points.	   Surprisingly,	   we	   found	   that	   BDNF	  
leads	   to	   more	   rapid	   TrkB	   ubiquitination	   than	   NT4.	   After	   prolonged	   neurotrophin	  
treatment,	   BDNF	   leads	   to	   faster	   degradation	   of	   the	   TrkB	   receptor	   than	   NT4.	   As	   a	  
result,	   NT4	   was	   cable	   of	   maintaining	   longer	   sustained	   downstream	   signaling	  
activation.	   Thus,	   these	   results	   suggest	   that	   the	   differences	   on	   the	   TrkB-­‐mediated	  
outcomes	  induced	  by	  these	  two	  neurotrophins	  are	  not	  associated	  with	  altered	  TrkB	  
activation,	  but	  rather	  lay	  on	  the	  duration	  of	  this	  effect.	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MATERIALS	  AND	  METHODS	  
Reagents	  and	  antibodies	  
Human	  recombinant	  BDNF	  and	  NT4	  were	  obtained	   from	  PeproTech	   (Rocky	  
Hill,	  NJ).	  Immunoprecipitations	  were	  performed	  with	  the	  following	  antibodies:	  rabbit	  
anti	  TrkB	  antibody	  from	  Upstate	  (catalog	  07-­‐225;	  1:100)	  or	  goat	  from	  R&D	  (AF1494	  
1:100);	  rabbit	  SHP2	  from	  Santa	  Cruz	  (SC-­‐280);	  Flag	  antibodies	  were	  purchased	  from	  
Sigma	  (M2	  and	  F2555	  both	  used	  at	  1:100).	  For	  western	  blot	  the	  following	  antibodies	  
were	   used:	   mouse	   TrkB	   antibody	   1:1000	   (610101),	   mouse	   SHP2	   1:1000	   (610621),	  
and	   mouse	   Grb2	   were	   obtained	   from	   BD	   Biosciences	   1:1000	   (610112);	  
phosphotyrosine	   PY99	   1:4000	   (SC-­‐7020),	   actin-­‐HRP	   1:4000	   (sc-­‐1616),	   Erk1	   (sc-­‐93),	  
Erk2	   (sc-­‐154)	  both	  used	  1:4000	  were	   from	  Santa	  Cruz.	  Tubulin	  1:4000	   (T6074)	  was	  
from	  Sigma.	  PhosphoErk	  1:4000	  (#9101S),	  phosphoAkt	  1:1000	  (#4060S),	  Akt	  1:1000	  
(9272)	  were	  from	  Cell	  Signaling.	  For	  immunocytochemistry,	  the	  rabbit	  and	  goat	  TrkB	  
antibody	   and	   both	   Flag	   antibodies	   were	   used;	   EEA1	   was	   from	   BD	   Biosciences	  
(610457).	  Alexa	   conjugated	   fluorescent	   secondary	  antibodies	  were	   from	  Molecular	  
Probes.	  All	  other	  compounds	  were	  from	  Sigma-­‐Aldrich.	  
	  
Cell	  culture	  
All	  reagents	  used	  to	  prepare	  primary	  neuronal	  cultures	  were	  purchased	  from	  
Invitrogen,	   except	   glucose	   that	   was	   from	   Sigma.	   The	   cortex	   and/or	   hippocampus,	  
were	   dissected	   from	   E18	   Sprague	   Dawley	   rat	   in	   Hanks	   Balanced	   solution	   (HBSS)	  
supplemented	  with	   0.37%	   glucose.	   Digestion	  was	   performed	   in	   the	   same	  medium	  
supplemented	   with	   0.05%	   trypsin	   for	   10-­‐15	   minutes	   at	   37°C.	   Neurons	   were	  
mechanically	   dissociated	   with	   fire-­‐polished	   Pasteur	   pipettes	   and	   plated	   in	   plating	  
medium	   (PM)	   (MEM	   containing	   10%	   FBS,	   1	  mM	  pyruvate,	   0.37%	   glucose,	   and	   0.1	  
mg/ml	   of	   Primocin	   from	   Invogen)	   for	   24	   hours.	   After	   one	   day	   in	   culture	   PM	   was	  
replaced	   by	   Neurobasal	   supplemented	   with	   B-­‐27,	   0.5mM	   glutamine,	   0.1	   mg/ml	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Primocin	  and	  2µM	  Ara-­‐C	  (Cytosine	  β-­‐D-­‐arabinofuranoside	  hydrochloride).	  Cells	  were	  
grown	   on	   poly-­‐D	   lysine-­‐coated	   surfaces:	   on	   glass	   coverslips	   a	   density	   of	   15x103	  
cells/cm2	   was	   used	   for	   immunocytochemistry;	   on	   polystyrene	   dishes,	   a	   density	   of	  
76x103	   cells/cm2	   was	   used	   for	   biochemistry.	   Neurons	   were	   kept	   in	   a	   humidified	  
incubator	  at	  37°C	  and	  5%	  CO2.	  293	  cells	   stably	  expressing	  TrkB	  were	  a	  kind	  gift	  of	  
Moses	  Chao	  lab	  at	  NYU	  Medical	  center	  and	  were	  maintained	  in	  regular	  293	  media,	  
DMEM	   (Invitrogen)	   containing	   10%	  heat	   inactivated	   fetal	   bovine	   serum	   (GemCell),	  
with	   100	   U/ml	   penicillin,	   100	   U/ml	   streptomycin	   (Pen/Strep)	   (Invitrogen),	   2	   mM	  




Cell	  surface	  biotinylation	  was	  used	  to	  specifically	  detect	  receptors	  present	  in	  
the	   plasma	   membrane	   and	   to	   measure	   their	   proteolysis.	   Neurons	   were	   washed	  
twice	  with	  ice-­‐cold	  PBS	  supplemented	  with	  Ca2+	  and	  Mg2+	  (PBS++)	  and	  incubated	  with	  
300	   µg/ml	   of	   sulfo-­‐NHS-­‐S-­‐biotin	   (Pierce	   Chemical,	   Rockford,	   IL)	   for	   20	   min	   on	   ice	  
with	   gentle	   agitation.	   Unreacted	   biotin	   was	   quenched	   and	   removed	   with	   50mM	  
Glycine	   in	   PBS++.	   Biotinylated	   cells	   were	   then	   transferred	   to	   pre-­‐warmed	  medium	  
containing	  ligand	  for	  the	  indicated	  times,	  and	  then	  cells	  were	  immediately	  chilled	  on	  
ice	  and	  lysed	  in	  Ripa	  buffer.	  Biotinylated	  proteins	  were	  isolated	  from	  cell	  extracts	  by	  
immobilization	   on	   high	   capacity	   streptavidin-­‐conjugated	   Sepharose	   beads	   (Pierce	  
Chemical,	   Rockford,	   IL).	   Washed	   beads	   were	   eluted	   with	   SDS	   sample	   buffer,	   and	  
eluted	  proteins	  were	  resolved	  by	  SDS-­‐PAGE.	  
	  
Biochemical	  internalization	  assay	  
Cells	  were	  prepared	  as	   for	  degradation	  assay	  however;	  a	  cleavable	   form	  of	  
biotion	   was	   used	   (Sulfo-­‐NHS-­‐SS-­‐Biotin	   from	   Pierce,	   21331).	   After	   neurotrophin	  
treatment	   and	   incubation,	   remaining	   surface-­‐bound	   biotin	   was	   cleaved	   with	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glutathione	   solution	   containing:	   50mM	   glutathione	   in	   75mM	   NaCl,	   10mM	   EDTA,	  
1%BSA,	  0.075	  NaOH;	  2	  times	  for	  15	  min	  each	  on	  ice	  and	  with	  gentle	  agitation.	  After	  
glutathione	   wash,	   cells	   were	   quenched	   with	   TBS	   buffer	   followed	   by	   lsysis	   in	   RIPA	  
buffer	  and	  avidin	  pull	  down.	  
	  
Western	  blotting	  and	  immunoprecipitation	  
Protein	   lysates	  for	  western	  blot	  and	  immunoprecipitation	  were	  prepared	  in	  
RIPA	  buffer	  (150	  mM	  NaCl,	  50	  mM	  Tris	  pH	  8.0;	  5	  mM	  EDTA,	  1%	  Triton	  X-­‐100,	  0.5%	  
DOC,	  0.1%	  SDS)	  containing	  protease	  and	  phosphatase	  inhibitors	  (2	  μg/ml	  leupeptin,	  
2	  μg/ml	  aprotinin,	  1	  mM	  sodium	  orthovanadate,	  10	  mM	  sodium	  fluoride,	  and	  1	  mM	  
phenylmethylsulfonyl	   fluoride).	   Extracts	   were	   rotated	   at	   4°C	   for	   15	   minutes	   and	  
cleared	  by	  centrifugation	  (12,000∗g	  for	  15	  min).	  For	  immunoprecipitation,	  antibody	  
was	   added	   at	   1:100	   concentration	   a	   rotated	   for	   2	   hours	   at	   4°C,	   followed	   by	   pull	  
down	  with	   either	   protein	   A	   beads	   (Sigma)	   or	   protein	   G	   (Roche),	   overnight	   at	   4°C.	  
Lysates	  were	  washed	  3-­‐6	  times	  in	  lysis	  buffer.	  Western	  blotting	  was	  performed	  using	  
10%	  BIS-­‐TRIS	  pre-­‐cast	  gels	  from	  Invitrogen.	  Protein	  samples	  were	  boiled	  with	  4X	  LDS	  
Nupage	   sample	   buffer	   from	   Invitrogen	   (NP0007)	   for	   2	   minutes	   before	   loading.	  
Electrophoresis	  was	   done	   at	   80mA	  using	  MES-­‐SDS	   running	   buffer	   from	   Invitrogen.	  
Transfer	  was	  done	  at	  4°C,	  100V	   for	  90	  minutes.	  PVDF	  membranes	  were	  blocked	   in	  
5%	  milk-­‐TBS-­‐T	  or	  3%	  BSA-­‐TBS-­‐T	  if	  PY99	  was	  being	  used	  in	  (0.1%	  Tween).	  Antibodies	  
were	  probed	  over-­‐night	  at	  4°C.	  
	  
Immunocytochemistry	  
DIV5-­‐7	   rat	   cortical	   neurons	   were	   serum-­‐starved	   over-­‐night	   in	   Neurobasal	  
supplemented	   with	   2%	   glucose.	   TrkB	   antibody	   was	   added	   to	   the	   covers-­‐slips	   at	  
1:1000	   dilution	   on	   ice	   for	   15	  min.	   Cells	  were	   fixed	   in	   3.7%	   formaldehyde	   solution	  
(from	  EMS)	   for	  15	  min	  at	  RT.	  Unreacted	   formaldehyde	  was	  quenched	  with	  glycine.	  
Permeabilization	   was	   done	   with	   0.2%	   Triton-­‐X	   with	   gentle	   agitation	   at	   RT	   for	   6	  
Chapter	  2	  –	  Endocytic	  Trafficking	  of	  TrkB	  receptor	  
	   61	  
minutes.	  Primary	  antibodies	  were	  incubated	  for	  60	  min	  at	  RT,	  followed	  by	  washes	  in	  
PBS	   with	   gentle	   agitation,	   followed	   by	   alexa-­‐conjugated	   secondary	   antibody	  
incubation	  for	  20	  min	  at	  RT.	  Antibodies	  were	  prepared	   in	  blocking	  solution	  3%BSA,	  
10%	  donkey	  serum	  in	  PBS.	  
	  
Endocytosis	  assay	  
DIV5-­‐7	  rat	  cortical	  neurons	  were	  grown	  on	  glass	  coverslips	  pre-­‐coated	  with	  
PDL.	  Medium	  was	  changed	  12h	  before	  the	  experiment	  to	  Neurobasal	  containing	  2%	  
glucose.	   Endogenous	   surface	   pool	   of	   TrkB	   receptor	   was	   live	   fed	   by	   adding	   the	  
antibody	   directly	   to	   the	   media	   on	   ice	   (rabbit	   Upstate	   antibody	   at	   1:1000	  
concentration).	  After	  surface	  labeling,	  neurons	  were	  incubated	  at	  37°C	  for	  an	  initial	  
10	   min	   temperature-­‐adaptation	   period	   and	   a	   further	   15	   min	   with	   BDNF	   or	   NT4,	  
50ng/ml.	  After	   internalization,	  cells	  were	   fixed	  and	  TrkB	  receptor	  remaining	  on	  the	  
surface	   was	   labeled	   with	   saturating	   concentrations	   of	   secondary	   antibody	  
conjugated	  with	  alexa488	  (1:300)	  in	  blocking	  solution,	  followed	  by	  permeabilization,	  
after	  which	   the	   internalized	   pool	  was	   labeled	  with	   secondary	   antibody	   conjugated	  
with	  alexa568,	  1:300	   in	  blocking	  solution.	  Control	  neurons	  were	   incubated	  without	  
neurotrophins.	   Quantification	   was	   performed	   blind	   to	   treatment.	   Internalization	  
index	  =	  ((Inter	  /	  (Intern	  +	  Surface))*100.	  For	  endocytosis	  measured	  as	  co-­‐localization	  
with	   EEA1,	   after	   antibody-­‐fed	   TrkB	   and	   neurotrophin	   treatment	   (15	  min),	   neurons	  
were	  fixed,	  permeabilized	  and	  stained	  for	  EEA1.	  Quantification	  of	  TrkB	  co-­‐localizing	  
with	   EEA1	   was	   done	   by	   manually	   counting	   total	   TrkB	   puncta	   and	   TrkB	   puncta	  
overlapping	  EEA1,	  using	  the	  manually	  count	  objects	  tool	  in	  Metamorph	  software.	  
	  
Fluorescence	  Microscopy	  
Images	  were	  acquired	  on	  an	   inverted	  microscope,	  Nikon	  Eclipse	  TE2000-­‐U,	  
light	   source	   was	   PhotoFluor	   from	   Chroma,	   using	   Metamorph	   Software.	   Objective	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used	  was	   PlanApo	   60xA/1.40	   oil	   Nikon.	   Image	   quantification	  was	   performed	   using	  
ImageJ	  and	  Metamorph	  software.	  	  
	  
SILAC	  (stable	  isotope	  labeling	  by	  amino	  acids	  in	  cell	  culture)	  
Preparation	   of	   cortical	   and	   hippocampal	   neurons	   was	   done	   as	   previously	  
described	  in	  this	  chapter.	  Neurons	  were	  cultured	  in	  regular	  complete	  Neurobasal	  or	  
an	   identical	   medium	   formulated	   without	   L-­‐arginine	   and	   L-­‐lysine	   (Specialty	   Media,	  
Philipsburg,	   NJ)	   supplemented	   with	   heavy	   13C	   isotope-­‐containing	   amino	   acids	  
(Cambridge	   Isotope	   Laboratories,	  Andover,	  MA)	  or	   isotopically	  normal	   amino	  acids	  
(Sigma-­‐Aldrich).	  Culture	  media	  were	  refreshed	  every	  3	  days	  by	  removing	  half	  of	  the	  
volume	  present	  on	  each	  plate	  and	   replacing	   it	  with	   fresh	  medium.	   	  After	   culturing	  
neurons	  for	  10	  days	  in	  vitro,	  BDNF	  or	  NT4	  (PeproTech,	  Rocky	  Hill,	  NJ)	  was	  added	  to	  
neuronal	  cultures	  at	  a	  concentration	  of	  25	  ng/ml	  for	  15	  min,	  and	  cells	  were	  washed	  
with	   ice-­‐cold	   PBS	   and	   immediately	   placed	  on	   ice	   in	   ice-­‐cold	   lysis	   buffer	   containing	  
appropriate	  inhibitors.	  Lysates	  from	  cells	  cultured	  in	  differently	  labeled	  media	  were	  
mixed	  in	  a	  1:1:1	  stimulated:control	  total	  protein	  ratio	  (based	  on	  Bradford	  assay)	  and	  
combined	  with	  agarose	  conjugated	  anti-­‐phosphotyrosine	  antibody	  pY99	  (Santa	  Cruz	  
Biotechnology,	   Inc.,	   Santa	   Cruz,	   CA)	   containing	   20	   μl	   of	   beads/ml	   of	   lysate	   for	  
overnight	   incubation	   at	   4	   °C.	   Beads	   were	   washed	   four	   times	   with	   lysis	   buffer.	  
Immunoprecipitated	  proteins	  were	  eluted	  by	  boiling	  in	  Laemmli	  SDS-­‐PAGE	  reducing	  
buffer	  (Bio-­‐Rad)	  for	  5	  min.	  	  All	  samples	  were	  separated	  by	  SDS-­‐PAGE	  using	  10%	  Tris-­‐
HCl	  gels	  (Bio-­‐Rad).	  Gels	  were	  stained	  with	  Coomassie	  Brilliant	  Blue	  (Bio-­‐Rad),	  and	  gel	  
lanes	  were	   cut	  horizontally	   into	  23	   sections.	   Excised	  gel	  bands	  were	   cut	   into	   small	  
pieces	   and	   destained	   in	   25	   mM	   ammonium	   bicarbonate,	   50%	   acetonitrile;	  
dehydrated	   with	   acetonitrile;	   and	   dried.	   The	   gel	   pieces	   were	   rehydrated	   with	   10	  
ng/μl	  trypsin	  solution	  in	  25	  mM	  ammonium	  bicarbonate	  and	  incubated	  overnight	  at	  
37	  °C.	  Peptides	  were	  extracted	  twice	  with	  5%	  formic	  acid,	  50%	  acetonitrile	  followed	  
by	   a	   final	   extraction	   with	   acetonitrile.	   Extracts	   were	   pooled,	   dried	   by	   vacuum	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centrifugation,	  and	  reconstituted	  in	  5	  μl	  of	  0.1%	  formic	  acid,	  2%	  acetonitrile	  for	  HPLC	  
sample	  injection.	  The	  peptide	  mixtures	  resulting	  from	  tryptic	   in-­‐gel	  digestions	  were	  
analyzed	   using	   nanoflow	   LC-­‐MS/MS.	   Proteome	   changes,	   experiments	   were	  
performed	  using	  a	  nanoACQUITY	  Ultra	  Performance	  Liquid	  Chromatography	  system	  
(Waters)	  coupled	  directly	  to	  a	  Q-­‐TOF	  Premier	  mass	  spectrometer	  (Micromass).	  Raw	  
mass	  spectrometry	  data	  were	  processed	  using	  ProteinLynxGlobalServer	  2.2	  software	  
(Waters).	   Proteins	   were	   identified	   using	   Mascot	   software	   (version	   2.1,	   Matrix	  
Science,	   London,	  UK)	   and	  parsed	  using	  ProteinCenter	   (Proxeon,	  Odense,	  Denmark)	  
MS	   spectra	   of	   labeled	   and	   non-­‐labeled	   peptide	   pairs	   were	   tracked	   in	   the	   raw	   LC-­‐
MS/MS	  files.	  Experimental	  Tyr(P)	  IP	  SILAC	  ratio	  quantification	  was	  carried	  out	  using	  
the	   open	   source	   software	   MSQuant	   (kindly	   provided	   by	   Peter	   Mortensen	   and	  
Matthias	  Mann	   (Source-­‐	   Forge,	   Inc.).	   As	   an	   additional	   measure	   to	   achieve	   proper	  
quantification,	   weighted	   mean	   ratios	   were	   calculated	   manually	   for	   proteins	  
observed	   in	   more	   than	   one	   band	   and	   in	   replicate	   experiments.	   Ratios	   were	  
calculated	   using	   MSQuant	   for	   proteins	   that	   had	   peptide	   signals	   with	   observable	  
unlabeled	  components.	  Ratios	  of	  less	  than	  10:1	  (the	  dynamic	  range	  limit	  of	  MSQuant	  
for	  our	  data)	  were	  corrected	  for	  labeling	  efficiency.	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RESULTS	  
NT4	  leads	  to	  efficient	  endocytosis	  of	  TrkB	  receptor	  and	  targets	  TrkB	  to	  the	  
early	  endosome	  compartment	  
TrkB	   is	   the	  neurotrophic	   receptor	  with	  highest	   expression	   in	   the	  brain	   and	  
the	  only	  member	  that	   is	  activated	  with	  similar	  affinity	  by	  two	  neurotrophins	   [168].	  
However	   they	   seem	   to	   mediate	   distinct	   biological	   outocomes.	   In	   order	   to	  
understand	   the	  mechanisms	  mediating	   these	   differences	  we	   sought	   to	   investigate	  
how	  BDNF	   and	  NT4	  might	   differentially	  modulate	   the	   endocytic	   trafficking	   of	   TrkB	  
receptor.	  
We	  started	  by	  analyzing	  the	  initial	  endocytic	  steps	  of	  TrkB	  upon	  BDNF	  or	  NT4	  
stimulation.	   It	   is	   known	   that	   BDNF	   treatment	   induces	   endocytosis	   of	   TrkB	   in	   a	  
clathrin-­‐dependent	   manner	   to	   an	   early	   endosome	   compartment.	   However,	   the	  
mechanisms	  of	  NT4	  mediated	  TrkB	  trafficking	  are	  unknown	  [191].	  To	  measure	  TrkB	  
endocytosis	  endogenous	  TrkB	  receptor	  was	  labeled	  with	  a	  live-­‐fed	  antibody.	  We	  first	  
aimed	   to	   understand	   if	   BDNF	   and	   NT4	   target	   TrkB	   to	   the	   same	   intracellular	  
compartment.	  To	  explore	  this	  we	  quantified	  the	  co-­‐localization	  of	  TrkB	  with	  an	  early	  
endocytic	  marker,	   EEA1.	   As	   shown	   in	   figure	   1	   a,	   both	   BDNF	   and	  NT4	   lead	   to	   TrkB	  
internalization	   that	   can	   be	   observed	   by	   the	   puncta-­‐like	   staining	   corresponding	   to	  
early	   endosomes.	   Non-­‐treated	   neurons	   show	   mostly	   surface	   TrkB	   staining;	  
consistent	   with	   the	   fact	   that	   antibody-­‐induced	   TrkB	   activation	   was	   minimal.	  
Quantification	  of	  TrkB	  co-­‐localization	  with	  EEA1	  revealed	  a	  comparable	  endocytosis	  
of	   the	   receptor	  at	  a	  15	  min	   time	  point,	  mediated	  by	  BDNF	  or	  NT4,	   suggesting	   that	  
both	   ligands	   induce	  endocytosis	   through	  a	  similar	  mechanism.	  The	   fraction	  of	  TrkB	  
that	   localizes	  to	  the	  early	  endosome	  containing	  EEA1	  is	  similar	   in	  cells	  treated	  with	  
BDNF	  or	  NT4	   (BDNF	  39.2%	  ±	  3.3%;	  NT4	  35.7%	  ±	  3.9%;	  p	  value	  0.5)	   (Figure	  1	  a,	  b).	  
Although	   at	   this	   time	  point	   there	   is	   a	   relatively	   small	   fraction	  of	   TrkB	   co-­‐localizing	  
with	   EEA1,	   this	   could	   be	   potentially	   explained	   by	   the	   fact	   that	   this	   marker	   is	  
exclusively	  associated	  with	  endosomes	  of	  the	  somatodendritic	  compartment	  and	  not	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with	  axonal	  endosomes	   [192].	  To	  overcome	  a	  possible	  underestimation	  with	   these	  
studies,	  we	  also	  measured	  total	  internalized	  TrkB	  divided	  by	  the	  surface	  fraction.	  In	  
this	   experiment,	   total	   surface	   TrkB	   receptor	   was	   live	   labeled	  with	   a	   fed	   antibody.	  
Cells	   were	   then	   incubated	   with	   BDNF,	   NT4	   or	   left	   untreated	   for	   15	   min	   at	   37°C.	  
Quantification	  of	  the	  ratio	  of	  internalized	  receptor	  versus	  the	  surface	  pool	  revealed	  
that	  BNDF	  and	  NT4	  induce	  similar	  endocytosis	  of	  TrkB	  receptor	  (BDNF	  72%	  ±	  1.5%;	  
NT4	  74.3%	  ±	  1.8%;	  p	  value	  0.4)	  (Figure	  1	  d,	  e).	  
To	   complement	   the	   immunocytochemical	   data,	   we	   also	   measured	   TrkB	  
internalization	  using	  a	  cleavable	  biotin	  assay.	   In	   this	  assay,	  membrane	  proteins	  are	  
surface	  biotinylated	  and	  after	  internalization	  had	  occurred,	  remaining	  surface	  biotin	  
is	  removed	  such	  that	  only	  internalized	  proteins	  are	  pull	  down.	  For	  technical	  reasons	  
this	   experiment	   was	   performed	   with	   HEK293	   cells	   stably	   expressing	   low	   levels	   of	  
TrkB	   protein,	   such	   that	   receptor	   auto-­‐activation	   does	   not	   occur.	   As	   a	   positive	  
control,	  we	  used	  biotinylated	  cells	  without	  cleavage	  and,	  as	  a	  negative	  control	  biotin	  
cleavage	   was	   done	   without	   the	   37°C	   incubation	   step.	   In	   agreement	   with	   our	  
previous	   observations,	   BDNF	   and	   NT4	   also	   elicit	   similar	   TrkB	   endocytosis	   in	   this	  
experimental	  setting	  (Figure	  1	  c).	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Figure	  1:	  Endocytosis	  of	  TrkB	  receptor	  mediated	  by	  BDNF	  and	  NT4.	  a)	  Rat	  cortical	  
neurons	  were	  live	  fed	  with	  TrkB	  antibody	  on	  ice,	  and	  subsequently	  treated	  with	  50ng/ml	  of	  
BDNF	  or	  NT4	   for	  15	  min	  at	   37	   °C.	  Co-­‐immuno	   localization	  with	   the	  early	   endocytic	  marker	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NT4	   treatment	   (BDNF	   39.2%	   ±	   3.3%;	   NT4	   35.7%	   ±	   3.9%;	   p	   value	   0.5);	   c)	   Biochemical	  
internalization	   assay	   with.	   HEK293	   cells	   stably	   expressing	   TrkB	   receptor	   were	   surface	  
biotinylated	   with	   cleavable	   sulfo-­‐NHS-­‐S-­‐biotin	   that	   is	   cell	   impermeable.	   After	   a	   50ng/ml	  
BDNF/NT4	   treatment	   and	   endocytosis	   had	   occurred	   (15	   min	   at	   37°C),	   remaining	   surface	  
biotin	   was	   cleaved	   with	   a	   reducing	   agent,	   and	   avidin	   was	   used	   to	   pull	   down	   internalized	  
proteins.	  Precipitates	  were	  run	  on	  Western	  blot	  and	  probed	  with	  TrkB	  antibody	  depicting	  the	  
internalized	  pool	  only.	  As	  a	  positive	  control,	  biotin	  was	  not	  cleaved	  and	  as	  a	  negative	  control,	  
biotin	  was	  cleaved	  without	  the	  incubation	  step.	  d)	  Endocytosis	  assay	  of	  TrkB	  receptor	  in	  rat	  
cortical	  neurons	   in	  which	  the	  endogenous	  surface	  pool	  of	  TrkB	  was	   labeled	  using	  a	   live	   fed	  
antibody	  on	  ice.	  After	  surface	  labeling,	  neurons	  were	  incubated	  at	  37°C	  for	  an	  initial	  10	  min	  
for	   temperature-­‐adaptation	   and	   a	   further	   15	   min	   with	   BDNF	   or	   NT4,	   50ng/ml.	   After	  
internalization,	  cells	  were	  fixed	  and	  TrkB	  receptor	  remaining	  on	  the	  surface	  was	  labeled	  with	  
saturating	   concentrations	   of	   secondary	   antibody	   conjugated	   with	   alexa488,	   followed	   by	  
permeabilization,	   after	   which	   the	   internalized	   pool	   was	   labeled	   with	   secondary	   antibody	  
conjugated	   with	   alexa568.	   Control	   neurons	   were	   incubated	   without	   neurotrophins.	   e)	  
Quantification	  of	  internalized	  TrkB	  (BDNF	  72%	  ±	  1.5%;	  NT4	  74.3%	  ±	  1.8%;	  p	  value	  0.4).	  Image	  
quantification	  was	  done	  using	  ImageJ	  software.	  	  
	  
BDNF	  and	  NT4	  activate	  TrkB	  receptor	  with	  similar	  kinetics	  
Ligand	   binding	   to	   Trk	   receptors	   leads	   to	   receptor	   activation	   and	   cells	   use	  
phosphorylation	   as	   a	  mechanism	   to	  modulate	   trafficking	   of	   RTKs.	   Previous	   studies	  
have	   highlighted	   the	   importance	   of	   phosphorylation	   in	   modulation	   of	   receptor	  
sorting.	  An	  EGFR	  mutated	  in	  the	  kinase	  domain,	  is	  endocytosed	  upon	  ligand	  binding	  
with	  similar	  kinetics	  to	  the	  wild	  type	  receptor,	  however,	  rather	  than	  being	  sorted	  to	  
the	  degradative	  pathway,	  a	  significant	  portion	  recycles	  back	  to	  the	  cell	  surface	  [193].	  
We	  asked	  the	  question	   if	  BDNF	  and	  NT4	  differentially	   induce	  TrkB	  phosphorylation	  
while	   at	   the	   early	   endosome	   compartment.	   Previous	   studies	   comparing	   TrkB	  
activation	  with	   BDNF	   and	  NT4	   used	   cell	   lines	   transfected	  with	   the	   receptor	   [169].	  
However	   studying	   ectopic	   expressed	   RTKs	   poses	   some	   limitations	   since	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overexpression	   itself	   can	   promote	   dimerization	   and	   activation	   in	   a	   ligand	  
independent-­‐manner.	   Moreover,	   endogenous	   molecular	   players	   that	   could	   be	  
differentially	   recruited	   by	   one	   of	   the	   ligands	   in	   neurons	  may	   not	   be	   expressed	   in	  
these	   cell	   lines.	   Therefore,	  we	   decided	   to	   analyze	   phosphorylation	   of	   endogenous	  
TrkB	   in	   rat	   cortical	   cultures.	   Neurons	  were	   treated	   for	   15	  min	  with	   the	   respective	  
neutrotophin.	  An	  initial	  immunoprecipitation	  step	  with	  a	  TrkB-­‐specific	  antibody	  was	  
performed	  and	  phosphorylation	  was	  assessed	  by	  phosphotyrosine	  western	  blot.	  At	  
this	  time	  point,	  when	  roughly	  75%	  of	  TrkB	  receptor	  has	  been	  internalized	  (figure	  1d),	  
BDNF	   and	   NT4	   led	   to	   similar	   activation	   of	   TrkB	   receptor	   (ratio	   of	   BDNF	   induced	  
phosphorylation	  1.4	  ±	  0.09;	  NT4	  ratio	  1.3	  ±	  0.01;	  p	  value	  =	  0.24,	   figure	  2	  a	  and	  b).	  
Even	  though	  this	  data	  strongly	  suggests	   that	  phosphorylation	  of	  TrkB	  by	  BDNF	  and	  
NT4	   is	  not	  different,	   it	  did	  not	  exclude	  the	  possibility	  that	  these	  two	  neuretrophins	  
activate	   TrkB	   with	   different	   kinetics.	   Thus,	   we	   performed	   a	   kinetic	   study	   of	   TrkB	  
phosphorylation	  at	  different	  time	  points	  following	  neurotrophin	  stimulation	  (1,	  2.5,	  
5,	   7	   and	   10	  min).	   As	   shown	   in	   figure	   2	   c,	   BDNF	   and	   NT4	   efficiently	   activate	   TrkB	  
receptor	  with	   similar	   kinetics,	   further	   supporting	   the	   hypothesis	   that	   activation	   of	  
TrkB	  by	   these	   two	  neurotrophins	   is	   similar	   (including	  endocytosis,	   phosphorylation	  
and	  kinetics).	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Figure	  2:	  BDNF	  and	  NT4	  induce	  similar	  phosphorylation	  of	  TrkB	  receptor.	  DIV5	  rat	  
cortical	   neurons,	   were	   treated	   for	   15	   min	   with	   50ng/ml	   of	   BDNF	   or	   NT4.	   Neurons	   were	  
subsequently	   lysed	   and	   TrkB	   was	   immunoprecipitated	   with	   a	   specific	   antibody.	   A	  
phosphotyrosine	   antibody	   (PY99)	   was	   used	   to	   measure	   TrkB	   phosphorylation.	   a)	  
Representative	   western	   blot	   with	   PY99	   antibody	   of	   immunoprecipiated	   TrkB.	  
Phosphorylation	   levels	   were	   normalized	   to	   total	   TrkB	   levels	   and	   relative	   quantification	   to	  
BDNF	  is	  shown	  in	  b)	  (BDNF	  94.6	  ±	  3.9%;	  NT4	  ratio	  90.3	  ±	  3.9%;	  p	  value	  =	  0.42).	  c)	  Time	  course	  
phosphorylation	  of	  TrkB	  receptor	  (2	  way	  ANOVA	  0.27).	  Quantification	  was	  done	  using	  ImageJ	  
software	  and	  it	  represents	  an	  average	  of	  three	  independent	  experiments.	  
	  
To	  gain	   insight	   into	   the	   signaling	   cascades	  activated	  by	  NT4	  we	  decided	   to	  
employ	   a	   functional	   proteomic	   approach	   for	   proteins	   that	   become	   tyrosine	  
phosphorylated	  upon	  NT4	  or	  BDNF	  treatment.	  We	  used	  stable	  isotope	  labeling	  with	  
amino	  acids	  (SILAC)	  coupled	  to	  mass	  spectrometry.	  This	  technique	  has	  been	  shown	  
to	   be	   a	   highly	   effective	  means	   for	   characterization	   of	   protein-­‐protein	   interactions	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and	  cellular	  signaling	  [194].	  To	  achieve	  maximum	  isotope	  incorporation,	  rat	  cortical	  
and	  hippocampal	  neurons	  were	  grown	  for	  10	  days	  in	  neurotrophin	  of	  interest,	  lysed,	  
and	   a	   phosphotyrosine	   antibody	   was	   used	   to	   culture.	   At	   this	   time	   point	   neurons	  
were	   treated	   for	   15	   minute	   with	   the	   precipitate	   protein	   complexes	   that	   become	  
tyrosine	   phosphorylated	   upon	   neurotrophin	   treatment.	   We	   compared	   proteins	  
recruited	  upon	  NT4	  or	  BDNF	  treatment	  or	  untreated	  control.	  
Signaling	   proteins	   known	   to	   interact	   with	   BDNF-­‐activated	   TrkB	   receptor,	  
such	   as	   Shc	   and	   PLC-­‐γ,	   were	   pulled	   down	   with	   significantly	   higher	   ratios	   in	   cells	  
treated	   with	   BDNF	   than	   in	   the	   untreated	   control,	   validating	   this	   approach.	  	  
Interestingly	  the	   intracellular	  signaling	  events	   initiated	  by	  BDNF	  and	  NT4	  were	  very	  
similar.	   We	   observed	   that	   proteins	   such	   as	   Shp2,	   PLC-­‐γ,	   Grb2	   and	   Shc,	   known	   to	  
mediate	   downstream	   signaling	   cascades	   of	   Trks,	   were	   immunoprecipiated	   with	   a	  
similar	   ratio	   in	   the	  BDNF	  and	  NT4	  condition,	  showing	  that	  NT4	  activates	  and	  elicits	  
downstream	  signaling	  as	  efficiently	  as	  BDNF	  (Table	  1).	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Phosphotyrosin	  immunoprecipiation	  of	  cortical	  neurons	  stimulated	  for	  15	  min	  with	  BDNF	  or	  
NT4.	  Only	  proteins	  with	  mass	  spectrometry	  ratios	  higher	  than	  the	  control	  are	  shown.	  
	  
To	   further	   confirm	   recruitment	   of	   specific	   targets,	   some	   proteins	   were	  
selected	   for	  western	   blot	   analysis.	   Neurons	   treated	   for	   15	  min	  with	   BDNF	   or	   NT4	  
were	  lysed	  and	  TrkB	  receptor	  was	  immunoprecipiated	  with	  a	  TrkB-­‐specific	  antibody.	  
In	  agreement	  with	   the	   results	  obtained	   in	   the	  mass	   spectrometry	  experiments,	  we	  
observed	  that	  BDNF	  and	  NT4	  efficiently	  recruit	  the	  adaptor	  protein	  Grb2,	  known	  to	  
mediate	  Ras/MAPK	  as	  well	   as	   PIP2	   signaling	   (Figure	  3	   a	   and	  b).	   The	  other	   selected	  
target	  was	  Shp2.	  Shp2	   is	  a	  SH2	  containing	  tyrosine	  phosphatase	  that	  promotes	  the	  
activation	  of	  the	  Ras/MAPK	  signaling	  pathway.	  Shp2	  becomes	  phosphorylated	  and	  is	  
recruited	   to	   Trk	   receptor	   upon	   neurotrophin	   treatment.	   SHP2	   also	   acts	   as	   a	  
scaffolding	  protein	  and	  recruits	  Grb2	  and	  PI3K	  [47].	  We	  examined	  Shp2	  activation	  by	  
measuring	  its	  phosphorylation	  and	  also	  the	  recruitment	  of	  Grb2	  elicited	  by	  BDNF	  or	  
NT4.	  Both	  neurotrophins	  induced	  activation	  of	  Shp2	  	  (BDNF	  ratio	  0.8	  ±	  0.2;	  NT4	  ratio	  
Protein	   NT4	   SD	   BDNF	   SD	  
	   Weighted	  
mean	  ratio	  
	   Weighted	  
mean	  ratio	  
	  
N-­‐Shc	   9.90	   7.07	   11.85	   6.76	  
TrkB	   7.99	   3.27	   10.46	   3.79	  
Hrs	   4.08	   1.33	   6.43	   1.39	  
PLCγ	   4.53	   2.51	   5.31	   1.84	  
STAM1	   2.63	   0.63	   5.50	   1.62	  
Shp2	   4.17	   2.99	   5.11	   3.50	  
MAPK	  1/2	   4.75	   1.26	   5.00	   1.05	  
p44MAPK	   4.57	   1.29	   4.98	   1.18	  
ARMS	   3.03	   0.00	   2.89	   0.00	  
Grb2	   2.25	   0.33	   2.75	   0.28	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0.76	  ±	  0.25;	  p	  value	  =	  0.75)	  and	  Grb2	  recruitment	  (BDNF	  ratio	  1.17	  ±	  0.40;	  NT4	  ratio	  
1.64	  ±	  0.54;	  p	  value	  =	  0.21).	  	  (Figure	  	  3	  c,	  d	  and	  e)	  with	  similar	  efficiency.	  These	  data	  
further	  support	  the	  idea	  that	  the	  difference	  on	  biological	  activity	  between	  BDNF	  and	  




Figure	  3:	  Short-­‐term	  signaling	  mediated	  by	  BDNF	  and	  NT4	  is	  similar.	  a)	  Grb2	  recruitment	  to	  
activated	  TrkB	  receptor.	  Cortical	  neurons	  were	  treated	  for	  15	  min	  with	  50ng/ml	  with	  BDNF	  or	  NT4.	  TrkB	  
receptor	   was	   immunoprecipitated	   and	   Grb2	   recruitment	   was	   analyzed	   by	   western	   blot.	   b)	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Quantification	  of	  an	  average	  of	  3	  experiments	   show	  no	   statistical	  difference	  between	  BDNF	  and	  NT4	  
(BDNF	  100	  ±	   12.7%	  NT4	  87.94	  ±	  14.6%,	  p	  =	  0.63).	   c)	  Activation	  of	   Shp2	  and	   recruitment	  of	  Grb2	   to	  
Shp2.	   At	   the	   same	   time	   point,	   Shp2	   was	   immunoprecipitated	   and	   phosphorylation	   was	   analyzed	   by	  
PY99	  western	  blot,	  recruitment	  of	  Grb2	  with	  Grb2	  antibody.	  d)	  and	  e)	  represents	  quantification	  of	  an	  
average	   of	   3	   independent	   experiments	   (phoshoShp2	   BDNF	   100	  ±	   10.0%,	   NT4	   93.4	  ±	   14.6%,	   p	   =	  
0.79;	  Grb2	  recruitment	  BDNF	  100	  ±	  9.0%,	  NT4	  124.1	  ±	  5.0%,	  p	  =	  0.29).	  
	  
BDNF	  leads	  to	  more	  efficient	  ubiquitination	  of	  TrkB	  receptor	  
Some	   RTKs	   require	   phosphorylation	   to	   recruit	   specific	   E3	   ubiquitin	   ligases	  
that	   bind	   to	   phosphorylated	   tyrosines	   in	   the	   receptor.	   Phosphorylation	   of	   EGFR	  
recruits	   and	   transphosphorylates	   the	   E3	   ligase	   Cbl,	   that	   in	   turn	   leads	   to	   receptor	  
ubiquitination	  [195].	  Ubiquitinated	  receptors	  are	  recruited	  by	  a	  complex	  of	  proteins	  
(the	  ESCRT	  complex)	   to	  the	   late	  endosome	  and	  degraded	   in	  the	   lysosome	  [196].	   In	  
the	   case	  of	  TrkA,	   the	  E3	   ligase	  Nedd4-­‐2	  binds	   specifically	   to	   the	  unphosphorylated	  
form	  of	   the	  receptor,	   leading	   to	   its	  ubiquitination	  and	  targeting	   to	   the	  degradative	  
pathway.	  	  Considering	  that	  TrkB	  is	  internalized	  and	  activated	  by	  BDNF	  and	  NT4	  in	  a	  
similar	   fashion	  we	   expected	   that	   ubiquitination	  would	   follow	   a	   similar	   pattern.	   To	  
investigate	   the	   kinetics	   of	   ligand	   induced	   TrkB	   ubiquitination,	   cultured	   cortical	  
neurons	   were	   treated	   for	   different	   times	   with	   neurotrophin,	   TrkB	   was	  
immunoprecipiated	  using	  a	   TrkB-­‐specific	   antibody	  and	  ubiquitination	  was	  analyzed	  
by	  western	  blot	  with	  an	  ubiquitin	  antibody	  (P4D1).	  We	  observed	  that	  ubiquitination	  
of	   the	   TrkB	   receptor	   increases	   with	   time	   after	   neurotrophins	   treatment.	  
Interestingly,	  BDNF	  induces	  more	  efficient	  ubiquitination	  of	  TrkB	  receptor	  than	  NT4,	  
with	  a	   faster	  kinetics	   (figure	  4	  a	  and	  b).	  As	  early	  as	  one	  minute	  after	  neurotrophin	  
treatment,	   TrkB	   ubiquitination	   induced	   by	   BDNF	   is	   significantly	   higher	   than	   that	  
induced	  by	  NT4.	  This	  effect	  is	  maintained	  for	  up	  to	  10	  minutes;	  however,	  at	  a	  15	  min	  
time	   point,	   this	   difference	   is	   no	   longer	   significant,	   suggesting	   that	   NT4-­‐induced	  
receptor	  ubiquitination	  occurs	  at	  a	  slower	  pace	  than	  that	  induced	  by	  BDNF,	  reaching	  
both	  a	  peak	  at	  15	  min.	  Considering	  the	  role	  of	  ubiquitination	  in	  sorting	  cargo	  to	  the	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degradative	  pathway,	  we	  questioned	  if	  neurotrophin-­‐mediated	  degradation	  of	  TrkB	  




Figure	  4.	  Time	  course	  ubiquitination	  of	  TrkB	  receptor	  mediated	  by	  BDNF	  and	  NT4.	  
a)	   Cortical	   neurons	   were	   treated	   for	   different	   times	   with	   50ng/ml	   of	   BDNF,	   NT4	   or	   left	  
untreated.	   TrkB	   receptor	   was	   immunoprecipitated	   and	   ubiquitination	   was	   analyzed	   by	  
western	   blot	   with	   an	   ubiquitin	   antibody	   (P4D1).	   b)	   Quantification	   of	   four	   independent	  
experiments.	  A	  2	  way	  ANOVA	  statistical	  analysis	  revealed	  a	  significant	  difference	  across	  time	  
and	  with	   treatment	   (p=	   0.004).	   c)	   Quantification	   of	   TrkB	   ubiquitination	   at	   15	  minute	   time	  
point	  (p	  =	  0.7).	  
	  
BDNF	  targets	  TrkB	  receptor	  efficiently	  to	  the	  degradative	  pathway	  whereas	  
NT4	  leads	  to	  sustained	  TrkB	  activation	  and	  decreased	  degradation	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It	  was	  previously	  shown	  that	  BDNF	  leads	  to	  effective	  downregulation	  of	  TrkB	  
receptor	   in	  cultured	  cerebellar	  granule	  neurons;	  however,	   it	   is	  still	  unknown	  if	  NT4	  
can	   lead	   to	   effective	   TrkB	   degradation	   [197].	   Considering	   that	   TrkB	   receptor	   is	  
ubiquitinated	  with	  a	  faster	  kinetics	  in	  neurons	  treated	  with	  BDNF	  than	  those	  treated	  
with	  NT4,	  we	  hypothesized	  that	  sorting	  to	  the	  degradative	  pathway	  would	  be	  more	  
efficient	   after	   BDNF	   treatment.	   To	   test	   this,	   the	   time	   course	   of	   BDNF	   and	   NT4-­‐
induced	  TrkB	  downregulation	  was	  analyzed	  using	  a	  surface	  biotinylation	  degradation	  
assay.	   In	   this	   assay,	   cultured	   cortical	   neurons	   are	   surface	   biotinylated	   with	  
membrane	   impermeable	   sulfo-­‐NHS-­‐S-­‐biotin	   that	   labels	   only	   membrane	   proteins.	  
Following	   biotinylation,	   neurons	   were	   returned	   to	   37°C	   and	   were	   treated	   for	  
different	   times	   with	   BDNF	   or	   NT4,	   or	   with	   vehicle.	   At	   the	   end	   of	   treatment,	   cells	  
were	   lysed	   and	   the	   initially	   biotinylated	   receptors	   are	   pulled	   down	   with	   avidin	  
sepharose.	   Finally,	  western	  blot	   analysis	  with	  TrkB	  antibody	  allowed	  quantification	  
of	   remaining	   non-­‐degraded	   receptors,	   since	   degradation	   obviously	   leads	   to	   loss	   of	  
the	  epitope	  (figure	  5).	  Exposure	  of	  neurons	  to	  50	  ng/ml	  of	  BDNF	  or	  NT4	  for	  one	  hour	  
reduced	   the	   TrkB	   protein	   levels	   to	   80%.	   After	   4	   hours	   of	   BDNF	   treatment,	   TrkB	  
protein	  levels	  were	  reduced	  to	  30%	  of	  controls.	  	  At	  this	  time	  point,	  cells	  treated	  with	  
NT4	   only	   had	   a	   reduction	   of	   TrkB	   levels	   to	   60%	   of	   those	   seen	   in	   controls.	   This	  
difference	  was	  more	  evident	  at	  a	  5-­‐hour	  treatment	  when	  BDNF	  treatment	   led	  to	  a	  
reduction	  to	  less	  than	  20%	  of	  controls,	  whereas	  in	  cells	  treated	  with	  NT4	  almost	  half	  
of	  receptors	  were	  still	  available	  (reduction	  to	  40%).	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Figure	  5.	   Time	   course	  degradation	  of	   TrkB	   receptor	  mediated	  by	  BDNF	  and	  NT4.	  
Cortical	   neurons	   were	   surface	   biotinylated	   with	   a	   cell	   impermeable	   sulfo-­‐biotin.	  
Subsequently	  neurons	  were	  incubated	  for	  the	  indicated	  times	  with	  50	  ng/ml	  of	  BDNF	  or	  NT4.	  
A)	  Avidin	  pulled	  down	  precipitates	  were	  analyzed	  by	  western	  blot	  with	  a	  TrkB	  antibody.	  The	  
upper	  band	  at	  140KDa	  represents	  full	  length	  TrkB,	  whereas	  the	  lower	  band	  likely	  represents	  
truncated	   TrkB	   (TrkB.T1)	   b)	   Quantification	   of	   TrkB	   degradation	   as	   percentage	   of	   the	  
untreated	  control;	  represents	  an	  average	  of	  5	  independent	  experiments.	  Asterisks	  represent	  
a	  p	  value	  ≤	  0.04.	  
	  
Our	   data	   suggests	   that	   NT4-­‐induced	   degradation	   of	   TrkB	   is	   different	   than	  
that	  induced	  by	  BDNF.	  Thus,	  it	  is	  possible	  that	  NT4	  sorts	  activated	  TrkB	  receptors	  to	  
a	  different	  trafficking	  destination	  that	  BDNF-­‐activated	  TrkB.	  Therefore,	  we	  sought	  to	  
investigate	   the	   degradation	   pathway	   mediated	   by	   these	   two	   ligands.	   Previous	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studies	   have	   suggested	   that	   BDNF	   induced	   TrkB	   degradation	   is	   proteasomal-­‐
dependent	   [197].	   Subsequent	   studies	  with	  TrkA	  showed	   that	  both	   the	  proteasome	  
system	  and	  the	  lysosome	  play	  a	  sequence	  coordinated	  role	  in	  the	  degradation	  of	  this	  
receptor	  [198].	  Extensive	  studies	  analyzing	  RTK	  downregulation	  have	  highlighted	  the	  
revelance	  of	   the	   lysosome	   for	   this	   pathway	   [53].	   To	   test	   if	   neurotrophin	  mediated	  
downregulation	   is	   lysosomal-­‐dependent	   we	   performed	   the	   same	   surface	  
biotinylation	   degradation	   assay	   in	   the	   presence	   of	   a	   lysosome	   inhibitor:	   leupeptin	  
(100	   μg/ml)	   (figure	   6).	   Given	   the	   unstable	   nature	   of	   this	   inhibitor	   in	   aqueous	  
solutions	  we	  tested	  degradation	  at	  a	  3-­‐4	  hour	   time	  point.	  Treatment	  with	  50ng/ml	  
with	  BDNF	  alone	   led	  to	  a	  degradation	   index	  of	  an	  average	  of	  27.0	  ±	  3.2%	  that	  was	  
significantly	  different	  than	  cortical	  neurons	  treated	  with	  the	  same	  concentration	  of	  
BDNF	  but	  in	  the	  presence	  of	  leupeptin	  68.5	  ±	  6.4	  %	  (p	  value	  =	  0.004).	  In	  the	  case	  of	  
NT4,	  treatment	  with	  50ng/ml	  led	  to	  a	  degradation	  index	  of	  68.9	  ±	  5.8	  %,	  whereas	  in	  
the	  presence	  of	  NT4	  and	  leupeptin	  it	  was	  90.3	  ±	  1.7%	  (p	  value	  =	  0.025).	  Thus,	  in	  both	  
cases	   leupeptin	   significantly	   inhibited	  neurotrophin-­‐induced	  degradation,	   however,	  
in	   the	   case	   of	   BDNF	   this	   effect	  was	  much	  more	   pronounced.	   In	   fact,	   at	   such	   time	  
point,	   even	   in	   the	   absence	   of	   neurotrophins	   and	   comparing	   the	   untreated	   group	  
with	   and	  without	   leupeptin,	  we	   observed	   that	   surface	   biotinylation	   alone	   led	   to	   a	  
degradation	   of	   20%	  of	   TrkB,	   as	   can	   see	   by	   the	   quantification	   showing	   that	   after	   3	  
hour	   incubation	   period,	   the	   untreated	   control	   had	   a	   degradation	   index	   of	   80.8	   ±	  
4.8%.	   This	   most	   likely	   represents	   endogenous	   protein	   turnover.	   Considering	   that	  
leupeptin	  only	  blocked	  20%	  of	  NT4	  mediated	  degradation	  whereas	  it	  blocked	  40%	  of	  
BDNF,	   we	   asked	   the	   question	   if	   degradation	   triggered	   by	   NT4	   is	  mediated	   by	   the	  
proteasome	   rather	   than	   the	   lysosome.	   On	   the	   other	   hand,	   the	   rather	   short	  
incubation	   period	   analyzed	  might	   have	   occluded	   an	   effect	   on	  NT4	   considering	   the	  
slow	  degradation	  kinetics	  mediated	  by	  this	  ligand.	  To	  clarify	  this	  matter	  we	  decided	  
to	  test	  both	  proteasomal	  and	  additional	   lysosomal	   inhibitors	  at	  a	   longer	  time	  point	  
(5h).	  A	  5h	  treatment	  with	  BDNF	  or	  NT-­‐4	  in	  the	  presence	  of	  leupeptin	  did	  not	  lead	  to	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significant	   blockage	   of	   TrkB	   degradation,	   possibly	   due	   to	   the	   labile	   nature	   of	   this	  
drug	   in	   aqueous	   solutions	   (Figure	   7	   a).	   Thus,	   we	   tested	   additional	   lysosome	  
inhibitors:	   ConcanamycinA	  and	  Bafilomycin	   (at	   the	   same	   time	  point),	  which	   impair	  
the	  acidification	  of	  the	  lysosome	  by	  inhibiting	  the	  vacuolar	  proton	  pump	  [198,199].	  
Bafilomycin	   significantly	   blocked	   neurotrophin-­‐induced	   degradation	   (BDNF	   60%	   p=	  
0.01	  and	  NT4	  85%	  of	  control,	  p	  =	  0.03).	  Concanamycin	  also	   reduced	  neurotrophin-­‐
mediated	  degradation	  however	  it	  was	  non-­‐significant.	  (Figure	  7b)	  
	  
Figure	  6.	  Lysosomal-­‐dependent	  degradation	  of	  TrkB	  mediated	  by	  BDNF	  or	  NT4.	  A	  
surface	  biotinylation	  degradation	  assay	  was	  performed	  with	  cortical	  neurons	  treated	  for	  3-­‐4	  
hours	  with	  50ng/ml	  BDNF,	  NT4	  or	  untreated	  in	  the	  presence	  (C	  +	  L,	  B	  +	  L	  N	  +	  L)	  or	  absence	  of	  
100	  μg/ml	  leupeptin	  (C,	  B,	  N).	  a)	  Representative	  western	  blot	  with	  TrkB	  antibody.	  The	  upper	  
band	  has	  an	  approximate	  size	  of	  140KDa	  represents	  full	  length	  TrkB,	  whereas	  the	  lower	  band	  
likely	   represents	   truncated	   TrkB	   (TrkB.T1)	   b)	   Quantification	   of	   an	   average	   of	   three	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independent	  experiments.	  50ng/ml	  with	  BDNF	  alone	  (B)	  led	  to	  a	  degradation	  index	  of	  27.0	  ±	  
3.2%M;	  BDNF	  and	  leupeptin	  (B	  +	  L)	  68.5	  ±	  6.4	  %	  (p	  value	  =	  0.004).	  50ng/ml	  of	  NT4	  (N)	  led	  to	  a	  
degradation	  index	  of	  68.9	  ±	  5.8	  %,	  NT4	  and	  leupeptin	  (N	  +	  L)	  90.3	  ±	  1.7%	  (p	  value	  =	  0.025).	  
	  
In	   order	   to	   test	   if	   the	   proteasome	   is	   involved	   in	   neurotrophin-­‐mediated	  
degradation	  of	  TrkB	  we	  tested	  the	  previously	  reported	  inhibitor	  lactacystin,	  which	  is	  
an	   irreversible	   proteasome	   inhibitor	   that	   binds	   to	   the	   catalytic	   domain	   of	   20S	  
subunit	  [200].	  Lactacystin	  has	  been	  shown	  to	  block	  BDNF-­‐mediated	  TrkB	  degradation	  
in	  cerebellar	  neurons	  at	  a	  3h	  time	  point,	  as	  well	  as	  NGF-­‐induced	  TrkA	  degradation	  in	  
PC12	   cells	   at	   a	   2h	   time	   point	   [197,198].	   In	   our	   studies,	   lactacystin	   (8	   μM)	   did	   not	  
significantly	   impair	   BDNF	   or	   NT4-­‐induced	   degradation	   of	   TrkB	   receptor	   in	   cortical	  
neurons	  (Figure	  7).	  
We	  decided	  to	  test	  a	  second	  proteasome	  inhibitor	  MG-­‐132	  (10	  μM)	  that	  is	  a	  
reversible,	   and	   cell-­‐permeable	   proteasome	   inhibitor,	   reducing	   the	   degradation	   of	  
ubiquitin-­‐conjugated	  by	  the	  26S	  proteasome.	  Using	  this	  inhibitor	  both	  BDNF	  as	  well	  
as	   NT4	   elicited	   degradation	   was	   significantly	   blocked	   (Figure	   7a	   and	   b).	   Thus	  
suggesting	   that	   these	   neurotrophins	   mediate	   degradation	   through	   the	   same	  
mechanisms	   and	   that	   both	   the	   proteasome	   and	   lysosome	  might	   be	   implicated	   in	  
TrkB	   degradation.	   However	   it	   is	   still	   puzzling	   how	   does	   NT4	   induce	   slower	   TrkB	  
downregulation.	  
	  
Chapter	  2	  –	  Endocytic	  Trafficking	  of	  TrkB	  receptor	  
	   81	  
	  
Chapter	  2	  –	  Endocytic	  Trafficking	  of	  TrkB	  receptor	  
	   82	  
	  
Figure	   7:	   Lysosomal	   and	   proteasomal	   degradation	   of	   TrkB	   receptor	   triggered	   by	  
BDNF	  and	  NT4.	  Cultured	  cortical	  neurons	  were	  surface	  biotinylated	  and	  treated	  for	  5	  hours	  
with	   50ng/ml	   of	   neurotrophin	   in	   the	   presence	   of	   absence	   of	   the	   indicated	   inhibitor.	   7	   a)	  
Lactacysin	   (8	   μM);	  MG-­‐132	   (10	   μM);	   leupeptin	  was	   refreshed	   every	   hour	   (100	   μg/μl).	   7	   b)	  
MG-­‐132	   (10	  μM);	   ConcanamycinA	   (20nM)	   and	  Bafilomycin	   (200nM).	  Quantification	   of	   four	  
independent	  experiments	  show	  a	  significant	   treatment	  of	  MG-­‐132	   (5h	  BDNF	  ±	  MG-­‐132	  p	  =	  
0.005;	  5h	  NT4	  ±	  MG-­‐132	  p	  =	  0.02)	  and	  Bafilomycin	  (5h	  BDNF	  ±	  Bafilomycin	  p	  =	  0.014;	  5h	  NT4	  
±	  Bafilomycin	  p	  =	  0.03)	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Studies	   on	   EGFR	   have	   shown	   that	   ligands	   (such	   as	   TGF-­‐α)	   that	   lead	   to	  
recycling	   rather	   than	  degradation,	   interact	   less	   efficiently	  with	   the	   receptor	  within	  
the	   acidic	   environment	   of	   the	   early	   endosome,	   whereas	   the	   EGF-­‐EGFR	   complex	  
remains	  tightly	  bound	  even	  at	  lower	  pHs	  [201].	  Recent	  studies	  on	  TrkA	  receptor	  have	  
also	   shown	   that	   NT3	   induces	   less	   efficient	   activation	   of	   the	   receptor	   than	   NGF	   at	  
more	  acidic	  pHs	  [202].	  Thus	  we	  decided	  to	  test	  the	  efficiency	  of	  NT4	  mediated	  TrkB	  
activation	   and	   ubiquitination	   at	   lower	   pHs	   that	   mimic	   environment	   of	   the	   early	  
endosome	  (pH	  5.5	  and	  6.5),	  at	  a	  time	  point	  where	  there	  is	  no	  difference	  at	  pH=7	  (30	  
min)	  (Figure	  8).	  Indeed	  we	  observed	  that	  BDNF	  induces	  more	  efficient	  ubiquitination	  
of	  TrkB	  receptor	  at	  lower	  pHs,	  as	  compared	  with	  NT4	  that	  explain	  the	  more	  efficient	  
downregulation	   of	   TrkB	  with	   BDNF	   stimulation.	   Interestingly,	   phosphorylation	  was	  
similar	  at	  all	  pHs	  tested,	  suggesting	  that	  these	  neurotrophins	  differ	  specifically	  in	  the	  
mechanisms	  of	  TrkB	  ubiquitination.	  
	   	  
	  
Figure	   8.	   BDNF	   and	   NT4	   induced	   TrkB	   activation	   at	   acidic	   pHs.	   Cortical	   neurons	  
were	  treated	  with	  BDNF	  or	  NT4	  (50ng/ml)	  for	  30	  min	  with	  medium	  adjusted	  at	  different	  pHs.	  
TrkB	  was	   immunoprecipitated	   and	   ubiquitination	   (P4D1)	   and	   phosphorylation	   (PY99)	  were	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analyzed	   by	   western	   blot.	   Quantification	   shows	   an	   average	   of	   three	   independent	  
experiments.	  
	  
Endocytic	   sorting	   of	   RTKs	   away	   from	   the	   degradative	   pathway	   can	   have	   a	  
large	  impact	  on	  biological	  outcomes.	  Degradation	  of	  the	  receptor	  leads	  to	  signaling	  
attenuation.	   Studies	   done	  with	   the	   EGFR	   have	   shown	   that	   TGFα,	   which	   promotes	  
recycling	   of	   the	   receptor	   rather	   than	   degradation,	   is	   a	  more	   potent	  mitogen	   than	  
EGF,	   which	   efficiently	   sorts	   EGFR	   to	   the	   lysosomal-­‐degradation	   pathway	   [57].	  
Considering	   that	   NT4	   maintains	   a	   stable	   pool	   of	   TrkB	   receptor	   even	   after	   long	  
sustained	   treatments,	   we	   expected	   that	   this	   ligand	   would	   also	   maintain	   active	  
downstream	  signaling	  cascades	  during	  the	  same	  time	  period.	  To	  test	  this,	  we	  treated	  
cortical	  neurons	  with	  BDNF	  or	  NT4	  for	  five	  hours	  and	  then	  analyzed	  the	  activation	  of	  
the	  two	  major	  signaling	  pathways	  MAPK,	  through	  Erk1/Erk2	  phosphorylation	  and	  Akt	  
(figure	  9).	  We	  observed	  that	  after	  5-­‐hour	  treatment,	  NT4	   led	  to	  significantly	  higher	  
phoshphorylation	  of	  Akt	  and	  Erk1/Erk2	  as	  compared	  with	  BDNF,	  most	   likely	  due	  to	  
the	  amount	  of	  TrkB	  receptor	  that	  is	  still	  available	  at	  this	  time	  point.	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Figure	  9.	  Sustained	  signaling	  mediated	  by	  BDNF	  or	  NT4.	   a)	  Cortical	  neurons	  were	  
treated	   for	   five	   hours	   with	   50ng/ml	   with	   BDNF,	   NT4	   or	   left	   untreated.	   Lysates	   were	  
immunobloted	  for	  phoshpo	  Akt	  (pAkt)	  and	  phospho	  Erk	  (pErk).	  b)	  Quantification	  represents	  
phosphorylation	  of	  Akt	  and	  Erk	  normalized	  to	  tubulin	  (pAkt	  BDNF	  =	  100	  ±	  3.6%,	  NT4	  =	  143.5	  ±	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DISCUSSION	  	  
The	  results	  presented	  here	  reveal	  for	  the	  first	  time	  that	  differential	  sorting	  of	  
endocytosed	  TrkB	  receptor,	   in	  cortical	  neurons,	  can	  be	  achieved	  by	  treatment	  with	  
two	   different	   neurotrophins:	   BDNF	   and	   NT4.	   BDNF	   and	   NT4	   induce	   similar	   TrkB	  
endocytosis	  measured	  biochemically	  in	  293	  cells	  stably	  expressing	  TrkB	  receptor.	  In	  
cortical	  neurons	  TrkB	  endocytosis	  was	  measured	  by	  immunocytochemistry	  using	  co-­‐
localization	  with	  an	  early	  endosome	  marker	  (EEA1)	  and	  also	  by	  assessing	  the	  ratio	  of	  
internalized-­‐surface	  receptor.	  Moreover,	  we	  observed	  that	  initial	  phosphorylation	  of	  
TrkB	   and	   recruitment	  of	   adaptor	   signaling	  proteins,	   such	   as	  Grb2	   and	   Shp2,	  which	  
mediate	  TrkB	  downstream	  signaling,	  was	  similarly	  triggered	  by	  these	  two	  ligands.	  	  
Differences	  between	  BDNF	  and	  NT4-­‐mediated	  TrkB	  signaling	  have	  previously	  
been	   shown	   for	   Shc	  mediated	  MAPK	   activation	   [203].	   In	   this	   report,	   a	  mouse	   line	  
was	  created	  with	  a	  point	  mutation	  in	  the	  NPQY	  site	  of	  TrkB	  in	  which	  Y515,	  which	  is	  in	  
the	  consensus	  site	  for	  Shc	  recruitment,	  was	  replaced	  by	  a	  phenylalanine	  [2].	  Analysis	  
of	  viability	  of	  several	  sensory	  neuron	  populations	  revealed	  a	  selective	  death	  of	  NT4-­‐
dependent	  neurons,	  whereas	  BDNF	  supported	  populations	  were	  mostly	  viable.	  This	  
correlated	   with	   a	   reduced	   ability	   of	   NT4	   to	   activate	   MAPK	   signaling	   in	   cortical	  
neurons	  derived	  form	  the	  mutant	  mouse	  [203].	  Our	  own	  mass	  spectrometry	  data	  in	  
which	   we	   stimulated	   cortical	   neurons	   with	   BDNF	   or	   NT4	   and	   immunoprecipitated	  
proteins	   with	   a	   phosphotyrosine	   antibody	   revealed	   similar	   activation	   and/or	  
recruitment	  of	  the	  protein	  Shc	  (Table	  1	  of).	  Our	  studies	  do	  not	  distinguish	  between	  
Shc	   recruitment	   to	   TrkB	   or	   Shc	   tyrosine-­‐phosphorylation	   so	   it	   is	   possible	   that	  NT4	  
leads	  to	  more	  efficient	  Shc	  interaction	  with	  TrkB	  receptor,	  however,	  BDNF	  is	  equally	  
capable	  of	  activating	  this	  protein.	  
Interestingly,	   and	   despite	   the	   similarities	   in	   the	   initial	   endocytic	   steps,	   we	  
observed	   that	   BDNF	   induces	   faster	   and	   more	   efficient	   ubiquitination	   of	   TrkB.	  
Considering	   the	  central	   role	  ubiquitination	  plays	   in	   sorting	  membrane	   receptors	   to	  
the	  degradative	  pathway	  we	  hypothesized	  that	  more	  efficient	  ubiquitination	  would	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be	  coupled	  to	  more	  efficient	   ligand-­‐induced	  receptor	  degradation.	  The	  time	  course	  
of	   BDNF	   and	  NT4-­‐induced	   TrkB	  downregulation	  was	   analyzed.	   Exposure	  of	   cortical	  
neurons	  to	  BDNF	  for	  2-­‐3	  hours	  reduced	  the	  surface	  pool	  of	  TrkB	  to	  half,	  whereas	  a	  
longer	   treatment	   (4-­‐5	   hours)	   with	   NT4	   was	   necessary	   to	   achieve	   a	   similar	  
downregulation.	   Previous	   studies	   analyzing	   BDNF	   induced	   TrkB	   degradation	   in	  
cerebellar	   neurons	   showed	   a	   T1/2	   of	   1-­‐2	   hours	   [197].	   The	   differences	   in	   the	  
degradation	   kinetics	   can	   be	   due	   to	   the	   cell	   types	   used	   (cortical	   vs	   cerebellar	  
neurons),	  and	  also	  to	  the	  use	  of	  slightly	  different	  technical	  methods.	  In	  all,	  prolonged	  
BDNF	  treatment	  leads	  to	  fast	  downregulation	  of	  TrkB.	  However,	  as	  shown	  here,	  even	  
after	  prolonged	  activation	  with	  NT4,	  TrkB	  receptor	  was	  still	  stable.	  
We	  then	  asked	  the	  question	  if	  the	  mechanisms	  mediating	  TrkB	  degradation	  
were	   similar	   with	   BDNF	   or	   NT4	   activation.	   To	   test	   this	   we	   performed	   the	   same	  
degradation	   assay,	   in	   the	   presence	   or	   absence	   of	   a	   lysosomal	   inhibitor,	   leupeptin.	  
Interestingly	   leupeptin	   was	   much	   more	   efficient	   in	   blocking	   BDNF	   induced	  
degradation	   than	   NT4	   induced	   degradation.	   One	   possible	   explanation	   for	   this	  
difference	  might	  rely	  on	  the	  time	  point	  analyzed,	  at	  which	  BDNF	  induces	  significantly	  
higher	   degradation	   than	   NT4	   (27%	   vs	   68%),	   therefore,	   the	   degree	   of	   leupeptin-­‐
induced	   inhibition	   might	   be	   masked	   in	   the	   case	   of	   NT4.	   On	   the	   other	   hand,	   it	   is	  
possible	   that	   NT4	   might	   sort	   TrkB	   to	   different	   degradation	   pathways	   such	   as	   the	  
proteasome.	  Indeed,	  previous	  studies	  in	  cerebellar	  granular	  neurons	  have	  suggested	  
that	  TrkB	  follows	  a	  proteasomal	  dependent	  degradation	  pathway	  [197].	  Subsequent	  
studies	  with	  TrkA	  showed	  that	  both	  the	  proteasome	  system	  and	  the	  lysosome	  play	  a	  
sequence	   coordinated	   role	   in	   the	   degradation	   of	   this	   receptor	   [198].	   In	   order	   to	  
better	  understand	  the	  mechanisms	  of	  neurotrophin-­‐mediated	  TrkB	  degradation,	  we	  
analyzed	  additional	  lysosomal	  as	  well	  as	  proteasomal	  inhibitors.	  Contrary	  to	  previous	  
work	   on	   TrkB,	   we	   did	   not	   observe	   a	   significant	   blockage	   of	   neurotrophin-­‐induced	  
degradation	  with	  lactacystin,	  however,	  MG-­‐132	  had	  the	  strongest	  effect	  in	  reverting	  
TrkB	  degradation	  [197].	  We	  also	  observed	  that	  the	  lsysosomal	  inhibitor	  Bafilomycin	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significantly	  blocked	  neurotrophin-­‐mediated	  TrkB	  degradation.	   It	   is	   interesting	   that	  
lacatcystin,	   a	   strong	   and	   irreversible	   inhibitor	   that	   binds	   the	   β-­‐catalytic	   domain	   of	  
the	  20S	  subunit	  of	  the	  proteasome,	  failed	  to	  block	  TrkB	  degradation.	  In	  addition,	  this	  
inhibitor	   has	   not	   been	   shown	   to	   block	   other	   proteases	   [197].	   On	   the	   other	   hand,	  
considering	   that	   peptide	   aldehydes,	   such	   as	   MG-­‐132,	   might	   also	   inhibit	   certain	  
lysosomal	   cysteine	   proteases	   and	   calpains,	   its	   possible	   that	   this	   inhibitor	   may	   be	  
blocking	   the	   ubiquitin-­‐dependent	   lysosomal	   degradation	   of	   the	   receptor	   [204].	   All	  
together,	   these	   results	   suggest	   that	  BDNF	  and	  NT4	  sort	  TrkB	   receptor	   to	   the	   same	  
degradation	  pathway	  however	  with	  different	  kinetics.	  
Even	  though	  NT4	  is	  widely	  expressed	  in	  the	  brain,	  little	  work	  has	  been	  done	  
on	  NT4	  mediated	  TrkB	  activation	  and	  signaling.	  In	  large	  this	  is	  mainly	  due	  to	  the	  mild	  
phenotype	  of	  the	  NT4	  null	  mouse	  in	  comparison	  with	  the	  BDNF	  null,	  that	  has	  severe	  
developmental	   defects	   and	   is	   lethal	   [176].	   However,	   it	   is	   interesting	   that	   the	  
complete	  TrkB	  null	  mouse	   shows	  neuronal	  death	   in	   the	  hippocampus	  whereas	   the	  
BDNF	  null	  does	  not,	  suggesting	  the	  need	  for	  a	  second	  ligand,	  perhaps	  NT4	  [33,205].	  
The	  lack	  of	  major	  developmental	  abnormalities	  in	  the	  CNS	  of	  NT4	  null	  mice	  is	  most	  
likely	  due	  to	  compensation	  by	  BDNF,	  given	  the	  overlapping	  expression	  of	  these	  two	  
neurotrophins	   and	   the	   levels	   at	   which	   they	   are	   expressed.	   Research	   groups	  
employing	   an	   RNA	   protection	   assay	   to	   quantify	   NT4	   in	   the	   adult	   brain,	   estimated	  
that	   in	  the	  rat	  there	   is	  approximately	  3	  ng	  of	  NT4	  RNA	  per	  g	  of	  tissue	  [29].	  Studies	  
comparing	   the	   levels	   of	   both	   neurotrophins	   in	   the	   rat	   brain	  with	   quantitative	   PCR	  
suggest	  that	  the	  levels	  of	  NT4	  are	  half	  of	  BDNF	  in	  the	  adult	  [28].	  NT4	  protein	  levels	  
have	  not	  been	  measured	  in	  detail,	  on	  the	  other	  hand,	  ELISA	  analysis	  of	  BDNF	  in	  the	  
mouse	  brain,	  suggests	  that	  this	  neurotrophin	  is	  present	  at	  200	  ng	  per	  g	  of	  tissue	  [27].	  
In	  addition	  BDNF	  is	  released	  in	  an	  activity-­‐dependent	  manner	  whereas	  NT4	  is	  sorted	  
to	   the	   constitutive	   secreted	   pathway,	   suggesting	   that	   the	   levels	   of	   BDNF	   can	   be	  
unregulated	  in	  the	  absence	  of	  NT4	  [182].	  Perhaps	  due	  to	  the	  scarceness	  of	  NT4,	  the	  
system	  evolved	  in	  a	  way	  that	  it	  became	  more	  sensitive	  to	  this	  neurotrophin,	  enabling	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long	   lasting	   effects	   on	   its	   receptor.	   There	   are	   several	   examples	   in	   the	   literature	  
suggesting	   that	   NT4	   is	   a	   more	   potent	   trophic	   factor	   than	   BDNF.	   Replacement	   of	  
BDNF	  with	  NT4	   in	   the	  BDNF	   locus	  not	  only	   rescued	  the	  major	  abnormalities	  of	   the	  
BDNF	  null	  mouse	  but	  also	  supported	  the	  survival	  of	  more	  vestibular	  neurons	  than	  in	  
wt	  mice.	   In	  addition,	  both	   synaptic	  maturation	  and	   function	  were	  enhanced	   [183].	  
[183].	   A	   similar	   effect	   was	   observed	   on	   the	   survival	   of	   nodose-­‐petrosal	   neurons,	  
whereas	  a	  single	  NT4	  allele	  is	  sufficient	  to	  support	  survival	  of	  these	  cells,	  while	  two	  
functional	  BDNF	  alleles	  were	  necessary	   to	  achieve	   the	   same	  effect	   [176].	  Our	  data	  
showing	  that	  NT4	  activation	  of	  TrkB	  does	  not	  lead	  to	  massive	  down-­‐regulation	  of	  the	  
receptor	   thus	   ensuring	   sustained	   signaling,	   presents	   the	   first	   molecular	   evidence	  
that	  could	  explain	  those	  findings.	  Moreover,	  we	  show	  that	  prolonged	  NT4	  treatment	  
leads	   to	   significantly	   higher	   sustained	   phosphorylation	   of	   Akt	   and	  MAPK	   pathway	  
than	  BDNF	  treatment,	  supporting	  the	  idea	  that	  NT4	  is	  a	  more	  potent	  neurotrophin.	  
Activation	  of	  TrkA	  by	  NGF	  and	  NT3	  is	  the	  other	  example	  in	  the	  neurotrophin	  
family	   of	   two	   ligands	   activating	   the	   same	   receptor	   and	  mediate	   ligand-­‐dependent	  
neuronal	   survival.	   Therefore	   it	   is	   plausible	   to	   speculate	   that	   activation	   of	   TrkB	   by	  
BDNF	  or	  NT4	  functions	   in	  a	  similar	  way.	  NGF	  and	  NT3	  act	  synergistically	  to	  support	  
the	  survival	  of	  sympathetic	  neurons	  in	  a	  TrkA	  dependent	  manner.	  However,	  they	  do	  
so	   in	   a	   mechanistically	   distinct	   fashion	   [65].	   NT3	   is	   expressed	   at	   higher	   levels	   in	  
intermediate	   targets	   whereas	   NGF	   is	   an	   established	   final	   target	   derived	   survival	  
factor	  [30].	  Studies	  employing	  compartmentalized	  sensory	  neuronal	  cultures	  showed	  
that	  treatment	  of	  distal	  axons	  with	  NGF	  leads	  to	  robust	  phosphorylation	  of	  TrkA,	  and	  
its	   effectors	   Akt	   and	   Erk.	  Moreover,	   a	   fraction	   of	   endosomes	   containing	   activated	  
TrkA	   is	   retrograde	   transported	   resulting	   in	   accumulation	   of	   the	   same	   signaling	  
proteins	   in	   the	   soma	   [30,206].	   In	   contrast,	   NT3	   treatment	   of	   distal	   axons	   did	   not	  
elicit	   somatic	   accumulation	   of	   phosphorylated	   proteins	   and	   rather	   showed	   a	  
selective	   local	   effect	   [30,202].	   One	   could	   speculate	   that	   NT4	   activates	   TrkB	   in	   a	  
similar	   way	   as	   NT3	   activates	   TrkA.	   However,	   there	   are	   striking	   differences	   that	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distinguish	   these	   two	   systems.	   The	   most	   obvious	   one	   is	   their	   distinct	   spatial	  
expression	  with	  TrkB,	  BDNF	  and	  NT4	  being	  strongly	  and	  widely	  expressed	  in	  the	  CNS,	  
whereas	  TrkA	  and	  NGF	  are	  mostly	  confined	  to	  the	  periphery	  [26].	   It	   is	  thought	  that	  
neurotrophins	  are	  not	  necessary	   for	  cell	   survival	   in	   the	  CNS	  and	   in	   fact,	   long-­‐range	  
retrograde	  movements	   of	   activated	   TrkB	   receptor	   has	   not	   been	  observed	   in	   these	  
cellular	  systems.	   Initial	  studies	  showing	  cell	  death	   in	  the	  CNS	   in	  TrkB	  null	  mice,	  are	  
confounded	   by	   massive	   neuronal	   death	   in	   sensory	   system	   [26].	   Therefore,	   it	   is	  
reasonable	   to	   speculate	   that	   both	   BDNF	   and	  NT4	   lead	   to	   confined	   TrkB	  mediated	  
signaling,	   which	   is	   consistent	   with	   the	   compact	   structure	   of	   the	   CNS.	   Secondly,	  
contrary	  to	  BDNF	  and	  NT4	  that	  bind	  TrkB	  with	  the	  similar	  affinity,	  NT3	  has	  a	  much	  
lower	   affinity	   for	   TrkA,	   and	   studies	   comparing	   these	   two	   ligands	   usually	   employ	  
amounts	  10	   fold	  higher	   for	  NT3	   than	   for	  NGF	   [168,207].	   Lastly,	   it	   has	  been	   shown	  
that	  NGF	  activated	  TrkA	  is	  predominantly	  trafficked	  to	  recycling	  endosomes	  whereas	  
BDNF	  activated	  TrkB	   is	  efficiently	   sorted	   to	   the	  degradative	  pathway	   [63,206].	   It	   is	  
interesting	   to	   hypothesize	   that	   the	   NT4-­‐TrkB	   signaling	   complex	   is	   trafficked	   in	   a	  
similar	  manner	   as	   NGF-­‐TrkA	   whereas,	   instead	   of	   promoting	   degradation,	   it	   would	  
sort	  the	  receptor	  to	  a	  signaling	  endosome	  that	  could	  be	  retrogradely	  trafficked	  and	  
sustain	  long	  term	  signaling.	  Moreover,	  experiments	  showing	  short-­‐range	  movements	  
of	   activated	   TrkB	   receptor	   in	   cortical	   neurons	   (Deinhardt	   K,	   Chao	   M,	   personal	  
communication)	  were	  only	  done	  in	  the	  presence	  of	  BDNF	  and	  not	  NT4.	  Therefore,	  it	  
is	  possible	   that	  NT4	   induces	   long-­‐range	  retrograde	  movements	  of	  TrkB.	   In	  order	   to	  
ultimately	   answer	   this	   question,	   the	  use	  of	   compartmentalized	   cultures	  where	   the	  
axonal	   and	   somatodendritic	   compartment	   are	   separated,	   would	   have	   to	   be	  
employed.	  Unfortunately,	  for	  CNS	  neurons	  these	  are	  particularly	  challenging	  from	  a	  
technical	  standpoint.	  
Our	   studies	   show	   that	   minor	   differences	   in	   the	   initial	   activation	   and	  
trafficking	   steps	   of	   TrkB	   receptor	   are	   critical	   for	   long-­‐term	   signaling.	  We	  were	   still	  
puzzled	  about	  how	  NT4,	  that	  binds	  TrkB	  with	  similar	  affinity	  as	  BDNF,	  might	  sort	  this	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receptor	   do	   alternate	   trafficking	   destinations	   that	   are	   less	   efficiently	   coupled	   to	  
degradation.	  Our	  data	  shows	  that	  BDNF	  induces	  more	  efficient	  ubiquitination	  of	  TrkB	  
receptor	  however;	  we	  did	  not	  observe	  differences	   in	  endocytosis	   rates,	   suggesting	  
that	  upon	  internalization	  the	  receptor	  is	  initially	  sorted	  to	  a	  similar	  compartment	  (as	  
suggested	   by	   co-­‐localization	   with	   EEA1).	   Ligand-­‐mediated	   receptor	   ubiquitination	  
and	   sorting	   to	   the	   degradative	   pathway	   is	   a	   common	   mechanism	   cells	   use	   to	  
regulate	  RTK	  signaling.	  The	  capacity	  of	  BDNF	  to	  induce	  faster	  ubiquitination	  of	  TrkB	  
might	  be	  due	  to	  its	  ability	  to	  bind	  tightly	  to	  the	  receptor,	  even	  at	  the	  mildly	  acidic	  pH	  
of	   the	   early	   endosome,	   whereas	   NT4	   binding	   may	   become	   unstable	   in	   this	  
compartment.	   This	   was	   suggested	   by	   the	   surface	   plasmogen	   studies	   where	   the	  
binding	  affinity	  of	  both	  BDNF	  and	  NT4	  was	  measured.	  In	  this	  report,	  the	  acidic	  wash	  
of	  the	  receptor	  showed	  that	  TrkB	  uncoupled	  from	  NT4	  much	  more	  efficiently	  than	  it	  
did	  from	  BDNF	  [168].	  Efficient	  ligand/receptor	  uncoupling	  has	  been	  associated	  with	  
increased	  EGFR	  recycling	  and	  decreased	  degradation	  [57].	  EGF,	  TGFα	  and	  E4T	  are	  all	  
ligands	   for	  EGFR	  capable	  of	   inducing	   similar	  phosphorylation	  and	   internalization	  of	  
the	   receptor,	   however	   only	   EGF	   induces	   efficient	   recruitment	   of	   the	   E3	   ligase	   Cbl,	  
ubiquitination	   and	   degradation	   of	   EGFR.	   In	   contrast,	   TGFα	   and	   E4T	   triggered	  
recycling	  of	   EGFR	  and	   inefficient	  ubiquitination	   [57,201].	   The	  EGF-­‐EGFR	   complex	   is	  
resistant	   to	   the	   mildly	   acidic	   pH	   of	   early	   and	   late	   endosomes	   and	   remains	   intact	  
along	   the	   endocytic	   route	   and	   this	   was	   critical	   to	   ensure	   degradation	   of	   EGFR,	  
whereas	   both	   TGFα	   and	   E4T	   binding	   to	   EGFR	   are	   unstable	   at	   the	   early	   endosome	  
[57].	  Interestingly	  studies	  have	  shown	  that	  TGFα	  is	  a	  more	  potent	  mitogen	  than	  EGF,	  
stressing	   how	   critical	   modulation	   of	   endocytic	   trafficking	   is	   to	   achieve	   specific	  
biological	  outcomes	  [57,201].	  Considering	  the	  efficient	  uncoupling	  of	  NT4	  from	  TrkB	  
upon	  exposure	   to	  an	  acidic	   solution	   suggests	   that	  NT4	  might	  behave	  as	  TGFα,	  and	  
would	   uncouple	   from	   TrkB	   faster	   at	   the	   early	   endocytic	   compartment	   leading	   to	  
more	  efficient	  recycling	  and	  consequently	  less	  degradation	  and	  sustained	  signaling.	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Based	   on	   these	   previous	   studies,	   we	   postulated	   that	   the	   NT4-­‐TrkB	  
interaction	   is	  more	   labile	  within	  the	  acidic	  environment	  of	   the	  endosome,	  whereas	  
BDNF	  remains	  bound	  to	  TrkB	  even	  at	   lower	  pHs.	  Indeed	  we	  observed	  that	  at	  acidic	  
pHs	   BDNF	   induced	   more	   efficient	   ubiquitination	   of	   TrkB	   receptor	   than	   NT4	   but	  
phosphorylation	   was	   similar.	   The	   differential	   ubiquitination	   might	   promote	   a	  
configuration	   that	   sorts	   the	   receptor	   either	   to	   an	   alternate	   compartment	   or	   a	  
different	   microenvironment	   within	   the	   early	   endosome	   that	   might	   facilitate	   the	  
recruitment	   of	   an	   E3	   ligase	   (still	   unidentified)	   and	   is	  more	   efficiently	   coupled	  with	  
the	  degradation	  pathway.	  
In	   all	   these	   studies	   reinforce	   the	   importance	   of	   addressing	   both	  
neurotrophins	  that	  activate	  TrkB	  and	  how	  mild	  differences	  in	  initial	  trafficking	  events	  
are	  reflected	  in	  opposing	  outcomes.	  Mutations	  in	  the	  NT4	  gene	  have	  recently	  been	  
associated	   with	   development	   of	   glaucoma	   in	   humans	   [208].	   TrkB	   phosphorylation	  
induced	   by	   NT4	   carrying	   these	  mutations	  was	   reduced,	   as	   compared	   to	  wild	   type	  
NT4,	  drawing	  attention	   to	   the	   relevance	  of	  precisely	   regulating	   receptor	  activation	  
and	   signaling	   and	   understanding	   the	   mechanisms	   of	   TrkB	   activation	   mediated	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INTRODUCTION	  
The	   Slitrk	   gene	   family	   was	   discovered	   in	   a	   screen	   for	   proteins	   that	   had	  
altered	   expression	   in	   mice	   with	   neural	   tube	   defects	   [8].	   This	   family	   comprises	   six	  
members	  that	  were	  named	  Slitrk1	  through	  Slitrk6	  and	  they	  are	  primarily	  expressed	  
in	  the	  brain.	  Given	  their	  expression	  at	  early	  developmental	  stages	  as	  well	  as	  high	  and	  
broad	   expression	   in	   the	   CNS,	   efforts	   have	   been	  made	   in	   trying	   to	   understand	   the	  
main	  functions	  of	  these	  proteins.	  
Several	  human	  and	  mouse	  genetic	  studies	  have	  associated	  Slitrk	  genes	  with	  
psychiatric	  disorders	   [9].	  The	  Slitrk1	  gene	  was	  the	   first	  member	   in	   the	   family	   to	  be	  
associated	  with	  a	  disorder,	  when	  mutations	  in	  this	  gene	  were	  found	  in	  patients	  with	  
Tourrete’s	   Syndrome	   (TS)	   [113].	   Later	   studies	   found	   mutations	   in	   Slitrk1	   in	  
individuals	   with	   Trichotillomania	   (TTM)	   [114].	   Given	   their	   common	   behavioral	  
characteristics	  these	  disorders	  fall	  into	  the	  broad	  spectrum	  of	  obsessive-­‐compulsive	  
disorder	  (OCD)	  [130,142,209].	  The	  Slitrk2	  gene	  was	  the	  second	  member	  in	  the	  family	  
to	  be	  found	  associated	  with	  a	  psychiatric	  disorder.	  A	  study	  performing	  systematic	  re-­‐
sequencing	  of	  X-­‐chromosome	  genes	  found	  two	  novel	  missense	  variants	  in	  Slitrk2	  in	  
patients	  with	  schizophrenia	  and	  in	  their	  affected	  siblings	  [115].	  
The	  Slitrk1	  null	  mouse	  was	  developed	  in	  order	  to	  provide	  a	  suitable	  model	  to	  
study	  TS	  [143].	  This	  mouse	  developed	  anxiety	  and	  depressive-­‐like	  behaviors	  as	  well	  
as	   increased	   norepinephrine	   levels	   in	   the	   brain,	   that	   is	   consistent	   with	   the	  
pathophysiology	   of	   TS	   [144].	   However,	   they	   did	   not	   develop	   behavioral	  
characteristics	   that	   resemble	   the	   hallmarks	   of	   TS,	   such	   as	   tics	   or	   repetitive	  
movements	  [143].	  
Evidences	  are	  mounting	  to	  indicate	  an	  involvement	  of	  the	  Slitrk	  gene	  family	  
with	   neuropsychiatric	   disorders;	   however,	   the	   underlying	   molecular	   mechanisms	  
remain	   are	   unknown.	   Some	   studies	   suggested	   that	   Slitrks	   can	   modulate	   neurite	  
outgrowth	  and	  one	  report	  has	  showed	  that	  Slitrk2	  has	  synaptogenic	  activity	  [9].	  The	  
goal	  of	  this	  thesis	  was	  to	  contribute	  to	  a	  better	  understanding	  of	  the	  functions	  these	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proteins	   play	   in	   the	   CNS.	   We	   focused	   on	   the	   Slitrk5	   member	   given	   its	   wide	  
distribution	  and	  strong	  expression	  in	  the	  brain	  and	  we	  hypothesize	  that	  this	  protein	  
would	  be	  involved	  in	  OCD-­‐spectrum	  disorders.	  In	  order	  to	  investigate	  the	  function	  of	  
this	   protein	   and	   to	   delineate	   the	   expression	   pattern	   of	   the	   Slitrk5	   gene	   in	  mouse	  





The	  following	  antibodies	  were	  used:	  FLAG	  rabbit	  (F255);	  mouse	  M1	  and	  M2,	  
mouse	  Tubulin,	  HA	  (rabbit	  and	  mouse	  H3663,	  H6908)	  were	  all	  from	  Sigma.	  Actin	  (sc-­‐
1616)	  from	  Santa	  Cruz;	  GluA1	  mouse	  (MAB2263)	  and	  rabbit	  (AB1504);	  GluA2	  mouse	  
(MAB397)	   and	   rabbit	   (AB1768),	   VGlut1	   guinea	   pig	   (AB5905)	   were	   from	  Millipore.	  
PhosphoErk	   (#9101S),	   phosphoAkt	   (#4060S),	   Akt	   (9272)	   were	   from	   Cell	   Signaling.	  
GluA2/3	  rabbit	   (ab53086),	  MAP2	  chicken	  (AB5392),	  MAP2	  rabbit	   (AB32454),	  PSD95	  
rabbit	   (ab18258)	   were	   from	   Abcam.	   Tau	   mouse	   (MAB3420),	   Synapsin	   rabbit	  
(AB1543)	  from	  Chemicon.	  C-­‐Myc	  (mouse	  sc-­‐40),	  Erk1	  (sc-­‐93),	  Erk2	  (sc-­‐154)	  was	  from	  




Male	   C57BL6/J	   mice	   were	   used	   for	   all	   behavioral	   experiments.	   Slitrk5	  
heterozygous	   mice	   were	   crossed	   and	   litters	   were	   weaned	   at	   P21.	   After	   genotype	  
male	   littermates	   heterozygous,	   knockout	   and	   wild	   type	   were	   used	   for	   behavioral	  
testing.	   Mice	   were	   housed	   a	   maximum	   of	   five	   per	   cage	   in	   a	   temperature-­‐	   and	  
humidity-­‐controlled	   vivarium	   maintained	   on	   a	   12-­‐h	   light/dark	   cycle.	   Mice	   had	   ad	  
libitum	   access	   to	   food	   and	   water.	   All	   procedures	   regarding	   animal	   care	   and	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treatment	  were	   in	  compliance	  with	  guidelines	  established	  by	  Weill	  Cornell	  Medical	  
College's	  Institutional	  Animal	  Care	  and	  Use	  Committee	  and	  the	  National	  Institutes	  of	  
Health.	  
	  
Generation	  of	   the	  Slitrk5	  knockout	   lacZ	  knock-­‐in	  mice	  and	  determination	  
of	  Slitrk5	  expression	  pattern	  
The	   Slitrk5	   encoding	   region	   was	   replaced	   with	   TM-­‐lacZ	   inserted	   at	   amino	  
acid	   47	   of	   Slitrk5	   after	   the	   initiator	   methionine	   (amino	   acid	   7	   after	   the	   signal	  
sequence	  cleavage	  site).	  Velocigene	  Allele	  Identification	  Number:	  VG737.	  Mice	  were	  
generated	  on	  C57BL/6	  and	  SV129	  mixed	  background	  and	  subsequently	  backcrossed	  
to	   C57BL/6	   background	   for	   five	   generations.	   Genotyping:	   forward	   primer	   –	   5’-­‐
GACCCCCTTCCGTCTACAC-­‐3’,	  reverse	  primer	  –	  5’-­‐	  TGGACAAAGTTCCTGCTTGGATAC-­‐3’	  
and	   the	   probe	   –	   5’-­‐CTCGTCCAAATCCC-­‐3’	   for	   wild	   type;	   forward	   primer	   –	   5’-­‐
GGGCGCCCGGTTCTT-­‐3’,	   reverse	  primer	  –	  5’-­‐	  CCTCGTCCTGCAGTTCATTCA-­‐3’	  and	   the	  
probe	  –	  5’-­‐ACCTGTCCGGTGCCC-­‐3’	  for	  the	  knockout.	  Expression	  pattern	  of	  Slitrk5	  was	  
determined	   by	   the	   detection	   of	   β-­‐galactosidase	   activity	   in	   mouse	   tissues.	   Fresh-­‐
frozen	  tissues	  were	  sectioned	  and	  subsequently	  incubated	  for	  4-­‐	  16	  hours	  with	  X-­‐gal	  
(1	  mg/ml,	  Calbiochem),	  then	  counterstained	  with	  Nuclear	  Fast	  Red	  (VectorLabs).	  
	  
Fluoxetine	  treatment	  
Fluoxetine	   was	   dissolved	   in	   tap	   water	   and	   delivered	   ad	   libitum	   in	   the	  
drinking	  water	   (tap)	   in	   glass	   bottles,	   and	   daily	  water	   intake	  was	  measured	   for	   the	  
first	  7	  days.	  An	  intake	  of	  2.0-­‐2.5	  ml	  per	  day	  was	  determined,	  similar	  to	  standard	  tap	  
water	   intake	   controls.	   Fluoxetine	   mixtures	   were	   changed	   every	   48h	   to	   insure	  
delivery	  of	  fresh	  drug.	  A	  dose	  of	  18	  mg/kg	  per	  day	  fluoxetine	  was	  given	  for	  21	  days,	  
which	  corresponded	  to	  160	  mg/L	  and	  was	  based	  on	  prior	  fluoxetine	  dosing	  regimens	  
in	  C57BL/6	  mice.	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Cell	  culture	  
All	  reagents	  used	  to	  prepare	  primary	  neuronal	  cultures	  were	  purchased	  from	  
Invitrogen,	   except	   glucose	   that	   was	   from	   Sigma.	   The	   striatum,	   cortex	   or	  
hippocampus,	  were	  dissected	  from	  E18	  Sprague	  Dawley	  rat	  or	  E16	  C57BL6	  (WT,	  Het	  
or	  KO)	  mouse	  embryos	  in	  Hanks	  Balanced	  solution	  (HBSS)	  supplemented	  with	  0.37%	  
glucose.	   Digestion	  was	   performed	   in	   the	   same	  medium	   supplemented	  with	   0.05%	  
trypsin	  for	  10-­‐15	  minutes	  at	  37°C.	  Neurons	  were	  mechanically	  dissociated	  with	  fire-­‐
polished	  Pasteur	  pipettes	  and	  plated	  in	  plating	  medium	  (PM)	  (MEM	  containing	  10%	  
FBS,	  1	  mM	  pyruvate,	  0.37%	  glucose,	  and	  0.1	  mg/ml	  of	  Primocin	  from	  Invivogen)	  for	  
24	  hours.	  After	  one	  day	   in	   culture,	  PM	  was	   replaced	  by	  Neurobasal	   supplemented	  
with	   B-­‐27,	   0.5mM	   glutamine,	   0.1	   mg/ml	   Primocin	   and	   2µM	   Ara-­‐C	   (Cytosine	   β-­‐D-­‐
arabinofuranoside	  hydrochloride).	  Cells	  were	  grown	  on	  1mg/ml	  poly-­‐D	  lysine-­‐coated	  
surfaces:	   for	   immunocytochemistry	   a	   density	   of	   15x103	   cells/cm2	   was;	   for	  
biochemistry,	   polystyrene	   dishes	   were	   used	   at	   a	   density	   of	   76x103	   cells/cm2.	  
Neurons	  were	  kept	  in	  a	  humidified	  incubator	  at	  37°C	  and	  5%	  CO2.	  COS7	  and	  HEK293	  
cells	  were	  maintained	   in	   DMEM	   (Invitrogen)	   containing	   10%	   heat	   inactivated	   fetal	  
bovine	   serum	   (FBS)	   (GemCell),	   supplemented	   with	   100	   U/ml	   penicillin,	   100	   U/ml	  
streptomycin	   (Pen/Strep)	   (Invitrogen),	   and	   2	   mM	   glutamine	   (GlutaMAX	   from	  
Invitrogen).	  	  
	  
Lentiviral	  vector	  production	  and	  constructs	  
The	  third	  generation	  lentiviral	  contructs	  used	  in	  this	  work	  were	  a	  kind	  gift	  of	  
Stefano	   Rivella	   lab	   at	   Weill	   Cornell	   Medical	   College.	   Lentiviral	   particles	   were	  
produced	  by	  transfecting	  low	  passage	  HEK293.	  Cells	  were	  plated	  on	  10	  cm	  dishes	  at	  
4-­‐5	  x	  106	  density	  the	  day	  before	  transfection	  on	  regular	  growth	  media.	  Medium	  was	  
changed	  2	  hour	  before	  transfection	  to	  Iscoves	  DMEM	  (CellGro),	  10%	  FBS	  (Hyclone),	  
PenStrep	   (Invitrogen)	   and	   2	   mM	   glutamine.	   For	   transfection	   the	   Ca2+	   phosphate	  
method	  was	  used.	  The	  plasmid	  DNA	  mix	  was	  prepared	  by	  adding	  3	  μg	  ENV	  plasmid	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(VSV-­‐G),	  5	  μg	  Packaging	  plasmid	   (pMDLg/p	  RRE),	  2.5	  μg	  of	  pRSV-­‐REV	  and	  10	  μg	  of	  
Gene	   Transfer	   plasmid	   together	   (human	   FlagSlitrk5	   and	   GFP	  was	   constructed	   into	  
pCCL	   vector).	   The	   plasmid	   solution	  was	  made	   up	   to	   a	   final	   volume	   of	   450	   μl	  with	  
0.1xTE/dH2O	  (2:1).	  Finally	  50	  μl	  of	  2.5M	  CaCl2	  was	  added,	  mixed	  and	  incubated	  for	  5	  
minute	   at	   RT.	   Precipitates	  were	   formed	   by	   drop	  wise	   addition	   of	   500	   μl	   of	   2xHBS	  
solution	  (281mM	  NaCl,	  100mM	  HEPES,	  1.5	  mM	  Na2HPO4	  pH=	  7.08	  –	  7.16	  –	  several	  
solutions	  of	  HBS	  with	  different	  pH	  were	  tested	  for	  efficiency	  before	  transfection	  of	  
viral	   particle	   constructs)	   to	   the	   DNA-­‐TE-­‐CaCl2	   mixture	   while	   vortexing.	   The	  
precipitate	  was	  added	  immediately	  after	  the	  addition	  of	  HBS	  (a	  maximum	  of	  3	  dishes	  
were	   transfected	   with	   the	   same	   solution).	   Cells	   were	   incubated	   and	   media	   was	  
changed	   12-­‐16	   hour	   after	   transfection.	   The	   supernatant	  was	   collected	   at	   24h	   and	  
48h	  after	  changing	  the	  media	  and	  it	  was	  used	  to	  transduce	  the	  neurons.	  
Second	   generation	   lentivirus	   were	   used	   to	   transduce	   neurons	   with	   shRNA	  
against	  mouse	  Slitrk5.	  pGIPZ	  vectors	  containing	  a	  target	  sequence	  for	  mouse	  Slitrk5	  
were	   obtained	   from	   Open	   Biosystem	   (5’-­‐catcatcagtctctctgaa-­‐3’	   and	   5’-­‐
cagctgctattcttgaata-­‐3’).	   Packaging	   vectors	   were	   obtained	   from	   Addgene.	   The	  
protocol	  for	  HEK293	  cell	  transfection	  and	  collection	  of	  viral	  particles	  was	  the	  same	  as	  
for	   third	   generation	   lentivirus,	   only	   differing	   in	   the	   vector	   composition.	   Vector	  
solution	   was	   as	   following:	   7.5	   μg	   of	   PsPAX2	   packaging	   plasmid,	   2.5	   μg	   pMD2.G	  
envelope	  plasmid,	  and	  10	  μg	  of	  pGIPZ	  vector.	  
Rat	   full	   lenght	   HA-­‐Pick1,	   rat	   MycPick1	   (Δ121),	   rat	   FlagPick1	   (Δ135),	   rat	  
MycGluA2	  were	  a	  kind	  of	  Edward	  Ziff	  lab,	  at	  NYU	  medical	  Center.	  Human	  FlagSlitrk5	  
was	  sub-­‐cloned	  into	  pcDNA3.1+;	  human	  Slitrk5GFP	  was	  sub-­‐cloned	  into	  pCCL	  vector;	  
mouse	  full	  length	  Slitrk5	  was	  initially	  amplified	  from	  cDNA	  library	  produced	  in	  the	  lab	  




Chapter	  3	  –	  Slitrk5	  as	  a	  new	  key	  player	  for	  CNS	  function	  
	   103	  
Western	  blotting	  
Brain	  tissue	  or	  cultured	  cells	  was	  lysed	  in	  RIPA	  buffer	  (150	  mM	  NaCl,	  50	  mM	  
Tris	  pH	  8.0;	  5	  mM	  EDTA,	  1%	  Triton	  X-­‐100,	  0.5%	  DOC,	  0.1%	  SDS)	  containing	  protease	  
and	   phosphatase	   inhibitors	   (2	   μg/ml	   leupeptin,	   2	   μg/ml	   aprotinin,	   1	   mM	   sodium	  
orthovanadate,	  10	  mM	  sodium	   fluoride,	  and	  1	  mM	  phenylmethylsulfonyl	   fluoride).	  
After	  mechanical	  trituration	  of	  tissue	  or	  cells,	  lysates	  were	  rotated	  at	  4°C	  for	  20	  min	  
for	  maximum	  protein	  extraction,	  followed	  by	  a	  10	  min	  centrifugation	  at	  14000	  rpm.	  
The	   pellet	   was	   discarded.	   Protein	   quantification	   was	   performed	   using	   Biorad	  
reagent.	   After	   bringing	   the	   samples	   to	   the	   same	   concentration,	   proteins	   were	  
separated	   on	   a	   10%	   Nupage	   Bis-­‐Tris	   Gel	   (Invitrogen)	   and	   transferred	   to	   PVDF	  
membranes	   (Biorad).	   These	  were	   then	  blocked	   for	  1	  h	   in	  TBS	  with	  0.1%	  Tween	  20	  
(TBS-­‐T)	   and	   5%	   low-­‐fat	  milk	   or	   3%	   BSA	   if	   phosphotyrosine	   antibody	   was	   used	   for	  
immunoblot.	  The	   incubation	  with	   the	  primary	  antibodies	  was	  performed	  overnight	  
at	  4°C	  in	  TBS-­‐T	  with	  3%	  BSA,	  followed	  by	  washes	   in	  TBS-­‐T	  and	  incubation	  with	  HRP	  
secondary	   antibodies	   at	   room	   temperature	   for	   1	   h	   at	   1:4000	   dilution.	  
Immunoreactive	  proteins	  were	  visualized	  by	  ECL	  detection	  and	  film	  autoradiography.	  
Striping	  was	   done	   by	  washing	   the	  membranes	   in	   0.1M	  Glycine	   pH	   2.5	   for	   15	  min,	  
followed	  by	  another	  wash	  in	  1%	  SDS	  for	  15	  min.	  
	  
Synaptosomal	  fractionation	  
The	   procedure	   of	   obtaining	   the	   PSD	   enriched	   fractions	   was	   adopted	   from	  
elsewhere	   [210].	  The	  striatum	  of	   three	  6	  and	  14	  months	  old	  Slitrk5-­‐/-­‐	  mice	  or	   their	  
wild	   type	   littermates	   were	   pooled	   together	   and	   subjected	   to	   dounce	  
homogenization	  in	  1	  ml	  of	  solution	  A	  (0.32	  M	  sucrose,	  1	  mM	  NaHCO3,	  1	  mM	  MgCl	  2,	  
0.5	  mM	  CaCl	  2,	  with	  protease	  and	  phosphatase	  inhibitors)	  and	  centrifuged	  at	  1,400	  g 
for	  10	  min.	  The	  supernatant	  was	  subjected	  to	  a	  second	  centrifugation	  at	  14,000	  g for	  
30	  min	  to	  obtain	  a	  crude	  P2	  fraction.	  The	  pellet	  was	  resuspendend	  in	  1ml	  of	  solution	  
B	   (0.32	   M	   sucrose,	   1	   mM	   NaHCO3).	   This	   homogenate	   was	   layered	   on	   top	   of	   the	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sucrose	  gradient	  (1	  M	  sucrose	  and	  1.2	  M	  sucrose)	  and	  centrifuged	  at	  82,500	  g for	  2	  
hrs.	  Purified	  synaptosomes	  were	  collected	  from	  the	  1	  M	  and	  1.2	  M	  sucrose	  interface.	  
The	  synaptosomes	  were	  resuspended	   in	  Solution	  B	  and	  subjected	  to	  centrifugation	  
at	   82,500	   g for	   45	   min.	   The	   pellet	   was	   resuspended	   in	   2%	   SDS	   and	   25	   mM	   Tris.	  
Protein	  lysates	  were	  subjected	  to	  western	  blot	  analysis.	  The	  normalization	  was	  done	  
with	  the	  actin.	  
	  
Open	  field	  test	  
The	   open	   field	   apparatus	   consisted	   of	   a	   (40	   cm	   x	   40	   cm	   x	   49	   cm)	   white	  
Plexiglas	  arena.	  The	  arena	  was	  set	  up	  in	  a	  dim	  room	  (2.0	  Lux)	  under	  a	  digital	  camera	  
connected	  to	  a	  video	  recorder	  and	  a	  computer	  under	  the	  control	  of	  the	  EthoVision	  
tracking	   system	   (Noldus	   Information	   Technology).	   The	   arena	   was	   digitally	   divided	  
into	  twelve	  equally	  sized	  quadrants.	  A	  single	  mouse	  (3	  months	  old)	  was	  placed	  into	  
the	  center	  of	  open-­‐field	  arena	  and	  their	  positions	  in	  the	  field	  were	  recorded	  over	  a	  
10	  min	   session.	  Anxiety	   level	  was	  assessed	  by	   the	  quantification	  of	   two	   indices:	   (i)	  
the	  percentage	  of	  time	  spent	  in	  the	  center	  quadrants	  and	  (ii)	  percentage	  of	  entries	  
into	  the	  center	  quadrants.	  An	  entry	  into	  a	  given	  quadrant	  was	  only	  registered	  if	  the	  
center	  mass	  of	  the	  mouse	  traveled	  inside	  of	  the	  quadrant.	  
	  
Elevated	  plus	  maze	  
The	  elevated	  plus-­‐maze	  was	  constructed	  of	  white	  Plexiglas,	  and	  raised	  70	  cm	  
above	   the	   floor,	   and	   consisted	   of	   two	   opposite	   enclosed	   arms	   with	   14	   cm	   high	  
opaque	  walls	   and	   two	   opposite	   open	   arms	   of	   the	   same	   size	   (30	   cm	   x	   5	   cm).	   The	  
elevated	  plus-­‐maze	  was	  set	  up	  under	  an	  infrared	  sensitive	  digital	  camera	  connected	  
to	  a	  video	  recorder.	  A	  single	  testing	  session	  lasting	  10	  min	  was	  carried	  out	  in	  a	  dark	  
room.	   To	   begin	   a	   trial,	   the	   test	   animal	  was	   placed	   in	   the	   center	   of	   the	   plus-­‐maze	  
facing	   an	   open	   arm,	   and	   their	   behavior	   was	   recorded	   for	   10	   min.	   The	   maze	   was	  
cleaned	  with	  a	  50%	  ethanol	  solution	  and	  dried	  after	  each	  trial	  to	  eliminate	  possible	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odor	  cues	   left	  by	  previous	  subjects.	  The	  number	  of	  entries	   into	  both	  the	  open	  and	  
enclosed	  arms	  was	  recorded	  (an	  entry	  is	  when	  the	  animal	  puts	  all	  four	  paws	  into	  one	  
arm);	   the	   time	   spent	   in	   those	   two	  areas;	   and	   the	   frequency	  of	   center	   crosses	  was	  
also	  recorded.	  Anxiety	   levels	  were	  measured	  by	  the	  relative	  amount	  of	  exploration	  
devoted	  to	  the	  open	  arms	  relative	  to	  that	  to	  the	  enclosed	  arms	  This	  was	  quantified	  
by	  two	  indices:	  (i)	  percentage	  of	  time	  spent	  in	  the	  open	  arms	  and	  (ii)	  percentage	  of	  
entries	  into	  in	  the	  open	  arms.	  
	  
Marble	  burying	  test	  
Mice	   (3	   months	   old)	   were	   placed	   individually	   in	   a	   standard	   shoebox	   cage	  
(internal	  dimensions	  265	  x	  160	  x	  140	  mm,	  L	  x	  W	  x	  H;	  floor	  area	  424	  cm2)	  without	  a	  lid	  
but	  with	  a	  filter	  top	  so	  that	  mice	  could	  not	  cling	  to	  the	  cage	  lid.	  The	  cage	  contained	  
20	   opaque	   (black	   or	   blue)	   glass	   marbles	   evenly	   spaced	   on	   a	   5	   cm	   thick	   layer	   of	  
sawdust.	  The	  mice	  were	  left	  in	  the	  cage	  with	  marbles	  for	  a	  30-­‐min	  period	  after	  which	  
the	   test	   was	   terminated	   by	   removing	   the	   mice	   from	   the	   cage.	   An	   overhead	  
photograph	   was	   taken	   of	   the	   cage,	   converted	   to	   grayscale	   in	   Photoshop	   and	  
imported	  into	  imageJ.	  The	  dimension	  of	  an	  uncovered	  marble	  were	  measured	  using	  
the	  particle	  analyze	  function.	  Using	  the	  uncovered	  marble	  as	  a	  baseline,	  the	  image	  of	  
the	  interior	  of	  the	  cage	  was	  thresholded	  and	  the	  particle	  analyze	  function	  was	  used	  
to	  count	  the	  number	  of	  marbles	  in	  which	  greater	  than	  33%	  of	  the	  area	  was	  covered.	  
This	  method	  insured	  an	  unbiased	  counting	  strategy.	  Each	  mouse	  was	  used	  only	  once	  
in	  the	  experiment.	  
	  
Rotarod	  test	  
Mice	  (3	  months	  old,	  10	  Slitrk5-­‐/-­‐	  and	  9	  wild	  type)	  were	  tested	  for	  three	  trials	  
in	   the	   same	   daily	   schedule,	   with	   intervals	   of	   20	   min	   between	   trials,	   for	   three	  
consecutive	   days	   (nine	   trials	   total).	   Mice	   were	   tested	   rotating	   the	   rotarod	  
(Economex,	   Columbus	   Instruments)	   at	   the	   following	   speeds:	   6	   rpm	   without	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acceleration	   (low	   speed),	   12	   rpm	   without	   acceleration	   (high	   speed),	   and	   4	   rpm	  
(baseline)	   with	   the	   acceleration	   of	   0.2	   rpm/s	   over	   2	   minutes.	   The	   total	   time	   on	  
rotarod	   before	   falling	   was	   determined	   in	   seconds	   and	   statistical	   analysis	   was	  
performed	  using	   a	   two-­‐tailed	   Student’s	   t-­‐test	   for	   the	   constant	   speed	  and	   two-­‐way	  
Anova	  with	  repeated	  measures	  for	  rotation	  with	  acceleration.	  
	  
Cylinder	  test	  
Mice	  (3	  months	  old,	  10	  Slitrk5-­‐/-­‐	  and	  9	  wild	  type)	  were	  individually	  placed	  in	  a	  
clear	   cylinder	   (diameter	   14	   inches	   and	   height	   19	   inches)	   and	   videotaped	   with	   a	  
reflective	  mirror	  for	  5	  minutes.	  Vertical	  rearings	  (the	  number	  of	  instances	  the	  mouse	  
lifted	  both	  of	  its	  front	  limbs	  off	  the	  surface,	  supporting	  its	  weight	  on	  the	  hind	  limbs)	  
were	  counted.	  The	   total	   time	  that	  each	  mouse	  spent	   rearing	  on	   its	  hind	   limbs	  was	  
scored.	  The	  time	  the	  mouse	  spent	  on	  its	  hind	  limbs	  is	  presented	  as	  percent	  of	  total	  
time	  in	  the	  cylinder.	  
	  
Golgi	  impregnation	  and	  tracing	  	  
We	   impregnated	  fresh	  brains	   in	  Golgi-­‐cox	  using	  the	  FD	  Rapid	  GolgiStain	  Kit	  
(Neurodigitech)	  solution	  for	  14	  d	  at	  25	  °C	  in	  the	  dark	  and	  then	  transferred	  them	  to	  
30%	   sucrose	   at	   4	   °C	   for	   72	   h.	  We	   prepared	   150-­‐μm	   coronal	   serial	   sections	  with	   a	  
vibrotome;	   slides	   were	   soaked	   in	   50%	   sucrose	   and	   air-­‐dried	   for	   72	   h	   in	   the	   dark.	  
Quantitative	  microscopy	  was	  performed	  on	  a	  Microbrightfield	  imaging	  system.	  Two	  
hundred	   striatal	   neurons	   were	   chosen	   by	   systemic	   random	   sampling,	   and	   40	  
‘traceable’	  neurons	  for	  each	  genotype	  were	  reconstructed	  three	  dimensionally	  with	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We	   killed	   4 month-­‐old	   mice	   by	   pentobarbital	   anesthesia	   to	   obtain	  
corticostriatal	  slices	  for	  electrophysiological	  recordings.	  Coronal	  brain	  slices	  (400	  μm)	  
were	   made	   on	   a	   vibrotome	   (Campden	   Instruments)	   and	   submerged	   in	   artificial	  
cerebrospinal	  fluid	  in	  a	  brain-­‐slice	  keeper	  (Scientific	  Systems	  Design)	  for	  90	  min	  at	  25	  
°C	  and	  gassed	  with	  95%	  O2,	   5%	  CO2	  before	   transfer	   to	   the	   recording	  chamber.	  The	  
artificial	  cerebrospinal	  fluid	  contained	  118	  mM	  NaCl,	  2.5	  mM	  KCl,	  10	  mM	  glucose,	  1	  
mM	  NaH2PO4,	  3	  mM	  CaCl2,	  2	  mM	  MgCl2	  and	  25	  mM	  NaHCO3.	  100	  μM	  picrotoxin	  was	  
included	   in	   the	   recording	   solution.	  Recording	  electrodes	  were	   filled	  with	  2	  M	  NaCl	  
solution,	   and	   population	   spikes	   were	   recorded	   from	   the	   striatum	   with	   the	   IE-­‐210	  
amplifier	   (Warner	   Instruments)	   using	   Digidata	   1440A	   and	   pClamp	   10	   software	  
(Molecular	  Devices)	  at	  32	  °C.	  For	  synaptic	  stimulation,	  we	  placed	  bipolar	  electrodes	  
in	  the	  white	  matter	  between	  the	  cortex	  and	  the	  striatum	  to	  activate	  corticostriatal	  
fibers.	   Population	   spike	   amplitude	   was	   calculated	   by	   the	   mean	   of	   the	   amplitude	  
from	  the	  first	  peak	  positivity	  to	  the	  peak	  negativity	  of	  the	  population	  spike	  and	  the	  
amplitude	   of	   the	   peak	   negativity	   of	   the	   population	   spike	   to	   the	   second	   peak	  
positivity.	   The	   presynaptic	   fiber	   volley	   amplitude	   was	   measured	   as	   a	   difference	  
between	   the	   initial	   positive	   and	   the	   following	   negative	   peak.	   Three	   consecutive	  
responses	  were	  averaged	  for	  measuring	  the	  spike	  and	  fiber	  volley	  amplitude.	  Paired-­‐
pulse	  responses	  were	  evoked	  at	  interstimulus	  intervals	  of	  20,	  40,	  80,	  120	  and	  200	  ms	  
using	  a	  stimulation	   intensity	  of	  0.9	  mA.	  Paired-­‐pulse	  ratio	   is	  defined	  as	  the	  ratio	  of	  
second	   population	   spike	   amplitude	   to	   the	   first	   population	   spike	   amplitude.	  
Population	   spike	   amplitudes	   were	   analyzed	   by	   Clampfit	   software	   (Molecular	  
Devices).	  
	  
Endocytosis	  assay	  	  
To	  measure	  AMPAR	  endocytosis	  endogenous	  GluA1	  or	  GluA2	  receptors	  were	  
live	  labeled	  using	  mouse	  antibodies	  at	  a	  dilution	  of	  1:100	  for	  10-­‐15	  min	  at	  37°C.	  After	  
a	   brief	  wash	   in	   pre-­‐warmed	   DMEM,	   neurons	  were	   either	   returned	   to	   conditioned	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media	   or	   stimulated	   for	   3	  minutes	  with	   100	  µM	  AMPA	   and	   50	   µM	  APV	  or	   50	   µM	  
NMDA,	  washed	   in	  DMEM,	   returned	   to	   conditioned	  medium	  and	   incubated	   for	   the	  
different	   periods	   of	   time.	   After	   endocytosis	   had	   occurred,	   neurons	   were	   fixed	   in	  
3.7%	   formaldehyde	   for	   15	   minutes	   at	   room	   temperature	   (RT).	   Remaining	   surface	  
receptors	  were	  labeled	  with	  Alexa647	  anti	  mouse	  at	  a	  dilution	  of	  1:300	  for	  20	  min	  at	  
RT.	  After	  20	  min	  with	  gentle	  agitation	  and	  PBS,	  cells	  were	  permeabilized	  with	  0.2%	  
Triton-­‐X	   for	   6	  min	  with	   gentle	   agitation.	   Endocytosed	   receptors	  were	   labeled	  with	  
Alexa568	  at	  a	  dilution	  of	  1:300	  for	  20	  min	  at	  RT.	  Images	  of	  a	  given	  fluorophore	  were	  
obtained	   with	   the	   same	   exposure	   times.	   Quantification	   of	   endocytosis	   was	  
performed	  with	  ImageJ,	  GFP	  was	  used	  as	  a	  mask	  to	  measure	  both	  internalization	  and	  
surface	   signaling	  within	   the	   exact	   same	   area.	   The	   experiments	   done	  with	   neurons	  
from	  WT	  and	  KO,	   co-­‐immunolabeling	  with	  Tuj	  antibody	   (β-­‐Tubulin)	  was	  performed	  
and	  this	  was	  used	  as	  a	  mask	  to	  measure	  intensity	  of	  internalized	  and	  surface	  signal	  
within	   the	   exact	   same	   area.	   Quantification	   was	   performed	   blind.	   Internalization	  
index	  =	  ((Inter	  /	  (Intern	  +	  Surface))*100.	  	  
	  
Surface	  biotinylation	  and	  degradation	  assay	  
Surface	  biotinylation	  was	  performed	  to	  specifically	  detect	  receptors	  present	  
in	  the	  plasma	  membrane.	  Cultured	  neurons	  were	  placed	  on	  ice	  and	  rinsed	  two	  times	  
with	   PBS	   containing	   1mM	  MgCl2	   and	   2.5	  mM	  CaCl2	   (PBS++)	   followed	  by	   incubation	  
with	  1mg/ml	  of	  sulfo-­‐NHS-­‐S-­‐biotin	  (Pierce	  Chemical,	  Rockford,	  IL)	  on	  ice	  with	  gentle	  
agitation.	   Biotin	   solution	   was	   initially	   prepared	   100mg/ml	   in	   DMSO	   and	   further	  
diluted	   to	   1mg/ml	   in	   PBS++.	   Unbound	   biotin	   was	   quenched	   with	   50mM	   Glycine	  
solution	   in	   PBS++	   two	   times	   for	   5	  minutes.	   Cells	   were	   then	   lyzed	   and	   biotinylated	  
proteins	   were	   pulled	   down	   using	   streptavidin-­‐conjugated	   sepharose	   beads	   (from	  
Pierce)	   over-­‐night	   at	   4°C	   with	   rotation	   and	   analyzed	   by	   immunoblot	   as	   described	  
previously.	  For	  degradation	  assay,	  after	  surface	  biotinylation	  cells	  were	  re-­‐incubated	  
at	  37°C	  for	  a	  given	  amount	  of	  time	  before	  lysis.	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Coculture	  assay	  
The	   co-­‐culture	   assay	   was	   adapted	   from	   elsewhere	   [211].	   Primary	  
hippocampal	   neuronal	   cultures	   from	   E16	   mice	   were	   used	   for	   synapse	   formation	  
assays.	   Transfected	  COS7	   cells	  were	   added	   to	   hippocampal	   neurons	   at	   6-­‐7	   days	   in	  
vitro.	  After	  1-­‐2	  days	  of	  co-­‐culture,	  cells	  were	  fixed	  in	  3.7%	  formaldehyde	  for	  15	  min	  
at	   RT.	   Synapse	   formation	   was	   determined	   by	   quantifying	   co-­‐immunostaining	  
between	  the	  presynaptic	  marker	  synapsin	  and	  transfected	  COS7	  cells,	  that	  were	  not	  
in	  contact	  with	  neuronal	  dendrites	  that	  were	  visualized	  with	  dendritic	  marker	  MAP2.	  
Images	  were	  acquired	  using	  a	  Nikon	  TE2000	   inverted	   fluorescente	  microscope	  and	  
quantification	   was	   done	   using	   ImageJ.	   For	   quantification,	   first	   the	   COS7	   area	   was	  
selected,	  and	  then	  either	  a	  tau	  image,	  or	  an	  over-­‐exposed	  synapsin	  picture	  was	  used	  
to	  select	  the	  area	  to	  quantify	  synapsin	  staning.	  A	  MAP2	  image	  was	  used	  to	  remove	  
puncta	   associated	   with	   neuronal	   dendrites.	   Afterwards,	   a	   threshold	   image	  
highlighted	   the	   synapsin	   puncta	   only	   within	   the	   target	   area	   (overlapping	   tau,	  
contacting	  COS7	  and	  not	  contacting	  MAP2).	  This	  image	  was	  used	  to	  measure	  puncta	  
intensity	  (ImageJ	  mean	  intensity)	  as	  well	  number	  (manual	  particle	  picker).	  
	  	  
Object	  placement	  test	  of	  spatial	  memory	  
Before	   starting	   object	   placement	   task,	   mice	   were	   acclimated	   to	   the	   open	  
field	  apparatus,	  for	  2	  days	  before	  testing.	  The	  first	  day	  of	  acclimation	  consisted	  of	  a	  
10-­‐min	  open	  field	  trial;	  the	  second	  day	  consisted	  of	  a	  5-­‐min	  open	  field	  trial.	  Testing	  
consisted	  of	  two	  trials,	  the	  sample	  trial	  (T1)	  and	  recognition	  trial	  (T2)	  separated	  by	  a	  
15	   minute	   inter	   trial	   interval	   (ITI).	   During	   the	   T1	   trial,	   the	   mouse	   explored	   two	  
identical	  objects	  (objects	  1	  and	  2)	  at	  one	  end	  of	  an	  open	  field	  that	  consisted	  of	  two	  
Lego	  trees	  for	  5	  min.	  During	  the	  T2	  trial,	  the	  mouse	  explored	  the	  same	  two	  objects,	  
with	   object	   1	   in	   the	   original	   location	   and	   object	   2	   in	   a	   new	   location.	   Object	   start	  
locations	   and	   new	   object	   locations	   were	   counterbalanced	   across	   mice	   and	   trials.	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Trials	  were	  recorded	  and	  analyzed	  using	  the	  Noldus	  Ethovision	  XT	  software	  (Noldus	  
Information	   Technology,	   Leesburg,	   VA,	   USA).	   An	   area	   of	   0.5	   cm	   surrounding	   the	  
objects	  was	   delineated	   using	   the	   software,	   and	   object	   exploration	  was	   defined	   as	  
when	  the	  nose	  of	  the	  mouse	  was	  within	  this	  object	  surround	  area.	  	  
	  
Morris	  Water	  Maze	  
Spatial	   reference	   memory	   was	   assessed	   in	   a	   78	   cm	   diameter	   watermaze	  
filled	  with	  opaque	  white	  water	   and	  with	   visual	   external	   cues.	   Before	   experimental	  
acquisition,	  one	  habituation	   session	  was	  performed.	   This	   consisted	  of	   allowing	   the	  
mice	  to	  swim	  for	  60	  seconds	  until	  they	  found	  a	  hidden	  platform	  that	  was	  submerged	  
1cm	  bellow	  the	  water	  surface	  in	  the	  center	  of	  one	  of	  the	  four	  quadrants	  of	  the	  pool.	  
Once	   they	   found	   the	  platform,	   they	  were	  allowed	   to	   sit	  on	   it	   for	  10	   seconds.	   If	   an	  
animal	  failed	  to	  find	  the	  platform	  in	  the	  allotted	  time	  it	  was	  placed	  on	  the	  platform	  
by	   the	   experimenter	   for	   10	   seconds	   (both	   during	   habituation	   and	   acquisition).	  
During	  acquisition	  mice	  received	  4	  training	  trials	  per	  day	  during	  4	  days	  with	  an	  inter-­‐
trial	   interval	   of	   approximately	   15-­‐20	  minutes.	   Latency	   to	   find	   the	   hidden	   platform	  
was	  recorded.	  After	  4	  days	  of	  training	  a	  24	  hour	  probe	  trial	  was	  conducted	  to	  test	  if	  
the	  mice	  had	   learned	   the	  spatial	   location	  of	   the	  platform.	   In	   this	   trial	   the	  platform	  
was	  removed	  and	  mice	  were	  allowed	  to	  swim	  for	  60	  seconds.	  The	  time	  spent	  in	  each	  
of	   the	   four	   quadrants	  was	  measured	   and	   the	   percent	   time	   the	  mice	   spent	   on	   the	  
target	  quadrant	  was	  used	  as	  an	   indication	  of	  memory.	  Statistical	  analysis	  was	  done	  
using	   SPSS	   software	   and	   ANOVA	   test	   with	   repeated	   measures	   with	   post-­‐Hoc	  
Bonferroni	  test	  was	  performed.	  
	  
Chapter	  3	  –	  Slitrk5	  as	  a	  new	  key	  player	  for	  CNS	  function	  
	   111	  
RESULTS	  	  
Bioinformatic	  analysis	  of	  the	  Slitrk	  protein	  family	  
There	   are	   six	   Slitrk	   genes	   in	   humans	   that	   are	   conserved	   in	   euteleostomi,	  
which	  comprises	  most	  vertebrates,	  commonly	  known	  as	  bony	  vertebrates	  (Figure	  2	  
Chapter	  1).	  An	  alignment	  analysis	  of	  the	  human	  Slitrk	  protein	  sequences	  (using	  the	  
ClustalW2	   website	   [212]),	   reveals	   a	   modest	   40%	   similarity	   within	   the	   members	  
(Table	   1,	   accessions:	   Q96PX8,	   Q9H156,	   O94933,	   Q8IW52,	   O94991,	   Q9H5Y7).	  
Interestingly,	  Slitrk2	  and	  Slitrk5	  are	  the	  most	  similar	  with	  a	  total	  protein	  homology	  of	  
49%.	  Slitrk2	  was	  the	  only	  member	  shown	  to	  have	  synaptogenic	  activity	  in	  a	  coculture	  
assay	  and	  my	  own	  findings	  suggest	  that	  Slitrk5	  has	  the	  same	  capability	  (see	  following	  
sections)	   [83].	   LRR-­‐containing	   synaptogenic	   proteins	   (such	   as	   LRRTM	   or	   NGLs)	  
interact	   via	   their	   extracellular	   LRR	   domains,	   with	   pre-­‐synaptic	   proteins	   and	  
contribute	  to	  synaptic	  formation	  and	  stability	  [90,97,98].	  It	  is	  not	  surprising	  then	  that	  
the	   highest	   homology	   between	   Slitrk2	   and	   Slitrk5	   is	   amongst	   the	   extracellular	  
domain	  with	  53%	  identity,	  also	  the	  highest	  observed	  in	  the	  family	  (Table	  2).	  In	  fact,	  it	  
is	   at	   the	   intracellular	   domain	   that	   Slitrks	   diverge	   the	   most,	   with	   an	   average	  
homology	  of	  only	  21%	  (and	  39%	  for	  Slitrk2	  and	  Slitrk5),	  suggesting	  that	  Slitrks	  might	  
interact	  with	  similar	  extracellular	  ligands	  but	  mediate	  different	  intracellular	  signaling	  
cascades	  (Table	  3).	  The	  homology	  is	  higher	  on	  the	  C-­‐terminal	  tail	  of	  Slitrk2-­‐6	  where	  it	  
goes	  up	  to	  58%.	  This	  region	  contains	  a	  conserved	  tyrosine	  that	  resembles	  the	  last	  15	  
amino	  acids	  of	   Trk	   (Y791	   in	  human	  TrkA)	   and	   spans	   the	  Trk	  PLC-­‐γ	   site	   [8].	   PLC-­‐γ	   is	  
recruited	  and	  activated	  by	  phosphorylated	  Trks	  and	  leads	  to	  the	  release	  of	  Ca2+	  from	  
internal	   stores	   and	   PKC	   activation,	   that	   ultimately	   modulates	   synaptic	   plasticity,	  
channel	  activity	  and	  activates	  downstream	  transcription	  factors	  [2,39,213].	   If	  Slitrks	  
can	   recruit	   PLC-­‐γ	   is	   still	   an	  open	  question.	   In	   addition,	   Slitrk2,	   3	   and	  5	   share	  more	  
similarities	   with	   Trk	   receptors	   in	   that	   they	   contain	   an	   NPxY	   motif	   near	   their	  
intracellular	   juxtamembrane	   region.	  Phosphorylation	  of	   the	  NPxY	  motif	   serves	  as	  a	  
binding	  site	  for	  adaptor	  proteins	  such	  as	  Shc	  (that	  initiates	  Ras	  and	  phosphoinositide	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3	   kinase	   downstream	   signaling)	   [41,42,44]	   and	   it	   can	   also	   signal	   for	   endocytosis	  
[214].	  The	  stretch	  of	  amino	  acids	  that	  spans	  the	  NPxY	  motif	  in	  human	  Slitrk5	  shares	  
25%	  amino	  acid	  identity	  with	  the	  TrkA	  NPxY	  region,	  and	  higher	  than	  60%	  with	  Slitrk2,	  
and	  3	  suggesting	  they	  might	  also	  recruit	  Shc	  and	  other	  adaptor	  proteins	  that	  could	  
initiate	  intracellular	  signaling	  cascades.	  The	  only	  Slitrk5	  residue	  reported	  to	  undergo	  
phosphorylation	   is	   the	   Y833,	   in	   a	   proteomic	   screen	   performed	   with	   HeLa	   cells.	  
However,	  the	  function	  and	  conservation	  of	  this	  site	  still	  needs	  to	  be	  clarified	  [215].	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Table&1:&Alignment&of&human&Slitrk&proteins&
Name% Length& Name& Length& Alignment%&
score&
Slitrk1% 696& Slitrk2& 845& 41&
Slitrk1% 696& Slitrk3& 977& 37&
Slitrk1% 696& Slitrk4& 837& 39&
Slitrk1% 696& Slitrk5& 958& 38&
Slitrk1% 696& Slitrk6& 840& 36&
Slitrk2% 845& Slitrk3& 977& 44&
Slitrk2% 845& Slitrk4& 837& 43&
Slitrk2% 845& Slitrk5& 958& 49&
Slitrk2% 845& Slitrk6& 840& 38&
Slitrk3% 977& Slitrk4& 837& 40&
Slitrk3% 977& Slitrk5& 958& 39&
Slitrk3% 977& Slitrk6& 840& 38&
Slitrk4% 837& Slitrk5& 958& 44&
Slitrk4% 837& Slitrk6& 840& 40&
Slitrk5% 958& Slitrk6& 840& 39&
& & & Average% 40%
!
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Table2:(Alignment(of(extracellular(domain(of(human(Slitrk(proteins(
Name% Length% Name% Length% Alignment%score%
Slitrk1% 605( Slitrk2( 600( 44(
Slitrk1% 605( Slitrk3( 626( 39(
Slitrk1% 605( Slitrk4( 600( 42(
Slitrk1% 605( Slitrk5( 624( 40(
Slitrk1% 605( Slitrk6( 582( 41(
Slitrk2% 600( Slitrk3( 626( 48(
Slitrk2% 600( Slitrk4( 600( 48(
Slitrk2% 600( Slitrk5( 624( 53(
Slitrk2% 600( Slitrk6( 582( 43(
Slitrk3% 626( Slitrk4( 600( 46(
Slitrk3% 626( Slitrk5( 624( 46(
Slitrk3% 626( Slitrk6( 582( 41(
Slitrk4% 600( Slitrk5( 624( 50(
Slitrk4% 600( Slitrk6( 582( 45(
Slitrk5% 624( Slitrk6( 582( 43(
% ( ( Average% 45%
!
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!
Table&3:&Alignment&of&intracellular&domain&of&human&Slitrk&proteins&
Name% Length& Name& Length& Alignment%&score&
Slitrk1% 53& Slitrk2& 203& 5&
Slitrk1% 53& Slitrk3& 302& 22&
Slitrk1% 53& Slitrk4& 198& 5&
Slitrk1% 53& Slitrk5& 273& 18&
Slitrk1% 53& Slitrk6& 212& 5&
Slitrk2% 203& Slitrk3& 302& 31&
Slitrk2% 203& Slitrk4& 198& 26&
Slitrk2% 203& Slitrk5& 273& 39&
Slitrk2% 203& Slitrk6& 212& 25&
Slitrk3% 302& Slitrk4& 198& 22&
Slitrk3% 302& Slitrk5& 273& 22&
Slitrk3% 302& Slitrk6& 212& 23&
Slitrk4% 198& Slitrk5& 273& 25&
Slitrk4% 198& Slitrk6& 212& 26&
Slitrk5% 273& Slitrk6& 212& 27&
& & & Average% 21%
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Generation	  of	  Slitrk5-­‐/-­‐	  mouse	  and	  Slitrk5	  expression	  
In	  order	  to	  understand	  the	  function	  of	  Slitrk	  genes	  we	  decided	  to	  focus	  our	  
attention	  in	  the	  member	  of	  the	  family	  that	  is	  most	  strongly	  and	  widely	  expressed	  in	  
the	   brain,	   the	   Slitrk5	   [118].	   We	   decided	   to	   generate	   a	   Slitrk5	   knockout	   mouse	  
(Slitrk5-­‐/-­‐)	  and	  analyze	  its	  behavior	  in	  order	  to	  obtain	  insights	  about	  Slitrk5’s	  function.	  
Analysis	  of	   the	  genomic	  structure	  of	  slitrk5	  gene	  revealed	  that	   the	  coding	  region	   is	  
localized	  to	  a	  single	  exon.	  Using	  Velocigene	  technology	  [216],	  we	  replaced	  the	  entire	  
encoding	   exon	   with	   lacZ	   gene	   (Figure	   1a).	   The	   expression	   analysis	   of	   lacZ	  
demonstrated	   that	   Slitrk5	   is	   widely	   expressed	   throughout	   the	   central	   nervous	  
system,	   including	   cortex	   and	   striatum	   (Figure	   1b).	   Co-­‐staining	   with	   a	   neuronal	  
marker	  NeuN	   showed	   that	   Slitrk5	   expression	   is	   restricted	   to	   neurons	   and	   that	   the	  
majority	   of	   neurons	   express	   Slitrk5	   (Figure	   1c).	   We	   developed	   a	   custom	   made	  
antibody	  for	  the	  intracellular	  domain	  of	  Slitrk5	  and	  performed	  western	  blot	  analysis	  
to	   further	   assess	   the	   protein	   distribution	   across	   the	   brain.	   We	   can	   observe	   how	  
Slitrk5	   is	  expressed	  at	  similar	   levels	   in	  the	  cortex,	  striatum	  and	  hippocampus	   in	  the	  
adult	  murine	  brain	  (4	  month	  old)	  (Figure	  2).	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Figure	  1:	  Targeted	  inactivation	  of	  Slitrk5	  in	  mice	  and	  its	  expression	  pattern	  in	  the	  
mouse	   brain.	   a)	   Genomic	   structure	   and	   the	   design	   of	   the	   Slitrk5-­‐knockout,	   lacZ–knock-­‐in	  
mouse.	   The	   entire	   open	   reading	   frame	   (ORF)	   is	   localized	   to	   exon	   2	   (Ex2);	   exon	   1	   (Ex1)	   is	  
noncoding.	   The	   Slitrk5-­‐encoding	   region	   was	   replaced	   with	   lacZ	   downstream	   of	   the	   signal	  
sequence	  cleavage	  site.	  WT,	  wild-­‐type;	  KO,	  knockout.	  b)	  X-­‐gal	  staining	  of	  mouse	  brain	  tissue,	  
showing	  ubiquitous	  expression	  of	   lacZ	   in	   the	  gray	  matter	  of	   the	  various	  parts	  of	   the	  brain,	  
including	  cortex	  and	  striatum.	  Cx,	  cortex;	  St,	  striatum;	  Hp,	  hippocampus;	  cc,	  corpus	  callosum;	  
Th,	  thalamus;	  Cbl,	  cerebellum.	  The	  higher	  magnification	  image	  shows	  the	  distribution	  of	  lacZ-­‐
expressing	   cells	   in	   the	   striatum	   of	   the	   Slitrk5-­‐knockout,	   lacZ–knock-­‐in	   mouse.	   c)	  
Immunostaining	   of	   cortex	   and	   striatum	  with	   antibodies	   to	   β-­‐galactosidase	   (anti–β-­‐gal)	   and	  
NeuN	  (anti-­‐NeuN),	  indicating	  that	  the	  majority	  of	  neurons	  express	  Slitrk5.	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Figure	   2.	   Slitrk5	   antibody	   characterization	   and	   expression	   across	   the	   brain.	   a)	  
mouse	  cortical	  neuronal	  cultures	  and	  b)	  brain	  lysates	  showing	  Slitrk5	  expression	  from	  Slitrk5-­‐
/-­‐	   (KO)	   and	  wild-­‐type	   (WT)	   animals.	  As	   a	  positive	   control	   lysates	   from	  293	   cells	   transfected	  
with	   FlagSlitrk5	   and	   SlitrkGFP	   were	   used.	   As	   expected,	   Slitrk5GFP	   is	   shifted	   upwards,	  
considering	   the	   additional	   GFP	   tag.	   c)	   Western	   blot	   of	   Slitrk5	   expression	   across	   the	   brain	  
from	  adult	  (4	  month	  old)	  mice	  (Cortex,	  Striatum	  and	  Hippo	  (hippocampus)).	  Tubulin	  was	  used	  
as	  a	  control.	  Slitrk5	  is	  similarly	  expressed	  in	  these	  brain	  regions.	  
	  
Slitrk5-­‐/-­‐	   mice	   were	   born	   in	   accordance	  with	  mendelian	   distribution.	   Gross	  
anatomical	   and	   thorough	   histological	   examination	   of	   young	   Slitrk5-­‐/-­‐	   mice	   did	   not	  
show	   any	   abnormalities.	   However,	   the	   analysis	   of	   older	   Slitrk5-­‐/-­‐	   mice	   revealed	   a	  
behavioral	   phenotype.	   Starting	   at	   4-­‐6	  months	   of	   age,	   Slitrk5-­‐/-­‐	   mice	   develop	   facial	  
hair	   loss	  and	  severe	  skin	   lesions.	  Over	   time	   these	   lesions	  produced	  ulceration	  with	  
hemorrhage	   (Figure	  3a).	   The	  penetrance	  of	   this	  phenotype	   increases	  with	  age	  and	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most	  of	  the	  knockout	  as	  well	  as	  the	  heterozygous	  mice	  are	  affected.	  The	   lesions	   in	  
heterozygous	  mice	  are	  similar	  to	  those	  in	  homozygous	  animals	  but	  their	  emergence	  
is	  delayed	  by	  7-­‐9	  months.	  We	  hypothesized	  that	  this	  phenotype	  could	  be	  the	  result	  
of	  excessive	  grooming.	  The	  lesions	  were	  not	  found	  in	  the	  wild	  type	  littermates	  even	  
if	   they	  were	  housed	   in	   the	   same	  cage	  with	  Slitrk5-­‐/-­‐	   knockout	  mice,	   indicating	   that	  
this	  phenotype	  can	  be	  attributed	  to	  self-­‐grooming.	  This	  type	  of	  behavior	  is	  similar	  to	  
that	   previously	   observed	   in	   mice	   deficient	   for	   the	   Sapap3	   gene	   [217].	   Targeted	  
deletion	   of	   this	   gene,	   which	   encodes	   a	   postsynaptic	   scaffold	   protein,	   leads	   to	  
compulsive	   overgrooming	   behavior,	   increased	   anxiety,	   and	   response	   to	   selective	  
serotonin	  reuptake	  inhibitors	  [217].	  
The	   grooming	   behavior	   of	   Slitrk5-­‐/-­‐	   mice	   was	   assessed	   by	   counting	   the	  
number	  and	  the	  length	  of	  grooming	  events	  in	  the	  knockout	  and	  wild	  type	  littermates	  
before	  any	  lesions	  or	  hair	  loss	  developed,	  to	  exclude	  the	  overgrooming	  as	  a	  result	  of	  
irritation	  in	  a	  wound	  area.	  Our	  data	  demonstrated	  a	  significant	  increase	  in	  the	  length	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Figure	   3.	   Facial	   lesions,	   OCD-­‐like	   behavior	   and	   its	   alleviation	   with	   fluoxetine	  
treatment	  in	  Slitrk5-­‐knockout	  mice.	  a)	  Phenotypic	  characteristic	  of	  Slitrk5−/−	  mice:	  excessive	  
grooming	   leads	   to	   severe	   facial	   lesions.	   b)	   Time	   spent	   grooming	   in	   Slitrk5−/−	   mice	   (n	   =	   9)	  
compared	  to	   their	  wild-­‐type	   littermates	   (n	  =	  8)	  before	  and	  after	   treatment	  with	   fluoxetine.	  
Error	  bars	  depict	  the	  s.e.m.	  c)	  Anxiety-­‐related	  behavior	  of	  Slitrk5−/−	  and	  WT	  mice	  in	  the	  open-­‐
field	  test.	  Percentage	  of	  time	  spent	  in	  the	  center	  and	  entries	  into	  the	  center	  of	  the	  open	  field	  
are	  shown.	  d),	  Anxiety-­‐related	  behavior	  of	  Slitrk5	  mice	  in	  the	  elevated	  plus	  test.	  Percentage	  
of	   time	   spent	   in	   open	   arms	   is	   shown.	   Total	   traveled	   distance	   is	   not	   different	   between	  
knockout	   and	  wild	   type	   littermates.	   All	   open-­‐field	   results	   are	   presented	   as	  means	   ±	   s.e.m.	  
determined	  from	  analysis	  of	  20	  mice	  per	  genotype	  e)	  OCD-­‐like	  behavior	  of	  Slitrk5	  mice	  in	  the	  
marble	   burying	   test.	   Percentage	   of	   marbles	   in	   which	   greater	   than	   33%	   of	   the	   area	   was	  
covered	  are	   shown.	  All	   results	  are	  presented	  as	  means	  ±	  SEM	  determined	   from	  analysis	  of	  
eight	  mice	  per	  genotype.	  
	  
	  
As	   OCD	   is	   linked	   to	   a	   deficit	   in	   serotonin	   production,	   and	   since	   selective	  
serotonin	   reuptake	   inhibitors	   (SSRI)	   are	   the	   major	   therapeutic	   agents	   for	   this	  
disorder,	   we	   sought	   to	   test	   the	   effect	   of	   chronic	   fluoxetine	   on	   overgrooming	  
behavior	  in	  Slitrk5-­‐/-­‐	  mice.	  Indeed,	  treatment	  of	  Slitrk5-­‐/-­‐	  mice	  with	  fluoxetine	  led	  to	  a	  
significant	  reduction	  in	  the	  length	  of	  grooming	  compared	  to	  pre-­‐treated	  animals.	  The	  
length	  of	   grooming	   in	  Slitrk5-­‐/-­‐	  mice	  after	   fluoxetine	   treatment	  was	   the	   same	  as	   in	  
wild	   type	   littermates.	   The	   length	   of	   grooming	   events	   in	   wild	   type	   mice	   was	   not	  
affected	   by	   fluoxetine	   (Figure	   3b).	   Thus,	   treatment	   of	   Slitrk5-­‐/-­‐	   mice	   with	   an	   SSRI	  
rescues	  the	  compulsive	  behavior	  in	  these	  animals.	  	  
	  
Slitrk5-­‐/-­‐	  mice	  display	  anxiety-­‐like	  behaviors	  
In	  order	  to	  determine	  whether	  Slitrk5-­‐/-­‐	  mice	  exhibited	  additional	  behavioral	  
phenotypes	   that	   also	   occur	   in	   OCD	   related	   conditions,	   we	   assessed	   anxiety-­‐like	  
behaviors	   in	   these	  mice.	  We	  performed	  the	  elevated	  plus	  maze	  and	  the	  open	   field	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tests,	   standard	   measures	   of	   anxiety-­‐like	   behavior	   that	   places	   subjects	   in	   conflict	  
situations.	   In	   comparison	   with	   littermate	   wild	   type	   mice,	   Slitrk5-­‐/-­‐	   mice	   displayed	  
decreased	  exploratory	  behavior	  as	  demonstrated	  by	  a	  reduction	  in	  the	  percentage	  of	  
time	   spent	   in	   the	   center	   compartment	   and	   the	   number	   of	   entries	   into	   the	   center	  
compartment	   in	   the	   open	   field	   test	   (Figure	   3c),	   and	   by	   reduction	   of	   time	   spent	   in	  
open	  arms	   in	  the	  elevated	  plus	  maze	  test	   (Figure	  3d).	  This	  reduction	   in	  exploration	  
could	  not	  be	  explained	  by	  changes	  in	  locomotor	  activity,	  as	  there	  were	  no	  significant	  
differences	  in	  total	  distance	  traveled.	  To	  further	  assess	  the	  behavioral	  consequences	  
of	  Slitrk5	  inactivation,	  we	  also	  tested	  Slitrk5-­‐/-­‐	  mice	  in	  a	  marble	  burying	  paradigm,	  a	  
behavioral	  task	  that	  assesses	  both	  OCD-­‐like	  and	  anxiety-­‐related	  behaviors.	  We	  found	  
that	   Slitrk5-­‐/-­‐	   mice	   displayed	   an	   increase	   in	   marble	   burying	   behavior,	   which	   is	  
consistent	  with	  the	  findings	  that	  this	  mouse	  models	  core	  symptoms	  in	  OCD	  spectrum	  
disorders	  (Figure	  3e).	  We	  also	  assessed	  motor	  function	  in	  Slitrk5-­‐/-­‐	  mice	  by	  using	  the	  
cylinder	  test	  (data	  not	  shown)	  and	  by	  measuring	  the	  latency	  to	  fall	  from	  the	  rotarod	  
and	  found	  no	  difference	   in	  gross	  motor	  skills	  and	  no	   impairment	   in	  motor	   learning	  
compared	  to	  the	  wild	  type	  mice,	   indicating	  that	  these	  functions	  are	  not	  affected	   in	  
Slitrk5-­‐/-­‐	  mice	  (Figure	  4).	  	  
	  
	  
Figure	   4.	  Motor	   coordination	   in	   Slitrk5	  mice	   in	   the	   rotarod	   test.	   a)	  Rotarod	   test	  
with	  acceleration.	  Mice	  were	  tested	  for	  3	  consecutive	  days,	  3	  trials	  per	  day.	  Baseline	  speed	  is	  
a)# c)#b)#
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4	  rpm,	  acceleration	  is	  0.2	  rpm/s	  for	  2	  min.	  Statistical	  analysis	  was	  performed	  using	  two-­‐way	  
Anova	  with	  repeated	  measures.	  Both	  Slitrk5	  mice	  and	  wild	  type	  controls	  have	  the	  capacity	  of	  
motor	  learning	  (P	  <	  0.001).	  There	  is	  no	  difference	  in	  motor	  learning	  ability	  between	  the	  two	  
groups	   for	   the	   duration	   of	   the	   test	   (P	  =	   0.4)	   and	   for	   each	   individual	   day	   (P	  =	   0.5).	  b)	   Low	  
speed	   (6	   rpm)	   rotarod	   test	  without	  acceleration.	   Statistical	   analysis	  was	  performed	  using	  a	  
two-­‐tailed	   Student’s	   t-­‐test.	   c)	   High	   speed	   (12	   rpm)	   rotarod	   test	   without	   acceleration.	  
Statistical	   analysis	   was	   performed	   using	   a	   two-­‐tailed	   Student’s	   t-­‐test.	   All	   results	   are	  
presented	  as	  means	  ±	   SEM	  determined	   from	   the	   analysis	   of	   nine	  wild	   type	   and	   ten	  Slitrk5	  
mice.	  
	  
Slitrk5-­‐/-­‐	  mice	  have	  impaired	  striatal	  function	  
Since	   cortico-­‐striatal	   circuitry	   has	   been	   previously	   implicated	   in	   the	  
pathogenesis	  of	  OCD,	  we	  performed	  detailed	  anatomical,	  histological	  and	  functional	  
analyses	   of	   cortex	   and	   striatum	   in	   Slitrk5-­‐/-­‐	   mice.	   Initially,	   we	   evaluated	   the	  
difference	   in	   baseline	   activity	   of	   selected	   brain	   regions	   between	   wild	   type	   and	  
Slitrk5-­‐/-­‐	  mice	  by	  assessing	  FosB	  expression,	  an	  established	  marker	  for	  neural	  activity	  
[218].	   FosB	  was	   found	   to	   be	   upregulated	   exclusively	   in	   the	   orbitofrontal	   cortex	   of	  
Slitrk5-­‐/-­‐	  mice	  (Figure	  5	  a,b).	  Other	  brain	  regions	  such	  as	  the	  caudate	  putamen,	  and	  
thalamus	   do	   not	   show	   upregulation	   of	   FosB	   expression.	   These	   findings	   are	   of	  
particular	   interest	   as	   it	   has	   been	   consistently	   shown	   in	   functional	   imaging	   studies	  
that	   there	   is	   an	   increase	   in	   activity	   of	   orbitofrontal	   cortex	   in	   patients	   with	   OCD	  
[126,219,220,221].	   Conversely,	   alterations	   in	   neural	   activity	   in	   the	   thalamus	   have	  
been	  less	  consistent	  [126,220,222].	  
As	  a	  next	   step,	  we	  measured	   the	  volume	  of	   the	   striatum	  relative	   to	  whole	  
brain	   volume	   using	   Cavalieri	   estimation.	   Our	   data	   showed	   that	   the	   volume	   of	  
striatum	   in	  Slitrk5-­‐/-­‐	  mice	  was	   significantly	   reduced.	   In	  both	   young	  and	  old	   animals	  
the	  ratio	  of	  striatal	  volume	  to	  the	  total	  brain	  volume	  was	  decreased,	  while	  volume	  
ratios	  of	  other	  brain	  structures,	  such	  as	  the	  dorsal	  hippocampus	  and	  the	  septum,	  to	  
the	  total	  brain	  volume	  were	  not	  changed,	  indicating	  that	  the	  anatomy	  of	  striatum	  is	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specifically	  affected	  by	  Slitrk5	  deficiency	   (Figure	  3	   c,	   g	  and	  h).	   This	   is	   an	   important	  
finding	   since	   it	   was	   earlier	   reported	   that	   specifically	   the	   volume	   of	   the	   caudate	   is	  
decreased	   in	   some	   patients	   with	   OCD	   [223,224,225],	   though	   this	   finding	   has	   not	  
been	   consistent	   across	   all	  OCD	  patient	   studies	   in	  which	   increased	  or	   no	   change	   in	  
striatal	  volumes	  have	  also	  been	  reported	  [126,220,222].	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Figure	  5.	  Metabolic	  changes	  in	  the	  cortex	  and	  anatomical	  defects	  in	  the	  striatum	  of	  
Slitrk5−/−	  mice.	  a)	  Expression	  of	  FosB	  in	  orbitofrontal	  cortex	  by	  immunostaining	  for	  FosB	  (red)	  
and	  with	  DAPI	  (blue).	  The	  top	  images	  show	  the	  distribution	  of	  FosB	  expression	  in	  the	  various	  
layers	  of	  orbitofrontal	  cortex.	  The	  bottom	  images	  show	  a	  higher	  magnification	  of	   layer	   II	  of	  
FosB	   immunoreactivity	   in	   nuclei.	   b)	  Quantification	   of	   FosB	   expression	   in	   all	   layers	   of	   the	  
orbitofrontal	   cortex.	   c)	   Cavalieri	   estimation	   of	   striatal	   volume	   in	  Slitrk5−/−	   and	  WT	  mice.	  d)	  
Examples	  of	  Golgi	  staining	  and	  Neurolucida	  reconstruction	  of	  striatal	  medium	  spiny	  neurons	  
in	   WT	   and	   Slitrk5−/−	   mice.	   e)	   Sholl	   analysis	   of	   striatal	   medium	   spiny	   neurons	   in	   WT	   and	  
Slitrk5−/−	   mice.	   All	   results	   are	   presented	   as	   means	   ±	   s.e.m.;	   40	   neurons	   per	   genotype.	   f)	  
Fractal	   dimension	   analysis	   of	   striatal	   medium	   spiny	   neurons	   in	   Slitrk5−/−	   and	  WT	  mice.	   All	  
results	  are	  presented	  as	  means	  ±	  s.e.m.;	  40	  neurons	  per	  genotype.	  g)	  h)	  Cavalieri	  estimation	  
of	  septal	  and	  dorsal	  hippocampal	  volume	  in	  Slitrk5−/−	  and	  WT	  mice.	  
	  
Slitrk5-­‐/-­‐	  mice	  have	  impaired	  cortico-­‐striatal	  transmission	  
Because	   Slitrk	   family	   members	   have	   been	   shown	   to	   influence	   neuronal	  
differentiation	  [113,119],	  the	  decreased	  striatal	  volume	  in	  the	  Slitrk5-­‐/-­‐	  mice	  may	  be	  
accounted	   for	  by	  altered	  neuronal	  morphology.	  We	  used	  Golgi	   staining	   to	  visualize	  
individual	   medium	   spiny	   neurons	   of	   the	   striatum	   in	   Slitrk5-­‐/-­‐	   mice.	   There	   was	   no	  
difference	   in	   striatal	   cell	   soma	   area	   between	   Slitrk5-­‐/-­‐	   mice	   and	   their	   wild	   type	  
littermate	  controls.	  Next,	  we	  analyzed	  dendritic	  complexity	   in	   these	  same	  neurons.	  
Sholl	  analysis	  revealed	  a	  decrease	  in	  dendritic	  arbor	  complexity	  at	  50	  µm	  and	  greater	  
distances	   from	   the	   soma	   in	   Slitrk5-­‐/-­‐	   mice	   (Figure	   5	   d,e).	   We	   also	   used	   fractal	  
dimension	  analysis	  to	  quantify	  how	  completely	  a	  neuron	  fills	  its	  dendritic	  field.	  There	  
was	  a	  significant	  decrease	  in	  dendritic	  complexity	  of	  striatal	  neurons	  in	  Slitrk5-­‐/-­‐	  mice	  
(Figure	  5f).	  Although	  the	  striatum	  contains	  two	  equally	  abundant	  sub-­‐populations	  of	  
medium	   spiny	   neurons,	   which	   are	   classified	   based	   on	   neuropeptides	   that	   they	  
produce	  and	  the	  dopamine	  receptors	   that	   they	  express	   (D1	  and	  D2),	  distinguishing	  
between	   these	   two	   types	   of	   cells	   is	   technically	   challenging	   [226].	   However,	   in	   our	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detailed	   comparative	   analysis	   of	   40	   randomly	   selected	   medium	   spiny	   neurons	   in	  
Slitrk5-­‐/-­‐	   mice,	   we	   found	   no	   evidence	   for	   a	   bimodal	   distribution	   in	   their	   dendritic	  
complexity.	   These	   data	   suggest	   that	   there	   is	   no	   selective	   deficit	   of	   arborization	   in	  
one	  sub-­‐population	  of	  medium	  spiny	  neurons,	  but	  rather	  indicate	  a	  general	  deficit	  in	  
all	  medium	  spiny	  neurons	  equally.	  	  
	  
Figure	  6.	  Deficiency	   in	   corticostriatal	   transmission	   in	  Slitrk5−/−	  mice	   is	  mediated	  
by	   changes	   in	   glutamate	   receptor	   composition.	   a)	   Immunostaining	   of	   primary	   striatal	   rat	  
neurons	   (infected	  with	   Flag-­‐Slitrk5	   lentivirus	   and	   transfected	  with	  PSD95	   fused	   to	  mCherry	  
(PSD95-­‐cherry))	   in	   culture	   with	   cortical	   neurons	   (isolated	   from	   transgenic	   mice	   that	  
ubiquitously	   express	   green	   fluorescent	   protein)	   with	   Flag-­‐specific	   antibody	   (anti-­‐Flag).	   The	  
arrow	   points	   to	   a	   magnified	   area	   (bottom	   images)	   that	   represents	   the	   synapses	   between	  
cortical	  and	  striatal	  neurons.	  b)	  Western	  blot	  analysis	  of	  NMDA	  and	  AMPA	  receptor	  subunits	  
in	  the	  striatum	  of	  5-­‐month-­‐old	  Slitrk5−/−	  and	  WT	  mice.	  The	  protein	  amounts	  are	  adjusted	  to	  
the	  expression	  of	  actin.	  c)	  Population	  spike	  amplitude	   in	  Slitrk5−/−	  mice	   (n	  =	  11,	   from	   four	  
mice)	   and	   matched	   WT	   mice	   (n	   =	   9,	   from	   four	   mice).	   The	   population	   spike	   amplitude	   is	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significantly	   lower	   in	  Slitrk5−/−	  mice,	  P	  <	  0.01,	   repeated-­‐measures	  analysis	  of	  variance.	  The	  
inset	   shows	   examples	   of	   corticostriatal	   population	   spike	   amplitudes	   in	   Slitrk5−/−	  mice	   and	  
matched	  WT	  mice.	  d)	  Average	  paired-­‐pulse	  ratios	  of	  the	  population	  spike	  in	  Slitrk5−/−	  mice	  
(n	  =	  17,	  from	  five	  mice)	  and	  matched	  WT	  mice	  (n	  =	  17,	  from	  five	  mice).	  There	  is	  no	  significant	  
difference	  in	  the	  paired-­‐pulse	  ratio	  between	  Slitrk5−/−	  mice	  and	  wild-­‐type	  mice.	  
	  
We	   subsequently	   assessed	   the	   cellular	   localization	   of	   Slitrk5	   in	   striatal	  
neurons,	   and	   found	   Slitrk5	   in	   dendritic	   spines	   that	   are	   positive	   for	   PSD95	   in	   co-­‐
cultures	   of	   cortical	   and	   striatal	   neurons	   (Figure	   6	   a).	   Next,	   we	   examined	   the	  
expression	  levels	  of	  glutamate	  receptors	  in	  the	  striatum	  and	  demonstrated	  that	  they	  
are	  downregulated	  in	  old	  slitrk5-­‐/-­‐	  mice.	  Indeed,	  GluN2A,	  GluN2B,	  GluA1,	  and	  GluA2	  
protein	   levels	   were	   decreased	   by	   20-­‐60%,	   with	   no	   significant	   changes	   in	   PSD95	  
levels.	  We	  found	  these	  changes	  in	  both	  the	  total	  lysates	  (Figure	  6b)	  and	  also	  in	  PSD	  
enriched	  fractions	  of	  synaptosomes	  (Figure	  7).	  	  
	  
	  
Figure	  7.	  The	  expression	  of	  NMDA	  and	  AMPA	  receptors	  subunits	  is	  downregulated	  in	  
PSD	  enriched	  fractions	  (synaptosomes)	  in	  Slitrk5	  mice.	  Each	  column	  represents	  data	  obtained	  
using	   combined	   together	   striatums	   from	  3	  mice	   (Slitrk5	  or	  wild	   type	   controls).	   The	  protein	  
levels	  are	  adjusted	  to	  the	  expression	  of	  actin.	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Due	  to	  these	  findings,	  we	  investigated	  whether	  Slitrk5-­‐/-­‐	  mice	  have	  deficiency	  
in	   cortico-­‐striatal	   neurotransmission	   by	   extracellular	   recordings	   in	   acute	   striatal	  
slices.	  We	  have	   recorded	  population	  spikes	   from	  striatum	  by	  stimulating	   the	  white	  
matter	   between	   cortex	   and	   striatum.	   We	   found	   significantly	   reduced	   population	  
spike	  amplitude	   in	  Slitrk5-­‐/-­‐	  mice	  (Figure	  6	  d).	  We	  did	  not	  observe	  any	  difference	  in	  
paired	  pulse	  ratios	  (PPR)	  of	  the	  population	  spike	  in	  Slitrk5-­‐/-­‐	  mice	  and	  their	  wild	  type	  
littermates,	   suggesting	   that	   the	   presynaptic	   mechanisms	   involved	   in	   paired	   pulse	  
facilitation	   is	   not	   responsible	   for	   the	   observed	   difference	   in	   population	   spike	  
amplitude	  (Figure	  6e).	  	  
	  
Slitrk5	  modulates	  surface	  expression	  of	  AMPARs	  
Considering	  the	  temporal	  and	  spatial	  distribution	  of	  Slitrk5	  it	  is	  surprising	  to	  
find	  a	  phenotype	  at	  such	  a	  late	  developmental	  stage.	  The	  functions	  this	  protein	  plays	  
in	  younger	  mice	  as	  well	  as	  in	  other	  brain	  structures	  are	  unknown.	  To	  gain	  insight	  into	  
the	   developmental	   expression	   of	   the	   Slitrk5-­‐/-­‐	   mouse	   phenotype,	   we	   decided	   to	  
perform	  whole-­‐cell	   patch	   clamp	   recordings	   in	   the	   striatum	  of	   younger	   (P20)	  mice.	  
Surprisingly	   we	   found	   that	   AMPA	   receptor	   currents	   were	   increased	   in	   the	   young	  
Slitrk5-­‐/-­‐	  mice	   (Figure	  8	  a)	  whereas	  NMDA	   receptor	   currents	  were	   indistinguishable	  
between	   Slitrk5-­‐/-­‐	   and	   wild	   type	   littermates	   (Figure	   8	   b).	   Moreover,	   we	   also	  
measured	  non-­‐NMDA	  spontaneous	  excitatory	  post-­‐synaptic	  activity	   in	  Slitrk5-­‐/-­‐	  and,	  
even	   though	   we	   did	   not	   observe	   differences	   in	   EPSC	   frequency,	   the	   non-­‐NMDA	  
amplitude	   was	   enhanced	   in	   the	   Slitrk5-­‐/-­‐	   (Figure	   8	   c).	   The	   increase	   in	   AMPAR	  
amplitude	  was	  not	  due	  to	  pre-­‐synaptic	  changes	  since	  PPR	  was	  normal	  in	  these	  mice,	  
thus	   suggesting	   that	   in	   the	   absence	   of	   Slitrk5	   there	   is	   an	   overall	   increase	   in	   the	  
synaptic	  pool	  of	  AMPARs.	  Moreover,	  it	  implies	  that	  the	  behavioral	  defects	  observed	  
in	  the	  older	  Slitrk5-­‐/-­‐	  are	  a	  consequent	  of	  a	  development	  deregulation	  of	  glutamate	  
receptors.	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Figure	   8.	   Electrophysiological	   analysis	   of	   young	   Slitrk5-­‐/-­‐	   mice.	   a)	   b)	  Whole-­‐cell	  
patch-­‐clamp	  recordings	  were	  made	  from	  a	  single	  striatal	  neurons	  of	  P20	  Slitrk5-­‐/-­‐	  mice	  and	  wt	  
littermate	   controls.	   c)	   Average	   mEPSC	   frequency	   and	   amplitude	   of	   striatal	   medium	   spiny	  
neurons	  of	  Slitrk5-­‐/-­‐	  mice	  (n	  =	  5)	  and	  wild-­‐type	  littermates	  (n	  =	  5).	  The	  mEPSC	  amplitude	  but	  
not	  frequency	  was	  significantly	  higher.	  d)	  Input–output	  curves	  of	  the	  CA3–CA1	  fEPSPs	  in	  the	  
2	  month	  old	  Slitrk5-­‐/-­‐	  mice	  (n=	  6)	  and	  wt	  littermate	  controls	  (n	  =	  6).	  
	  
To	  directly	  investigate	  if	  Slitrk5	  modulates	  surface	  expression	  of	  AMPARs,	  we	  
assessed	   the	  surface	   levels	  of	   these	   receptors	   in	  cultured	  striatal	  neurons	   in	  which	  
Slitrk5	   levels	  were	  manipulated.	  We	   hypothesized	   that	   Slitrk5	  may	   act	   to	   stabilize	  
intracellular	  pools	  of	  AMPARs	  or	  simply	  reduce	  surface	  delivery	  of	  these	  receptors.	  
In	   order	   to	   test	   this,	   striatal	   neurons	   were	   transduced	   with	   lentivirus	   carrying	  
FlagSlitrk5	   (or	   GFP	   as	   a	   control)	   and	   surface	   protein	   levels	   were	   measured	   with	  
surface	   biotinylation.	   We	   observed	   that	   Slitrk5	   expression	   led	   to	   a	   decrease	   in	  
surface	  AMPAR	  levels,	  specifically	  surface	  GluA2	  was	  reduced	  to	  40%	  (figure	  9	  a).	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Figure	   9.	   Surface	   levels	   of	   AMPARs	   upon	   Slitrk5	   expression.	   a)	   Striatal	   neurons	  
from	  wt	  mice	  were	  grown	  in	  culture.	  Slitrk5	  levels	  were	  manipulated	  by	  lentiviral	  delivery	  of	  
FlagSlitrk5	  cDNA,	  control	  cells	  were	  transduced	  with	  GFP	  cDNA.	  Surface	  biotinylation	  allowed	  
assessment	  of	  surface	  levels	  of	  AMPARS.	  a)	  Western	  blot	  of	  GluA1	  and	  GluA2	  quantified	  by	  
normalization	   to	   transferrine	   receptor	   (TfnR)	   levels.	   b)	   Similar	   surface	   biotinylation	  
experiment	   using	   hippocampal	   neurons	   from	  Slitrk5-­‐/-­‐	  mice,	   therefore	   in	   this	   condition	   the	  
control	  has	  no	  expression	  of	  Slitrk5.	  
	  
Slitrk5	   is	   highly	   expressed	   throughout	   the	   brain	   including	   in	   the	   striatum,	  
hippocampus	  and	  cortex	  (Figure	  1).	  Therefore	  it	  is	  plausible	  to	  think	  that	  this	  protein	  
plays	   key	   roles	   for	   development	   and	   function	   of	   brain	   regions	   other	   than	   the	  
striatum.	  Glutamate	  receptor	  activity	  in	  the	  hippocampus	  has	  been	  intensely	  studied	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and	   AMPAR-­‐mediated	   hippocampal	   plasticity	   has	   been	   widely	   associated	   with	  
memory	  formation	  and	  learning	  [151,156].	  To	  assess	  if	  Slitrk5	  also	  modulates	  surface	  
AMPAR	   expression	   in	   the	   hippocampus,	   we	   repeated	   the	   previous	   experimental	  
setting	  utilizing	  hippocampal	  neurons	  from	  Slitrk5-­‐/-­‐	  mice	  in	  which	  Slitrk5	  expression	  
was	  rescued	  through	  lentiviral	  delivery	  of	  FlagSlitrk5.	  We	  found	  a	  striking	  reduction	  
in	   the	   expression	   of	   surface	   GluA2	   upon	   Slitrk5	   delivery.	   Surface	   levels	   of	   GluA1	  
appeared	  unchanged	  (Figure	  9	  b).	  
To	  test	  if	  the	  differential	  expression	  of	  AMPARs	  in	  hippocampal	  neurons	  was	  
overall	   reflected	   in	   hippocampal	   function,	   we	   performed	   electrophysiological	  
analysis	  of	  this	  brain	  region	  in	  young	  (2	  month	  old)	  Slitrk5-­‐/-­‐	  mice.	  Consistent	  with	  a	  
higher	  surface	  expression	  of	  AMPARs,	   these	  measures	   revealed	   that	  basal	   synaptic	  
neurotransmission	  in	  CA3-­‐CA1	  were	  increased	  (Figure	  8	  d).	  In	  fact,	  analysis	  of	  Slitrk5	  
expression	  in	  murine	  hippocampus	  across	  development	  revealed	  that	  this	  protein	  is	  
expressed	  as	  early	  as	  embryonic	  day	  17	  (Figure	  10).	  Slitrk5	  levels	  are	  stable	  until	  P5,	  
after	  which	  they	  increase	  to	  reach	  a	  peak	  at	  P15,	  which	  is	  the	  period	  when	  synapse	  
development	   is	   occuring.	   After	   this,	   Slitrk5	   levels	   remained	   stable	   throughout	  
adulthood	   (Figure	   10).	   Interestingly,	   GluA1,	   GluA2	   and	   TrkB	   followed	   a	   similar	  
expression	   pattern,	   peaking	   at	   P15	   and	   being	   maintained	   thereafter	   throughout	  
adulthood.	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Figure	  10.	  Analysis	  of	  Slitrk5	  expression	  across	  development	  and	  comparison	  with	  
other	   developmentally	   regulated	   proteins.	  WT	  mouse	   hippocampus	   protein	   extracts	   from	  
the	  indicated	  developmental	  stages	  (E17	  to	  P90)	  were	  analyzed	  by	  western	  blot	  with	  Slitrk5,	  
GluA1,	   GluA2,	   PSD95	   and	   TrkB	   antibodies	   and	   tubulin	   as	   a	   control.	   In	   order	   to	   obtain	  
sufficient	   amounts	   of	   protein,	   several	   hippocampi	   were	   combined	   for	   the	   following	  
developmental	  stages:	  E17,	  P0	  and	  P5.	  
	  
Slitrk5	  interacts	  with	  PICK1,	  a	  known	  modulator	  of	  GluA2	  trafficking	  
Few	  proteins	  have	  been	  described	  to	  interact	  with	  AMPARs	  and	  modulate	  its	  
location	   and	   traffic.	   Pick1	   is	   a	   cytoplasmic	   protein	   originally	   identified	   as	   a	   PKC	  
binding	   protein,	   that	   has	   been	   shown	   to	   bind	  GluA2	   and	  GluA3	   subunits	   [227].	   In	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hippocampal	   neurons,	   activity-­‐dependent	   phosphorylation	   of	   GluA2	   at	   Ser880	  
enhances	   the	   affinity	   of	   this	   subunit	   for	   Pick1,	   promoting	   endocytosis	   of	   GluA2	  
receptors,	   increasing	   the	  proportion	  of	  GluA1	  homomers	  at	   the	   synapses,	   that	   are	  
Ca2+	  permeable	  [228,229].	  	  
Since	  we	  observed	  a	  selective	  reduction	  of	  GluA2	  from	  surface	  hippocampal	  
neurons	   upon	   Slitrk5	   expression,	   and	   Pick1	   has	   been	   described	   to	   affect	   GluA2	  
trafficking	  and	  not	  GluA1,	  we	  hypothesized	   that	   Slitrk5	  may	  alter	  GluA2	   trafficking	  
through	   Pick1	   interactions.	   In	   order	   to	   test	   this,	   HEK293	   cells	  were	   co-­‐transfected	  
with	   cDNA	   of	   FlagSlitrk5	   and	   MycPICK1.	   Indeed	   we	   observed	   that	  
immunoprecipitation	   of	   Pick1	   pulled	   down	   Slitrk5	   (Figure	   11	   a).	   Even	   though	   this	  
data	  suggests	  that	  Slitrk5	  interacts	  with	  GluA2	  through	  Pick1,	  it	  does	  not	  exclude	  the	  
possibility	  that	  Slitrk5	  may	  directly	  interact	  with	  GluA2.	  Therefore,	  we	  co-­‐expressed	  
FlagSlitrk5	  and	  Myc-­‐tagged	  GluA2	  in	  heterologous	  cells.	  We	  found	  that	  in	  this	  system	  
Slitrk5	  and	  GluA2	  interacted	  (Figure	  11	  c).	  The	  interaction	  between	  Slitrk5	  and	  GluA2	  
could	  either	  be	  direct	  or	  mediated	  by	  Pick1	  (which	  is	  endogenously	  expressed	  in	  293	  
cells).	   To	   examine	   if	   Pick1	   regulates	   Slitrk5-­‐GluA2	   interaction	   we	   tested	   this	  
interaction	   in	   the	   presence	   or	   absence	   of	   co-­‐transfected	   Pick1	   (Figure	   11	   c).	   We	  
observed	   that	   expression	   of	   Pick1	   did	   not	   enhance	   Slitrk5-­‐GluA2	   interaction,	  
suggesting	  that	  this	  interaction	  may	  be	  direct.	  
Pick1	  protein	   is	  composed	  of	  two	  acidic	  domains,	  a	  BAR	  and	  a	  PDZ	  domain	  
that	   interacts	   with	   GluA2	   but	   not	   GluA1	   [228].	   In	   order	   to	   map	   the	   domain	   of	  
interaction	  with	  Slitrk5,	  we	  used	  two	  deletion	  constructs	  in	  which	  either	  N-­‐terminal	  
portion	   of	   the	   protein	   (containing	   an	   acidic	   and	   PDZ	   domain)	   or	   the	   C-­‐terminal	  
region	  (containing	  another	  acid	  and	  the	  BAR	  domain)	  were	  removed.	  We	  observed	  
that	   removal	   of	   the	   BAR	   domain,	   which	   mediates	   interactions	   with	   membrane	  
phospholipids,	  did	  not	  alter	  the	  interaction	  with	  Slitrk5.	  However,	  when	  PDZ	  and	  the	  
acidic	  domain	  were	   truncated,	   the	   interaction	  was	   lost	   (Figure	  11	  b).	  This	   suggests	  
that	  one	  or	  both	  of	  these	  domains	  mediate	  the	  interaction	  with	  Slitrk5.	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Figure	   11.	   Slitrk5	   interaction	   with	   Pick1	   and	   GluA2	   subunit.	   a)	   HEK293	   co-­‐
transfected	   with	   FlagSlitrk5	   and	   HAPick1	   were	   subjected	   to	   immunoprecipitation	   with	   HA	  
antibodies.	  Western	  blot	  reveals	  Slitrk5	  and	  Pick1	  interaction.	  b)	  HEK293	  were	  co-­‐transfected	  
with	  Slitrk5GFP	  and	  either	  one	  of	  two	  Pick1	  deletion	  constructs	  (ΔPDZ	  which	  also	  lacks	  the	  N-­‐
terminal	   acidic	   domain	   and	   ΔBAR,	   also	   lacking	   N-­‐terminal	   acidic	   domain).	   BAR	   domain	   is	  
dispensable	   for	   interaction	  with	  Slitrk5.	  d)	  Testing	   if	  Pick1	  enhances	  Slitrk5	   interaction	  with	  
GluA2.	  Co-­‐transfection	  of	  Myc-­‐GluA2	  and	  FlagSlitrk5	  into	  293	  cells	  and	  immunoprecipitation	  
showed	   that	   these	   two	   proteins	   interacted	   in	   this	   system.	   Addition	   of	   HAPick1	   did	   not	  
enhance	  Slitrk5	  and	  GluA2	  interaction.	  
	  
Slitrk5	  interaction	  with	  Pick1	  and	  GluA2	  may	  explain	  the	  reduction	  in	  GluA2	  
surface	   receptors.	   The	   underlying	   mechanisms	   are	   still	   unclear;	   however	   it	   could	  
involve	   either	   a)	   increase	   AMPAR	   endocytosis;	   b)	   decrease	   AMPAR	   recycling;	   c)	  
decrease	   ER-­‐forward	   trafficking	   of	   newly	   synthesized	   AMPARs;	   or	   lastly,	   d)	   Slitrk5	  
could	  simply	  act	  as	  a	  intracellular	  scaffolding	  protein	  such	  as	  ABP/GRIP,	  that	  stabilize	  
AMPARs	   in	   intracellular	   storage	   compartments	   [230,231].	   To	   begin	   to	   test	   these	  
hypotheses,	  we	  started	  by	  measuring	  endocytosis	  of	  GluA1	  and	  GluA2	  by	  modulating	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Slitrk5	  levels.	  In	  order	  to	  accomplish	  this	  we	  developed	  shRNA	  against	  mouse	  Slitrk5.	  
Two	  of	   the	   shRNA	   sequences	   tested	   led	   to	   a	   50%	   knock-­‐down	  of	   Slitrk5	  when	   co-­‐
expressed	   in	   HEK293	   cells.	   Quantification	   of	   endocytosis	   in	   mouse	   hippocampal	  
neurons	   from	  wt	  mice	  co-­‐transfected	  with	   the	  shRNA	  and	  Myc-­‐GluA1	  or	  HA-­‐GluA1	  
revealed	   that	   knocking	   down	   Slitrk5	   did	   not	   affect	   AMPAR	   endocytosis	   (data	   not	  
shown).	   We	   wondered	   if	   the	   lack	   of	   an	   effect	   could	   be	   due	   to	   the	   exogenous	  
expression	  of	  AMPARS.	  Therefore,	  we	  developed	  an	  assay	   to	  measure	  endogenous	  
GluA1	   and	   GluA2	   endocytosis.	   AMPA-­‐mediated	   as	   well	   as	   basal	   and	   NMDA-­‐
dependent	  endocytosis	  occurred	  normally	  in	  hippocampal	  neurons	  transfected	  with	  
shRNA	  for	  Slitrk5	  or	  control	  	  (Figure	  12).	  We	  then	  asked	  if	  these	  results	  could	  be	  due	  
to	   a	   low	   efficiency	   of	   shRNAs.	   Therefore,	  we	   compared	   AMPAR	   endocytosis	   using	  
cultured	   hippocampal	   neurons	   from	   Slitrk5-­‐/-­‐	   and	   WT	   mice	   (from	   heterozygous	  
crosses).	  Also	  in	  this	  setting,	  AMPAR	  endocytosis	  occurred	  with	  a	  similar	  rate	  in	  both	  
groups,	  irrespective	  of	  the	  stimulation	  condition	  or	  the	  time	  point	  used	  (Figure	  12).	  
These	   data	   strongly	   suggests	   that	   the	   mechanism	   by	   which	   Slitrk5	   leads	   to	  
downregulation	   of	   surface	   AMPARs	   is	   not	   through	   modulating	   their	   endocytosis.	  
Future	  studies	  will	  be	  required	  to	  elucidate	  if	  Slitrk5	  affects	  the	  recycling	  of	  AMPARs,	  
the	   forward	   ER-­‐trafficking	   of	   newly	   synthetized	   proteins	   or	   stabilizes	   intracellular	  
pools	  of	  AMPAR.	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Figure	   12.	   Endocytosis	   of	   AMPARs	   occurs	   normaly	   upon	   Slitrk5	   kockdown.	  
Endocytosis	  of	  endogenous	  GluA2	  and	  GluA1	  was	  measured	  using	  an	  immuno-­‐cytochemistry	  
technique.	  Hippocampal	  neurons	  from	  wt	  animals	  (a	  and	  c)	  were	  transfected	  with	  shRNA	  for	  
Slitrk5	   (siSlitrk5)	   or	   a	   scrambled	   shRNA	   (siCtrl);	   or	   neurons	   from	  wild	   type	   (WT)	   or	   Slitrk5	  
knockout	  (KO)	  were	  used.	  Surface	  GluA1	  or	  GluA2	  were	  labeled	  with	  an	  antibody	  recognizing	  
the	  N-­‐terminal	  portion	  of	  this	  protein,	  live	  at	  37°C.	  Neurons	  were	  then	  either	  stimulated	  with	  
AMPA,	   or	   basal	   endocytosis	  was	   analyzed.	   Following	   endocytosis,	   cells	  were	   fixed	   and	   the	  
remaining	   surface	   pool	   of	   AMPARs	   was	   measured	   with	   a	   fluorescent	   secondary	   antibody.	  
Subsequent	   permeabilization	   and	   staining	   with	   another	   fluorescent	   antibody	   labeled	   the	  
internalized	   pool	   of	   AMPARs.	   An	   average	   of	   25	   images	   per	   condition	  were	   analyzed	   using	  
ImageJ	   software	   and	   endocytosis	  was	  measure	   as	   percent-­‐internalized	   pool	   divided	  by	   the	  
sum	  of	  internalized	  and	  surface	  (%Int	  =	  Int/(Int+Surf)).	  Error	  bars	  represent	  s.e.m..	  
	  
Slitrk5-­‐deficient	  mice	  are	  impaired	  in	  spatial	  reference	  memory	  
It	   is	   widely	   accepted	   that	   AMPARs	   mediate	   synaptic	   plasticity	   involved	   in	  
learning	   and	   memory.	   Hippocampal-­‐dependent	   learning	   and	   memory	   tasks	   are	  
dependent	  on	  AMPA	  receptor	  function	  [156].	  Considering	  the	  altered	  expression	  of	  
AMPA	  receptors	   in	  the	  Slitrk5-­‐/-­‐	  mice	  and	  the	  altered	  basal	  synaptic	  transmission	   in	  
CA3-­‐CA1,	   we	   hypothesized	   that	   hippocampal-­‐dependent	   spatial	   learning	   and	  
memory	   could	   be	   impaired.	  We	   tested	   the	   Slitrk5-­‐/-­‐	   mice	   in	   the	   object	   placement	  
task,	  a	  spatial	  episodic	  hippocampal-­‐dependent	  memory	  task.	  This	  task	  explores	  the	  
natural	   exploratory	   activity	   for	   novel	   object	   locations.	   The	   animals	   are	   allowed	   to	  
explore	   two	   identical	   fixed	   objects	   for	   5	   minutes.	   After	   a	   15-­‐minute	   inter-­‐trial	  
interval	   one	   of	   the	   objects	   was	   moved	   to	   a	   new	   location.	   Given	   the	   natural	  
exploratory	  activity	  of	  the	  mice,	  wild	  type	  mice	  tend	  to	  spend	  more	  time	  exploring	  
the	   object	   that	   is	   associated	  with	   a	   new	   context,	   than	   the	   object	   left	   in	   the	   same	  
location.	  When	  we	  tested	  the	  Slitrk5-­‐deficient	  mice	  on	  this	  task,	  along	  with	  their	  wild	  
type	   and	   heterozygous	   littermates.	   We	   observed	   that	   wild	   type	   mice	   spent	  
approximately	  60%	  of	   the	   time	  exploring	   the	  displaced	  object.	  On	   the	  other	  hand,	  
Chapter	  3	  –	  Slitrk5	  as	  a	  new	  key	  player	  for	  CNS	  function	  
	   138	  
Slitrk5-­‐deficient	  mice	  were	  unable	  to	  detect	  the	  object	  had	  been	  moved	  and	  spent	  
an	  equal	  amount	  of	  time	  exploring	  both	  objects	  (Figure	  13	  a).	  
To	  further	  investigate	  the	  role	  of	  Slitrk5	  for	  spatial	  memory	  we	  examined	  the	  
Slitrk5-­‐/-­‐	  mice	   and	   their	  wild-­‐type	   and	  heterozygous	   littermate	   controls	   in	   a	   spatial	  
reference	  memory	  task	  the	  Morris	  Water	  Maze	  (MWM).	  The	  mice	  were	  allowed	  to	  
swim	  for	  60	  seconds	  or	  until	   they	   found	  a	  hidden	  platform	  that	  was	   located	   in	   the	  
center	  of	  an	  arbitrarily	  chosen	  quadrant.	  Slitrk5-­‐/-­‐	  mice	  exhibited	  significantly	  higher	  
latency	   than	   their	   wt	   or	   het	   littermates	   to	   find	   a	   hidden	   platform	   during	   the	  
acquisition	   phase	   of	  MWM	   task	   (Figure	   13	   c).	   Additionally,	  we	  performed	   a	   probe	  
test	   24	  hours	   after	   the	   fourth	   training	  day	  where	   the	  platform	  had	  been	   removed	  
from	  the	  pool	  and	  the	  mice	  were	  allowed	  to	  swim	  freely.	  The	  percent	  time	  spent	  on	  
each	  quadrant	  was	  recorded.	  Slitrk5-­‐/-­‐	  mice	  spent	  approximately	  25%	  of	  the	  time	  on	  
the	   target	   quadrant	   (that	   corresponds	   to	   chance),	   whereas	   their	   wild-­‐type	  
littermates	   spent	   47%	   of	   the	   time	   in	   the	   target	   quadrant,	   a	   difference	   that	   was	  
significant	   (Figure	   13	   b).	   Together,	   the	   behavioral	   analyses	   show	   that	   Slitrk5	   is	  
essential	  for	  normal	  expression	  of	  hippocampal	  spatial-­‐reference	  memory	  tasks.	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Figure	  13.	  Slitrk5-­‐/-­‐	  mice	  exhibit	  spatial	  reference	  learning	  and	  memory	  deficits	   in	  
the	   object	   placement	   and	  morris	   water	  maze	   tasks	   a)	   The	  mean	   object	   exploration	   time	  
during	   test	  phase	   (when	  object	  has	  been	  moved	   to	  a	  new	  context)	   calculated	  as	  a	   ratio	  of	  
time	  spent	  exploring	  novel	  placed	  object	  over	  the	  total	  time	  exploring	  both	  objects.	  Dashed	  
line	  represents	  chance.	  An	  n	  of	  10	  animals	  per	  genotype	  was	  analyzed;	  error	  barrs	  represent	  
s.e.m.	  	  (T-­‐test	  comparing	  WT	  and	  KO	  is	  0.05;	  WT	  and	  het	  is	  0.9).	  b	  and	  c)	  Morris	  water	  maze	  
(MWM)	   task.	  c)	  Acquisition	  phase	  of	  MWM	  task	   showing	   the	  mean	   latency	   to	   find	  a	   fixed-­‐
location	  hidden	  platform	  was	  averaged	  across	  trials.	  Animals	  received	  4	  trials	  per	  day	  during	  
5	  days	  with	  a	  15	  min	  inter-­‐trial	  interval,	  n	  =	  7-­‐10	  (statistical	  analysis	  using	  repetitive	  measures	  
ANOVA	  p	  =	  0.007).	  b)	  Probe	  trial	  of	  MWM	  was	  performed	  24h	  after	  4	  days	  of	  training,	  dashed	  
line	   represents	   chance.	   Shown	   is	   the	   percent	   time	   spent	   exploring	   the	   target	   quadrant	  
(where	  hidden	  platform	  was	  previously	   located)	   for	   the	  duration	  of	   60	   seconds.	   Error	  bars	  
represent	  s.e.m..	  (T-­‐test	  comparing	  WT	  and	  KO	  was	  0.0026,	  comparing	  WT	  and	  Het	  was	  0.3).	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FUTURE	  DIRECTIONS,	  SLITRK5	  A	  MULTITALENTED	  PROTEIN	  
	  
Slitrk5	  induces	  synapse	  formation	  
AMPARs,	   together	   with	   NMDARs	   are	   structural	   components	   of	   excitatory	  
synapses.	  The	  extracellular	  domain	  of	  GluA2	  plays	  a	  critical	   role	   in	  maintaining	   the	  
stability	  of	  excitatory	  synapses	  [232].	  LRRTM2	  is	  another	  LRR-­‐containing	  protein	  that	  
modulates	   surface	   levels	  of	  AMPARs,	  namely	  GluA1.	   In	  addittion,	   LRRTM2	  can	  also	  
induce	   synapse	   formation	   in	   hippocampal	   neurons	   [98].	   Recently,	   a	   study	  
performing	   a	   screen	   for	   new	   synaptogenic	   proteins	   identified	   Slitrk2	   as	   a	   positive	  
candidate	   [83].	   The	  extracellular	   domain	  of	   Slitrk2	   shares	  52%	   identity	  with	   Slitrk5	  
(Table	  2).	  In	  all,	  given	  its	  structural	  characteristics,	  it	  is	  reasonable	  to	  speculate	  that	  
Slitrk5	  could	  also	  induce	  synapse	  formation.	  To	  address	  this	  question,	  we	  performed	  
a	   coculture	   assay	   in	   which	   COS	   cells	   transfected	   with	   Slitrk5	   were	   cultured	   with	  
hippocampal	  neurons	  and	  synapse	  formation	  was	  quantified	  by	  immunostaining	  of	  a	  
pre-­‐synaptic	  marker.	  Neuroligin	  was	   the	   first	   synaptogenic	   protein	   identified	   using	  
this	  method,	  therefore	   it	  was	  used	  as	  a	  positive	  control	  [233].	  Human	  Slitrk5	  cDNA	  
was	  cloned	  fused	  with	  GFP	  or	  RFP	  (FL-­‐Slitrk5).	  A	  construct	  in	  which	  Slitrk5	  lacked	  the	  
intracellular	  domain	  was	  also	  used	  to	  test	   if	  the	  extracellular	  domain	  was	  sufficient	  
to	   induce	   synapse	   formation	   (ECD-­‐Slitrk5)	   (Figure	   14).	   To	   obtain	   a	   quantitative	  
measure	   of	   each	   protein’s	   ability	   to	   instruct	   presynaptic	   differentiation,	   we	  
measured	  the	  amount	  of	  a	  pre-­‐synaptic	  protein,	  synapsin,	  clustering	  associated	  with	  
transfected	  COS	   cells	   and	  not	   associated	  with	  MAP2-­‐positive	  dendrites,	   to	   exclude	  
interneuronal	  synapses	  (Figure	  14	  b).	  Synapsin	   intensity	  was	  also	  quantified	  (Figure	  
14	   c).	   Robust	   synaptogenic	   activity	   for	   FL-­‐Slitrk5,	   ECD-­‐Slitrk5	   and	   Neuroligin	   was	  
observed.	   Interestingly,	   in	   some	   occasions	   FL-­‐Slitrk5	   formed	   clusters	   that	   would	  
juxtapose	   to	   synapsin	   staining	   (Figure	   14	   a).	   Intracellular	   FL-­‐Slitrk5	   appeared	   in	   a	  
puncta-­‐like	   shape,	   characteristic	   of	   early	   endosomes.	   ECD-­‐Slitrk5	   did	   not	   form	  
clusters	  and	  had	  a	  more	  diffuse	  distribution	  compared	  to	  FL-­‐Slitrk5,	  suggesting	  that	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even	   though	   the	   extracellular	   domain	   is	   sufficient	   to	   induce	   pre-­‐synaptic	  
differentiation,	   the	   cytoplasmic	   domain	   is	   critical	   for	   proper	   cellular	   targeting.	   In	  




Figure	   14.	   Slitrk5	   induces	   synapse	   formation.	   a)	   COS7	   cells	   transfected	   with	   the	  
indicated	   constructs	   cultured	   with	   hippocampal	   neurons	   were	   immunostained	   with	   a	   pre-­‐
synaptic	   partner	   synapsin	   (shown	   either	   in	   green	   or	   red	   as	   indicated).	   b)	  Quantification	   of	  
synapsin	  number	  clustering	  with	   transfected	  cells	   that	  were	  not	   juxtaposing	  MAP2	  staining	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(not	   shown).	   c)	  Quantification	  of	   synapsin	   intensity	  of	   clusters	  contacting	   transfected	  COS7	  
cells.	   An	   average	   of	   30	   cells	   per	   condition	  was	   quantified	   and	   3	   independent	   experiments	  
were	   performed.	   Error	   bars	   represent	   s.e.m..	   RFP	   (red	   fluorescent	   protein);	   Slitrk5ECD	  
(truncated	  Slitrk5	  containing	  only	  the	  extracellular	  domain);	  Nrl1	  (Neuroligin	  1).	  
	  
	  
Slitrk5	  modulates	  TrkB	  trafficking	  and	  signaling	  
Considering	   the	   shared	   structural	   characteristics	   between	   the	   Slitrk	   family	  
and	   Trks	   such	   as	   the	   LRR	   domains,	   the	   intracellular	   tyrosines,	   as	   well	   as	   the	  
similarities	   between	   the	   Slitrk5	   knockout	   mouse	   and	   the	   BDNF	   knockout	   mouse	  
(both	   show	   selective	   atrophy	   of	   the	   striatum),	   together	   with	   the	   previously	  
described	   associations	   between	   Slitrk6	   and	   neurotrophin	   system	   [117],	   we	   were	  
curious	   to	   see	   if	   Slitrk5	   and	   TrkB	   (the	   Trk	   member	   most	   highly	   expressed	   in	   the	  
brain)	   crosstalk.	   We	   started	   by	   looking	   at	   their	   cellular	   localization.	   Since	   our	  
custom-­‐made	   antibody	   is	   improper	   for	   immunocytochemistry	   analysis,	   we	  
transfected	   cortical	   neurons	   with	   FlagSlitrk5.	   We	   added	   antibodies	   to	   the	  
extracelluar	  domain	  of	  TrkB	  live	  to	  neurons	  as	  well	  as	  a	  Flag	  antibody	  and	  stimulated	  
the	   neurons	   with	   BDNF	   to	   induce	   TrkB	   internalization.	   After	   a	   short	   incubation	  
period	  we	  observed	  that	  these	  proteins	  co-­‐localized	  (Figure	  15).	  In	  fact,	  the	  fraction	  
of	  TrkB	  co-­‐localizing	  with	  Slitrk5	  upon	  BDNF	  treatment	  (65.9	  ±	  2.7%)	  is	  almost	  double	  
than	  with	   EEA1	   (39.2%	  ±	   3.3%)	   at	   the	   similar	   time	  point	   (Chapter	   2).	   It	   is	   possible	  
that	  the	  phenotype	  observed	  in	  the	  Slitrk5	  knockout	  mouse	  may	  be	  in	  part	  mediated	  
by	   deficient	   neurotrophin	   signaling,	   and	   that	   would	   explain	   the	   similarities	   with	  
BDNF	  knockout	  mice.	  Moreover,	  the	  fact	  that	  Slitrk5	  localizes	  mainly	  to	  endosome-­‐
like	   compartments	   and	   it	   can	   modulate	   trafficking	   of	   AMPARs,	   may	   indicate	   that	  
Slitrk5	  can	  also	  modulate	  the	  endocytic	  trafficking	  of	  TrkB.	  To	  test	  this	  we	  performed	  
a	  TrkB	  degradation	  assay	  with	   cortical	  neurons	   transduced	  with	  FlagSlitrk5	  or	  GFP.	  
We	  assessed	  single	  BDNF	  treatment	  time	  point	   (180	  min)	  that	  had	  previously	  been	  
shown	   to	   induce	   significant	   degradation	   of	   TrkB	   (Chapter	   2).	   Indeed,	  we	   observed	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that	  over-­‐expression	  of	  Slitrk5	  delayed	  BDNF-­‐mediated	  TrkB	  degradation	  (Figure	  16).	  
Treatment	   of	   control	   neurons	   with	   BDNF	   led	   to	   an	   average	   of	   45.1	   ±	   8.9%	  
degradation	   index,	   as	   compared	   with	   the	   untreated	   control.	   However,	  
overexpression	  of	  Slitrk5	  led	  to	  a	  degradation	  of	  only	  72.1	  ±	  3.4%.	  Thus,	  Slitrk5	  slows	  
BDNF	  induced	  degradation	  of	  TrkB	  receptor	  by	  a	  still	  unknown	  mechanism	  (p	  value	  =	  
0.03).	  
	  We	   showed	   in	   chapter	   2	   that	   NT4	   delays	   TrkB	   degradation	   and	   this	   is	  
reflected	   in	   prolonged	   signaling	   of	   the	   lingering	   receptor.	  We	   then	   asked	   if	   over-­‐
expression	  of	  Slitrk5	  would	  also	  lead	  to	  prolonged	  signaling.	  To	  our	  surprise,	  higher	  
levels	  of	  Slitrk5	  were	  associated	  with	  reduced	  phosphorylation	  of	  Akt	  and	  Erk1/Erk2,	  
upon	  BDNF	  treatment.	   In	  the	  absence	  of	  BDNF,	   in	  both	  conditions	  (Slitrk5	  and	  GFP	  
over-­‐expression)	   the	   basal	   phosphorylation	   levels	   of	   these	   proteins	   were	  
undetectable.	  Thus,	  our	  data	  suggests	  that	  Slitrk5	  co-­‐localizes	  with	  TrkB	  to	  the	  same	  
compartment,	   where	   they	   seem	   to	   interact.	   Moreover,	   we	   observed	   that	   Slitrk5	  
modulates	  BDNF	  mediated	  trafficking	  of	  TrkB	  and	  it	  impairs	  its	  signaling.	  Considering	  
the	  similarities	  of	  the	  BDNF	  and	  Slitrk5	  null	  mice	  we	  would	  expect	  that	  Slitrk5	  would	  
promote	   TrkB	   signaling.	   It	   is	   possible	   that,	   as	   it	   has	   been	   observed	   with	   other	  
proteins	   of	   the	   trafficking	   machinery,	   manipulating	   the	   levels	   of	   these	   proteins	  
either	   by	   over-­‐expression	   or	   down-­‐regulation,	   has	   a	   similar	   effect	   in	   delaying	   the	  
trafficking	   flow.	   Slitrk5	  might	   sort	   TrkB	   to	   an	   alternate	   compartment	   not	   coupled	  
with	   the	   lysosomal	   degradation	   neither	   with	   signaling	   partners.	   Analysis	   of	   the	  
endocytic	  trafficking	  of	  TrkB	  in	  a	  Slitrk5	  knockout	  background	  will	  help	  us	  elucidate	  
these	  questions.	  
Chapter	  3	  –	  Slitrk5	  as	  a	  new	  key	  player	  for	  CNS	  function	  




Figure	   15.	   Co-­‐localization	   of	   Slitrk5	   with	   TrkB.	   DIV5	   cortical	   neurons	   were	  
transfected	   with	   FlagSlitrk5.	   Antibodies	   against	   Flag	   and	   TrkB	   were	   live	   fed	   to	   cortical	  
neurons	  to	  label	  surface	  fraction	  of	  these	  proteins.	  Neurons	  were	  then	  treated	  with	  BDNF	  for	  
15	  min	  prior	  fixation	  and	   immunocytochemistry.	  Quantification	  of	  co-­‐localization	  was	  made	  
with	  Metamorph	   by	   initially	   counting	   total	   TrkB	   puncta,	   followed	   by	   TrkB	   puncta	   that	   co-­‐




Figure	  16.	  Slitrk5	   slows	  BDNF	   induced	  degradation	  of	  TrkB	   receptor.	  Degradation	  
assay	   of	   TrkB	   receptor	   with	   cortical	   neurons	   transduced	   or	   not	   with	   FlagSlitrk5,	   control	  
neurons	  were	  transduced	  with	  GFP.	  Neurons	  were	  treated	  or	  not	  (untreated)	  with	  50	  ng/ml	  
of	   BDNF	   for	   180	  min.	   Untreated	   cells	   were	   also	   surface	   biotinylated	   an	   incubated	   for	   the	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same	  amount	  of	  time	  without	  neurotrophin.	  a)	  Western	  blot	  showing	  TrkB	  after	  avidin	  pull	  
down.	  b)	   Quantification	   of	   an	   average	   of	   2	   experiments	  was	   done	  with	   ImageJ.	   Error	   bars	  
represent	  s.e.m.	  Treatment	  of	  control	  neurons	  with	  BDNF	   led	  to	  an	  average	  of	  45.1	  ±	  8.9%	  
degradation	   index,	   as	   compared	   with	   the	   untreated	   control.	   However,	   overexpression	   of	  
Slitrk5	  led	  to	  a	  degradation	  of	  only	  72.1	  ±	  3.4%.	  Thus,	  Slitrk5	  slows	  BDNF	  induced	  degradation	  
of	  TrkB	  receptor	  in	  a	  significant	  manner	  (p	  value	  =	  0.03).	  c)	  Signaling	  mediated	  by	  BDNF	  in	  the	  
presence	  or	   absence	  of	   Slitrk5	  over-­‐expression.	   Lysates	   from	  extracts	   of	   degradation	   assay	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DISCUSSION	  
Taken	  together,	  our	  data	  demonstrate	  that	  targeted	  inactivation	  of	  Slitrk5	  in	  
mice	   leads	   to	   OCD-­‐like	   behavioral	   phenotypes,	   including	   overgrooming	   with	  
elements	  of	   self-­‐mutilation.	  Mechanistically	   Slitrk5	  decreases	   surface	  expression	  of	  
AMPARs	   leading	   to	   altered	   hippocampal	   activity	   that	   was	   reflected	   in	   impaired	  
spatial	   reference	   memory.	   Slitrk5	   also	   induces	   synapse	   formation	   in	   hippocampal	  
neurons.	  
We	  found	  increased	  neuronal	  activity	  in	  the	  orbitofrontal	  cortex	  of	  Slitrk5−/−	  
mice,	  which	  is	  consistent	  with	  functional	  imaging	  findings	  in	  humans	  with	  OCD	  that	  
implicated	   deregulation	   of	   the	   CSTC	   circuitry	   [223,234].	   In	   addition,	   Slitrk5−/−	  mice	  
have	  anatomical	  deficits	  in	  the	  striatum,	  such	  as	  reduced	  striatal	  volume,	  as	  well	  as	  
decreased	   dendritic	   complexity	   of	   striatal	   medium	   spiny	   neurons.	   Although	   this	  
region	   has	   not	   been	   consistently	   found	   to	   be	   altered	   anatomically	   in	   people	   with	  
OCD	   [126,220,222]	   emerging	   literature	   suggests	   that	   striatal	   dysfunction	   may	  
underlie	   behavioral	   deficits	   in	   individuals	   with	   OCD	   [234].	   In	   this	   context,	   it	   has	  
recently	  been	  postulated	  that	  striatal	  defects,	  in	  the	  presence	  of	  orbitofrontal	  cortex	  
over-­‐activation,	  could	  lead	  to	  deficits	  in	  thalamic	  filtering	  or	  imbalance	  in	  the	  direct	  
and	   indirect	   pathways	   of	   the	   basal	   ganglia	   (figure	   2	   Chapter	   1)	   [235].	   Given	   the	  
ubiquitous	  neuronal	  expression	  of	  Slitrk5,	  we	  were	  surprised	  by	  the	  selective	  effect	  
observed	  on	  the	  orbitofrontal	  cortex	  and	  on	  striatal	  neurons.	  Analysis	  of	  the	  caudate	  
putamen	   and	   thalamus	   did	   not	   show	   upregulation	   of	   FosB	   expression.	  Moreover,	  
fractal	  dimension	  analysis	  of	  dentate	  granular	  neurons	   in	   the	  hippocampus	  did	  not	  
show	   significant	   dendritic	   arborization	   defects	   in	   this	   region.	   On	   one	   hand	   this	  
selectivity,	  is	  reminiscent	  of	  the	  effect	  of	  other	  proteins	  such	  as	  huntingtin,	  which	  is	  
also	  widely	  expressed	   in	  the	  CNS,	  but	  alterations	   in	  the	  huntingtin	  protein	  result	   in	  
functional	  defects	  predominantly	  in	  striatal	  and	  cortical	  neurons,	  directly	  leading	  to	  
Huntington’s	  disease	  pathology	   [236].	  On	   the	  other	  hand,	   it	   is	   possible	   that	   Slitrk5	  
may	   form	   a	   signaling	   complex	   with	   corticostriatal-­‐specific	   proteins,	   which	   could	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explain	  these	  region-­‐specific	  effects.	  These	  findings	  prompt	  us	  to	  look	  more	  carefully	  
not	   only	   at	   other	   brain	   regions	   but	   also	   at	   the	   developmental	   expression	   of	   the	  
Slitrk5−/−	  mouse	  phenotype.	  We	  started	  by	  analyzing	  young	  Slitrk5−/−	  mice	  and	  then	  
expanded	  our	  studies	  to	  different	  brain	  structures	  that	  also	  highly	  express	  Slitrk5.	  
Electrophysiological	   analysis	   of	   the	   striatum	   of	   young	   Slitrk5−/−	  mice	   (P20),	  
revealed	   increased	   basal	   synaptic	   transmission	   that	   was	   selectively	   mediated	   by	  
AMPARs,	   and	  not	  NMDARs,	   suggesting	   that	  even	   though	   subtle,	   the	  Slitrk5−/−	  mice	  
already	   show	   some	   brain	   abnormalities	   early	   in	   development.	   It	   is	   possible	   that	  
overall	   activation	  of	   the	  brain	  due	   to	  an	   increase	   in	   surface	  expression	  of	  AMPARs	  
led	  to	  cytotoxicity	  that	  was	  reflected	  in	  a	  smaller	  brain	  at	  5	  month	  old	  and	  an	  even	  
smaller	  striatal	  volume	  leading	  to	  OCD-­‐like	  behaviors.	  The	  elevated	  AMPAR	  currents	  
in	   the	   striatum	   of	   young	   Slitrk5−/−	   mice	   suggest	   that	   Slitrk5	   somehow	   stabilizes	  
AMPARs	  intracellularly,	  leading	  to	  a	  decrease	  in	  the	  surface	  pool	  of	  these	  receptors.	  
We	   tested	   this	   hypothesis	   by	   overexpressing	   Slitrk5	   cDNA	   in	   striatal	   cultured	  
neurons	   and	   quantifying	   the	   surface	   pool	   of	   AMPARs.	   Indeed	   we	   observed	   that	  
lentiviral	   delivery	   of	   FlagSlitrk5	   led	   to	   a	   reduction	   in	   surface	   AMPARs,	  
complementing	  the	  electrophysiological	  findings.	  Interestingly,	  over-­‐activation	  of	  the	  
glutamatergic	  system	  within	  the	  CSTC	  pathway	  has	  been	  implicated	  in	  humans	  with	  
OCD	   [152].	   Research	   groups	   that	   investigated	   the	   actions	   of	   anti-­‐glutamatergic	  
drugs,	  namely	  riluzole,	  alone	  or	  in	  combination	  with	  SSRIS,	  found	  that	  inhibiting	  this	  
pathway	  contributed	  to	  alleviate	  the	  symptoms	  of	  OCD	  [237,238].	  
Changes	   in	   hippocampal	   volume	   have	   been	   associated	   with	   patients	  
suffering	  of	  OCD	  [239].	  Considering	  the	  high	  expression	  level	  of	  Slitrk5	  in	  this	  region	  
we	  decided	  to	  investigate	  the	  mechanism	  of	  action	  of	  Slitrk5	  in	  this	  brain	  structure.	  
We	  analyzed	  mice	  at	  2	  months,	  before	  the	  development	  of	  over-­‐grooming	  behavior,	  
and	   observed	   that	   basal	   synaptic	   transmission	   in	   the	   hippocampus	  was	   enhanced.	  
Similarly	   to	   the	  striatum,	   this	  correlated	  with	  the	  biochemical	  studies	  showing	  that	  
rescuing	  expression	  of	  Slitrk5	  in	  hippocampal	  neurons	  cultured	  from	  Slitrk5−/−	  mice,	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led	   to	   a	   decreased	   AMPAR	   surface	   expression.	   Intriguingly	   we	   found	   a	   selective	  
reduction	   in	   the	   GluA2	   subunit,	   with	   no	   effects	   on	   GluA1	   surface	   levels.	   Of	   all	  
AMPAR	  subunits,	  GluA2	  is	  the	  one	  that	  has	  the	  strongest	  impact	  on	  the	  biophysical	  
properties	  of	  oligomeric	  AMPARs.	  This	   is	  due	   to	   the	  presence	  of	  an	  arginine	   in	   the	  
pore-­‐forming	   sequence	  of	  GluA2,	  whereas	   the	  other	   subunits	   contain	  a	   glutamine,	  
conferring	  impermeability	  to	  bivalent	  cations,	  such	  as	  Ca2+	  [240].	  As	  a	  result,	  GluA2-­‐
lacking	   AMPARs	   are	   strongly	   inwardly	   rectifying	   and	   Ca2+	   permeable	   [230].	   An	  
interesting	   theory	   is	   that	   neurons	   may	   utilize	   Slitrk5	   to	   regulate	   the	   GluA2	  
composition	   of	   surface	   AMPARs	   (synaptic	   and	   extra-­‐synaptic)	   within	   specific	  
contexts	   and	   thus	   change	   the	   cell’s	   output.	   Naturally	   occurring	   GluA2-­‐lacking	  
AMPARs	  appear	  to	  be	  inexistent	  in	  the	  hippocampal	  CA1	  region.	  A	  recent	  study	  that	  
employed	   a	   molecular	   quantification	   of	   subunit	   composition	   of	   AMPARs	   at	   CA1	  
synaptic	  and	  extra-­‐synaptic	  sites	  showed	  that	  virtually	  all	  surface	  receptors	  contain	  
GluA2,	  with	  the	  majority	  comprising	  of	  GluA1GluA2	  heteromers	  and,	  the	  remaining	  
consisting	   of	   GluA2GluA3	   [241].	   However,	   studies	   have	   shown	   that	   in	   certain	  
conditions	   GluA1	   homomers	   can	   appear.	   Analysis	   of	   the	   GluA2-­‐knockout	   mouse	  
have	   shown	   that	   in	   the	   absence	   of	   this	   subunit,	   GluA1	   and	   GluA3	   homomeric	  
receptors	   can	   form	   in	   hippocampal	   neurons	   [242].	   Moreover,	   prolonged	   AMPAR	  
blockade	  in	  cultured	  hippocampal	  neurons,	  leads	  to	  an	  increase	  in	  GluA1	  expression	  
and	   GluA1	   homomeric	   receptors	   at	   synapses	   [243].	   Together,	   and	   given	   the	  
particular	   biophysical	   properties	   of	   AMPARs	   lacking	   GluA2,	   these	   studies	   suggest	  
that	  in	  specific	  contexts	  neurons	  may	  utilize	  mechanisms,	  such	  as	  those	  mediated	  by	  
Slitrk5,	  to	  modulate	  the	  GluA2	  content	  of	  surface	  AMPARs.	  	  
In	   trying	   to	   understand	   the	   mechanisms	   underlying	   Slitrk5-­‐dependent	  
selective	  decrease	  of	  GluA2	  subunit	  surface	  expression,	  we	  found	  that	  Slitrk5	  could	  
interact	  with	   a	   known	  modulator	   of	  GluA2	   traffic,	   Pick1.	   Interestingly,	   a	   truncated	  
form	   of	   Pick1	   protein	   lacking	   the	   PDZ	   domain	   (which	   mediates	   interaction	   with	  
GluA2)	   and	   the	   N-­‐terminal	   acidic	   domain,	   was	   unable	   to	   interact	   with	   Slitrk5,	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suggesting	   that	   the	   binding	   may	   be	   mediated	   by	   the	   PDZ	   domain	   and	   that	   this	  
interaction	  may	  be	  mutually	  exclusive.	  GluA2	  receptors	  are	  anchored	  at	  surface	  and	  
intracellular	   membranes	   by	   ABP/GRIP	   but	   undergo	   cycling	   between	   these	  
membranes	   in	   association	   with	   Pick1	   [229,244].	   Binding	   of	   Pick1	   to	   Slitrk5	   in	  
intracellular	   compartments	   might	   prevent	   Pick1	   interaction	   with	   GluA2	   and	   thus	  
favor	  GluA2	  binding	  to	  ABP/GRIP,	  stabilizing	  AMPARs	  at	  intracellular	  compartments.	  	  
Future	   electrophysiological	   studies	   should	   elucidate	   the	   precise	   subunit	  
composition	  of	  AMPARs	   in	   the	  hippocampus	  of	   the	  Slitrk5−/−	  mouse;	   however,	   our	  
studies	   suggest	   that	   by	   modulating	   both	   expression	   and	   availability	   of	   Slitrk5,	  
neurons	  can	  selectively	  regulate	  the	  biophysical	  properties	  of	  AMPARs.	  
The	   extracellular	   domain	   of	   GluA2	   plays	   a	   critical	   role	   in	   maintaining	   the	  
stability	   of	   excitatory	   synapses,	   and	   also	   contributes	   to	   spine	   size	   and	   density	  
[232,245].	  Recent	   studies	  employing	  screens	   in	  order	   to	   identify	  new	  proteins	   that	  
can	   induce	   synapse	   formation	  have	   found	   a	   prevalence	  of	   LRR-­‐containing	  proteins	  
with	  this	  capability	  (Table	  1	  Chapter	  1)	  [83].	  Slitrk2	  was	  also	  identified	  in	  this	  screen	  
as	  a	  new	  synaptogenic	  protein	   [83].	  The	  extracellular	  domain	  of	  Slitrk2	  shares	  52%	  
identity	  with	   Slitrk5	   (Table	  2).	   In	   all,	   these	  observations	   led	  us	   to	  hypothesize	   that	  
Slitrk5	  may	  also	  induce	  synapse	  formation.	  Indeed	  we	  observed	  that	  when	  expressed	  
in	  COS7	  cells,	  which	  were	  cocultured	  with	  hippocampal	  neurons,	  Slitrk5	  instructs	  the	  
accumulation	   of	   pre-­‐synaptic	   markers	   at	   cell	   contacts.	   We	   also	   found	   that,	   even	  
though	   the	  extracellular	  domain	  of	   Slitrk5	  was	   sufficient	   to	  achieve	   this	   function	   it	  
altered	  the	  cellular	  targeting	  of	  the	  protein.	  Future	  studies	  should	  elucidate	  if	  Slitrk5	  
acts	  like	  other	  LRR-­‐containing	  synaptic	  proteins,	  such	  as	  LRRTM	  or	  NGL,	  binding	  to	  a	  
pre-­‐synaptic	   partner	   in	   order	   to	   induce	   synapse	   formation.	  Ongoing	   studies	   in	   our	  
laboratory	   are	   aiming	   to	   answer	   this	   question	   by	   performing	   mass	   spectromic	  
analysis	  of	  Slitrk5	  binding	  proteins.	  
Considering	  the	  crucial	  function	  Slitrk5	  plays	  for	  efficient	  surface	  expression	  
of	   AMPARs,	   proper	   hippocampal	   functioning	   and	   for	   synapse	   formation,	   we	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hypothesized	   that	   in	   the	   absence	   of	   Slitrk5,	   hippocampal-­‐dependent	   learning	   and	  
memory	  tasks	  would	  be	  compromised.	  We	  tested	  the	  Slitrk5−/−	  mice	  on	  two	  distinct	  
hippocampal-­‐dependent	   tasks:	   the	   novel	   object	   placement	   and	   the	   Morris	   water	  
maze	  task.	  The	  novel	  object	  placement	  task	  allows	  measurement	  of	  the	  memory	  for	  
spatial	  location	  within	  a	  familiar	  arena	  where	  the	  objects	  were	  previously	  explored.	  
This	   spatial	   episodic	   memory	   task	   has	   been	   shown	   to	   depend	   on	   an	   intact	  
hippocampus	   [246].	   Indeed	   we	   observed	   that	   the	   Slitrk5−/−	   mice	   were	   unable	   to	  
recognize	   a	   displaced	   object	   associated	   with	   a	   new	   context.	   At	   2	   month	   old	   the	  
heterozygous	   mice	   showed	   a	   performance	   similar	   to	   wild	   types,	   however,	   at	   3	  
month	   old,	   they	   behaved	   like	   Slitrk5−/−	   (data	   not	   shown),	   suggesting	   that	   Slitrk5	  
dosage	   is	   important	   and	   that	   the	   defects	   are	   developmentally	   regulated.	  We	   then	  
tested	   the	  Slitrk5−/−	  mice	  on	   an	   additional	   hippocampal-­‐dependent	   spatial	   learning	  
task	   the	   Morris	   water	   maze	   [247].	   The	   Slitrk5−/−	   mice	   were	   significantly	   impaired	  
during	   the	   acquisition	   phase	   as	   wells	   as	   on	   a	   24	   hour	   probe	   trial	   in	   this	   task,	  
reinforcing	  the	  importance	  of	  Slitrk5	  for	  spatial	   learning	  and	  memory.	  Interestingly,	  
patients	  with	  OCD,	  also	  display	  learning	  and	  memory	  impairments	  [248,249].	  
Collectively	   these	   studies	   suggest	   that	   Slitrk5	   plays	   critical	   roles	   for	   CNS	  
development	   and	   function.	   In	   the	   absence	   of	   Slitrk5,	   there	   is	   an	   aberrant	  
enhancement	   of	   surface	   AMPARs,	   which	   was	   reflected	   in	   altered	   basal	   synaptic	  
transmission	  of	  key	  CNS	  structures.	  Moreover,	  Slitrk5	  acts	  as	  a	  synaptogenic	  protein	  
critical	   for	   hippocampal-­‐dependent	   learning	   and	   memory.	   These	   developmental	  
abnormalities	  were	  reflected	  in	  behaviors	  that	  recapitulate	  the	  hallmarks	  of	  OCD-­‐like	  
phenotypes:	   repetitive	   overgrooming	   that	   is	   ameliorated	   with	   SSRI	   treatment;	  
enhanced	  orbitofrontal	  cortical	  activation;	  deficient	  cortico-­‐striatal	  transmission	  and	  
morphological	  changes	  in	  the	  medium	  spiny	  neurons	  of	  the	  striatum.	  	  
Future	  genetic	   studies	  with	  OCD	  patients	  will	  be	  determinant	   to	  ultimately	  
link	   Slitrk5	   and	   OCD.	   Previous	   reports	   on	   Slitrk1	   have	   revealed	   the	   difficulties	   of	  
associating	  a	  rare	  genetic	  variant	  with	  a	  psychiatric	  disorder	  [9].	  Their	  low	  frequency,	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together	   with	   the	   inherently	   variability	   associated	   with	   human	   psychiatric	   studies	  
that	   are	   caused	   both	   by	   symptomatic	   variability	   and	   ethnic	   heterogeneity,	  
contribute	   to	   the	  difficulties	  of	  associating	  a	   single	  genetic	  variant	  with	  a	  disorder.	  
Moreover,	   given	   the	   complexity	   of	   human	   psychiatric	   disorders,	   a	   combination	   of	  
genetic	  factors	  rather	  than	  a	  single	  variant	  might	  be	  the	  cause	  of	  a	  given	  condition.	  It	  
is	  possible	  that	  mutations	  in	  Slitrk5	  will	  be	  associated	  with	  a	  selective	  subset	  of	  OCD	  
patients	   with	   specific	   behavioral	   symptoms.	   OCD	   is	   a	   heterogeneous	   disorder	  
composed	   of	   a	   multitude	   of	   symptoms	   [128].	   Even	   though	   the	   Diagnostic	   and	  
Statistical	   Manual	   of	   Mental	   Disorders	   offers	   a	   single	   definition	   for	   OCD,	   it	   is	  
established	  amongst	   researchers	  and	  clinicians	   that	   there	  are	  different	  subtypes	  of	  
OCD	   that	   differ	   not	   only	   in	   symptomology	   but	   also	   in	   susceptibility	   to	  
pharmacological	   treatments	   [250].	   Age	  of	   onset	   in	  OCD	  has	   a	   bimodal	   distribution	  
and	   evidences	   suggest	   that	   early	   onset	   OCD	   is	   distinct	   from	   late	   onset	   OCD	  
[125,251].	   Based	   on	   our	   results	   with	   the	   Slitrk5-­‐/-­‐	   mice,	   it	   would	   be	   interesting	   to	  
know	  if	  Slitrk5	  is	  associated	  with	  a	  specific	  subtype	  of	  OCD	  with	  adult	  onset	  in	  which	  
cognitive	  impairments	  are	  also	  observed.	  
In	   all,	   we	   provide	   a	   new	  mouse	   model	   of	   OCD-­‐like	   behaviors,	   involving	   a	  
previously	  uncharacterized	  neuronal	  transmembrane	  protein	  that	  modulates	  region-­‐
specific	  glutamatergic	  neurotransmission.	  This	  model	  can	  be	  used	  to	  further	  dissect	  
the	  role	  of	  Slitrk5	   in	  molecular	  pathways	  underlying	  the	  pathogenesis	  of	  obsessive-­‐
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GENERAL	  DISCUSSION	  
The	   aim	   of	   this	   thesis	   was	   to	   study	   the	   cell	   biology	   of	   protein	   families	  
involved	  in	  CNS	  function	  and	  disease.	  We	  started	  by	  investigating	  a	  well-­‐established	  
protein	   family	   that	   is	   essential	   for	   nervous	   system	  development	   and	   function:	   the	  
neurotrophin	   family	   of	   ligands	   and	   receptors.	   Since	   the	   discovery	   of	   NGF	   as	   a	  
secreted	   molecule	   that	   could	   sustain	   survival	   of	   sensory	   neurons	   and	   induce	  
differentiation,	   research	   on	   this	   growth	   factor	   family	   soared	   [3,18].	   Subsequent	  
studies	   attempting	   to	   find	   a	   similar	   function	   for	   this	   factor	   in	   the	   CNS	   actually	  
revealed	  the	  scarceness	  of	  NGF	  in	  this	  region,	  therefore,	  the	  search	  for	  a	  molecular	  
counterpart	  of	  NGF	   in	   the	  brain	  began.	   Strenuous	  efforts	   led	   to	   the	  purification	  of	  
BDNF	  from	  the	  pig	  brain	  and,	  interestingly,	  this	  new	  neurotrophic	  factor	  was	  capable	  
of	   sustaining	  survival	  of	  neuronal	  populations	   irresponsive	   to	  NGF	   [11].	  Due	   to	   the	  
conserved	   sequences	   of	   these	   two	   proteins,	   the	   identification	   of	   two	   additional	  
members:	  NT3	  and	  NT4,	  was	  facilitated.	  The	  expression	  profile	  of	  neurotrophins	  and	  
their	  receptors	  is	  spatially	  and	  developmentally	  regulated.	  NGF	  and	  its	  receptor	  TrkA	  
are	  highly	  expressed	  in	  the	  PNS	  but	  their	  presence	  and	  function	  in	  the	  CNS	  is	  limited.	  
On	  the	  contrary,	  TrkB	  and	  its	  two	  ligands,	  BDNF	  and	  NT4,	  are	  widely	  expressed	  in	  the	  
CNS.	  TrkC	  and	  NT3	  are	  expressed	  in	  both	  systems	  [2,28,29].	  The	  hallmark	  mechanism	  
of	  neurotrophins	  actions	  involves	  the	  secretion	  of	  limiting	  amounts	  of	  neurotrophins	  
by	  target	  cells,	  which	  ensures	  survival	  of	  responsive	  cells	  that	  bind,	   internalize	  and,	  
allow	   retrograde	   trafficking	   of	   the	   ligand-­‐receptor	   complex	   through	   a	   signaling	  
endosome.	   Studies	   leading	   to	   the	   description	   of	   these	   mechanisms	   were	   mainly	  
performed	  with	  peripheral	  neurons	   [65].	   In	   sensory	  neurons,	   retrograde	   trafficking	  
of	  the	  signaling	  endosome	  triggers	  activation	  of	  signaling	  proteins	  along	  the	  axon	  as	  
well	  as	  in	  the	  soma.	  In	  addition,	  it	  also	  modulates	  transcription	  of	  critical	  genes	  [65].	  
Recent	  studies	  have	  suggested	  that,	  as	  opposed	  to	   the	  PNS,	  neurotrophins	  are	  not	  
essential	   for	   survival	   of	   neurons	   in	   the	   CNS,	   but	   rather	   play	   important	   roles	   for	  
neuronal	   differentiation,	   function	   and,	   plasticity	   [27].	   Another	   major	   difference	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between	  these	  two	  systems	  is	  the	  ligand	  heterogeneity	  and	  specificity.	  While	  in	  the	  
periphery	  NGF-­‐TrkA	  are	  the	  predominant	  axis,	  in	  the	  CNS	  system	  two	  ligands,	  BDNF	  
and	  NT4,	  have	  been	  described	   to	  bind	  with	   similar	  affinities	   to	   the	   same	   receptor,	  
seemingly	   fulfilling	   different	   functions.	   However,	   the	  mechanisms	  mediating	   these	  
differential	  effects	  are	  still	  unknown	  and	  were	  one	  of	  the	  focuses	  of	  this	  thesis.	  We	  
discovered	   that,	   even	   though	   BDNF	   and	   NT4	   can	   efficiently	   activate	   TrkB	   and	  
promote	  endocytosis,	   they	   sort	   the	   receptor	   to	  distinct	   endocytic	   fates.	   Prolonged	  
neurotrophin	  treatments	  revealed	  that	  BDNF	   leads	   to	   fast	  down-­‐regulation	  of	  TrkB	  
whereas	  NT4	  does	  not.	  Thus,	  NT4	  leads	  to	  longer	  lasting	  signaling	  mediated	  through	  
TrkB	  which,	  most	   likely	  explains	  previous	   studies	   suggesting	   that	  NT4	   is	   a	   stronger	  
trophic	   factor	   (supporting	   survival	   of	   more	   sensory	   neurons;	   promoting	   synaptic	  
function	   and	   maturation;	   reversing	   monocular	   deprivation,	   to	   name	   a	   few	  
[176,183,184]).	   Hence,	   even	   though	   NT4	   is	   expressed	   at	   much	   lower	   levels	   than	  
BDNF	   in	   the	   brain,	   it	   induces	   sustained	   and	   prolonged	   activation	   of	   TrkB	  whereas	  
BDNF	  triggers	  fast	  signaling	  [28].	  
Previous	  work	   analyzing	   the	   endocytic	   trafficking	   of	   Trk	   receptors	   focused	  
their	   attention	   on	   specific	   domains	   of	   the	   receptor	   and	   did	   not	   address	   ligand	  
variability.	  Analysis	  of	   the	  endocytic	   trafficking	  of	  TrkA	  and	  TrkB	  showed	  that	  upon	  
NGF	   treatment,	   TrkA	   predominantly	   recycles	   back	   to	   the	   surface	   (80%)	   whereas	  
BDNF-­‐activated	   TrkB	   is	   mostly	   sorted	   to	   the	   degradative	   pathway	   (only	   40%	  
recycles).	  However,	  only	  NGF	  and	  BDNF	  were	  analyzed	   in	   this	   study,	  NT3	  and	  NT4	  
were	   not	   investigated	   [63].	   A	   fraction	   of	   TrkA	   is	   also	   sorted	   to	   the	   degradative	  
pathway	  and	  binding	  to	  a	  specific	  E3	  ligase,	  Nedd4-­‐2,	  was	  found	  to	  be	  modulated	  by	  
phosphorylation	   of	   cytoplasmic	   tyrosines	   [62].	   The	   authors	   then	   sought	   to	  
investigate	   which	   region	   in	   TrkA	   would	   be	   responsible	   for	   the	   ligand-­‐dependent	  
recycling.	  A	  series	  of	  mutation	  analysis	  led	  to	  the	  identification	  of	  a	  stretch	  of	  amino	  
acids	  near	  the	  juxtamembrane	  region	  as	  being	  key	  for	  this	  process.	  This	  sequence	  is	  
different	  from	  TrkB	  and	  when	  transplanted	  into	  TrkB,	  it	  redirected	  this	  receptor	  into	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recycling	   versus	   degradative	   pathway	   [63].	   Subsequent	   studies	   showed	   that	   an	  
isoform	  of	  TrkB	  lacking	  the	  intracellular	  domain	  TrkB.T1,	  which	  is	  highly	  expressed	  in	  
the	   brain,	   predominantly	   recycles	   to	   the	   membrane	   upon	   BDNF	   treatment	   by	   a	  
default	  mechanism	  (NT4	  was	  not	   tested).	   In	  contrast,	   full	   length	  TrkB	  recycled	   in	  a	  
sequence-­‐directed	   manner	   and	   it	   was	   dependent	   on	   interaction	   with	   hepatocyte	  
growth	   factor-­‐regulated	   tyrosine	   kinase	   substrate	   (Hrs)	   [252].	   Hrs	   was	   initially	  
established	  as	  a	  key	  molecular	  player	  recognizing	  and	  sorting	  ubiquitinated	  cargo	  to	  
the	   lysosome,	   promoting	   its	   degradation	   [253].	   Subsequent	   studies	   revealed	   a	  
surprising	  role	  for	  Hrs	  in	  mediating	  sequence-­‐directed	  recycling	  of	  the	  β2	  adrenergic	  
receptor	   [254].	   This	   study	   was	   noteworthy	   since	   it	   introduced	   a	   new	   level	   of	  
regulation	   into	   the	   endocytic	   trafficking	   field	   previously	   disregarded.	   Prior	   studies,	  
mainly	   using	   EGFR	   and	   TfnR	   as	   models,	   coined	   the	   idea	   that	   sorting	   to	   the	   late	  
endosome	   and	   lysosome	   is	   sequence	   directed,	  whereas	   in	   the	   absence	   of	   specific	  
target	   information,	   receptors	   are	   transported	  with	   the	   bulk	   of	   the	  membrane	   and	  
recycle	   to	   the	   surface	   [54,255].	   The	   finding	   that	   TrkA	   recycling	   is	   sequence-­‐
dependent	   suggests	   that	   this	   receptor	   also	   recycles	   through	   a	   specific	   sorting	  
molecule.	  
In	   our	   studies	   we	   asked	   the	   question	   if	   sorting	   to	   different	   endocytic	  
compartments	   could	   be	   achieved	   by	   modulating	   the	   system	   from	   a	   ligand	  
perspective.	  Our	   finding	   that	  BDNF	   induces	   similar	  endocytosis	  of	  TrkB	   receptor	  as	  
NT4	   but	   sorts	   the	   receptor	   to	   a	   degradative	   pathway	   confirmed	   our	   hypothesis.	  
Considering	   the	   much	   slower	   degradation	   curve	   elicited	   by	   NT4	   we	   believe	   this	  
ligand	   is	   sorting	   the	   receptor	   to	   the	   recycling	  pathway,	   therefore,	   one	   could	   ask	   if	  
NT4	   recruits	   Hrs	   in	   a	   more	   efficient	   manner	   than	   BDNF.	   However,	   our	   mass	  
spectrometry	  analysis	  shows	  that	  both	  ligands	  recruit	  Hrs	  efficiently	  (Table	  1	  Chapter	  
2).	   An	   alternate	   hypothesis	   is	   that	   the	   acidic	   pH	   of	   the	   early	   endosome	   that	  
negatively	   modulates	   NT4-­‐mediated	   ubiquitination	  might	   sort	   the	   receptor	   to	   the	  
recycling	   pathway	   rather	   than	   to	   degradation	   (Figure	   1).	   Experiments	   testing	   NT3	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and	   NGF	   induced	   phosphorylation	   of	   TrkA	   at	   different	   pHs,	   showed	   that	   in	   acidic	  
environments	  mimicking	   the	  early	  endosome	  compartment	   (pH	  =	  6),	  NT3	  could	  no	  
longer	  maintain	   TrkA	  phosphorylation,	  whereas	  NGF	   could.	   This	   suggests	   that	  NT3	  
uncouples	   from	   TrkA	   in	   the	   early	   endosome	   leading	   to	   recycling	   of	   the	   receptor	  
[202].	   Indeed	   NT3	   is	   unable	   of	   eliciting	   retrograde	   trafficking	   of	   TrkA	   containing	  
signaling	  endosomes	  [30].	  These	  experiments	  were	  performed	  using	  concentrations	  
at	  which	  both	   ligands	  elicit	   similar	  TrkA	  phosphorylation	  at	  pH=7	   (NT3	  was	  10	   fold	  
more	   concentrated	   than	  NGF)	   [202].	   In	   the	   case	  of	  NT4	  and	  BDNF,	   the	   affinity	   for	  
TrkB	  is	  similar	  at	  pH=7,	  however,	  upon	  acidic	  wash	  it	  was	  shown	  that	  the	  dissociation	  
was	  much	   faster	   for	  NT4	   [168].	  Similar	  experiments	  with	  EGFR	   ligands	  have	  shown	  
that	   ligand-­‐receptor	   uncoupling	   in	   the	   early	   endosome	   promotes	   recycling	   as	  
opposed	  to	  degradation	   [57].	   In	   the	  case	  of	  BDNF	  and	  NT4,	  we	  think	  that	  a	  similar	  
mechanism	  is	  in	  place.	  We	  observed	  that	  BDNF	  induces	  more	  efficient	  ubiquitination	  
of	   TrkB	   than	   NT4	   at	   acidic	   pHs,	   whereas	   phosphorylation	   was	   similar.	   Thus	   these	  
neurotrophins	  probably	  sort	  the	  receptor	  to	  different	  microdomains	  within	  the	  early	  
endosome,	  with	  BDNF	  probably	  allowing	  a	   conformation	   that	   recruits	  a	   specific	  E3	  
ligase	  or	  other	  players	  involved	  in	  sorting	  ubiquitinated	  cargo	  to	  the	  lysosome,	  more	  
efficiently,	   thus	   leading	   to	   faster	   degradation	   (Figure	  2).	  NT4	  might	  promote	  more	  
efficiently	   recruitment	   of	   molecules	   mediating	   recycling	   or	   retrograde	   trafficking.	  
The	   identification	   of	   TrkB	   E3	   ligase	   will	   greatly	   contribute	   to	   elucidate	   these	  
pathways,	  as	  we	  will	  be	  able	  to	  directly	  assess	  the	  recruitment	  of	  this	  protein	  upon	  
BDNF	   or	   NT4	   treatment.	   Unfortunately,	   analysis	   of	   candidate	  molecules	   based	   on	  
our	  mass	  spectrometry	  analysis,	  did	  not	  lead	  to	  fruitful	  outcomes	  suggesting	  that	  the	  
binding	  of	  E3	  ligase	  to	  TrkB	  might	  be	  transient	  and	  labile.	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Figure	  1:	  Model	  of	  endocytic	   trafficking	  of	  TrkB	   receptor	  elicited	  by	  BDNF	  or	  NT4.	  
BDNF	   and	   NT4	   bind	   to	   TrkB	   receptor	   with	   the	   same	   affinity	   and	   induce	   equivalent	  
phosphorylation	  and	  endocytosis,	  in	  a	  clathrin-­‐dependent	  way.	  The	  acidic	  environment	  of	  the	  
early	  endosome	  reduces	  the	  affinity	  of	  NT4	  to	  TrkB	  and	  ligand-­‐receptor	  uncoupling	  promotes	  
recycling	   of	   the	   receptor.	  On	   the	   other	   hand,	   BDNF	   and	   TrkB	   remain	   bound.	   This	   leads	   to	  
different	  receptor	  conformations	  elicited	  by	  BDNF	  and	  NT4.	  Most	  likely,	  BDNF	  allows	  a	  more	  
efficient	   recruitment	   of	   a	   specific	   E3	   ligase,	   as	   supported	   by	   the	   higher	   ubiquination	   state	  
achieved	  with	  this	  ligand	  at	  acidic	  pHs,	  sorting	  the	  receptor	  to	  the	  degradative	  pathway.	  NT4	  
sorts	   the	   receptor	   either	   to	   a	   separate	   compartment	   that	   is	   not	   linked	   to	   the	   degradative	  
pathway	  and	  thus	  allows	  sustained	  signaling.	  	  
 
The	   studies	   depicted	   here	   clearly	   show	   the	   importance	   of	   regulating	   the	  
endocytic	  trafficking	  of	  Trk	  receptors,	  and	  how	  modulation	  of	  this	  system	  can	  lead	  to	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opposite	  biological	  outcomes.	   In	  addition	   to	   regulating	   the	  sorting	  of	   the	   receptor,	  
the	  neurotrophins	  themselves	  follow	  different	  sorting	  pathways.	  Neurotrophins	  are	  
initially	   synthetized	   as	   precursors	   or	   pro-­‐neurotrophins,	   which	   are	   cleaved	   to	  
produce	   the	   mature	   proteins	   [256].	   The	   pro-­‐domain	   of	   BDNF	   contains	   sequences	  
unique	   to	   this	   protein	   that	   allows	   binding	   of	   the	   sorting	  molecule	   sortilin.	   Sortilin	  
sorts	  BDNF	   to	   the	   regulated	   secretory	  pathway	  and,	   disruption	  of	   this	   binding	   site	  
reroutes	  BDNF	   to	   the	   constitutive	   secretory	  pathway,	  without	   affecting	  NT4	   [257].	  
NT4	  and	  BDNF	  protein	  sequences	  are	  most	  divergent	  in	  the	  pro-­‐domain.	  Therefore	  it	  
was	  not	  surprising	  that	  sortilin	  did	  not	  bind	  NT4.	  Identification	  of	  the	  molecules	  that	  
regulate	   NT4	   sorting	   will	   be	   critical	   do	   understand	   how	   this	   process	   can	   be	  
regulated.	  Humans	  carrying	  a	  common	  Val/Met	  genetic	  variant	  in	  the	  pro-­‐domain	  of	  
BDNF	   have	   high	   anxiety	   and	   hippocampal	   deficits	   [171,258,259].	   The	   finding	   that	  
BDNF	  with	  the	  Met	  allele	  bound	  less	  efficiently	  to	  sortilin	  and	  as	  a	  consequence	  was	  
sorted	   to	   the	   constitutive	   secreted	  pathway,	  as	  opposed	   to	   the	  activity-­‐dependent	  
secreted	  pathway,	  reinforces	  the	  importance	  of	  finding	  similar	  molecules	  regulating	  
the	  trafficking	  of	  NT4	  [257].	  
It	  is	  interesting	  to	  note	  that	  neurotrophins	  and	  their	  receptors	  do	  not	  exist	  in	  
Drosophila	   melanogaster	   or	   Caenorhabditis	   elegans,	   both	   invertebrate	   organisms	  
with	  a	  nervous	  system,	  strengthening	  the	  idea	  that	  these	  proteins	  are	  not	  absolutely	  
necessary	   for	   the	   development	   of	   neural	   circuits	   [18].	   Instead,	   they	   appeared	   in	  
evolution	  to	  allow	  complex	  systems	  to	  engage	  in	  higher	  order	  cognitive	  functions.	  In	  
this	  line	  of	  thought	  it	  is	  curious	  that	  NT4	  is	  the	  less	  conserved	  amongst	  species	  and,	  
homologues	   of	   this	   protein	   have	  not	   been	   found	   in	   neither	   fish	   nor	   birds,	   that	   do	  
express	  BDNF	  and	  NGF	  homologues,	   implying	   that	   it	   is	   the	   latest	   “addition”	   to	   the	  
neurotrophin	   family	   [260].	   According	   to	   phylogenetic	   analysis	   the	   four	   vertebrate	  
neurotrophins	  were	  generated	  by	  gene	  duplication	  of	   the	  NGF/NT3	  and	  BDNF/NT4	  
groups	   after	   the	   lamprey	   split	   from	   the	   common	   vertebrate	   lineage.	   Despite	   this	  
major	  duplication	  that	  was	  conserved	  up	  to	  mammals,	  other	  rounds	  of	  duplications	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occurred.	   For	   instance,	   fish	   express	   Neurotrophin	   6	   and	   7	   and	   the	   acquisition	   of	  
specific	   different	   functions	   correlates	   with	   the	   increase	   in	   complexity	   of	   the	  
vertebrate	   lineage	   [260,261].	   Considering	   these	   findings,	   NT4	   may	   have	   emerged	  
with	  the	  increase	  in	  complexity	  of	  the	  nervous	  systems	  across	  evolution,	  as	  an	  extra	  
member	   in	   the	   neurotrophin	   family	   was	   necessary	   to	   allow	   more	   variability	   and	  
sustain	   higher	   order	   complex	   behaviors.	   Besides	   expansion	   of	   existing	   families,	  
throughout	  evolution	  new	  gene	  families	  have	  arisen	  as	  a	  way	  to	  allow	  more	  complex	  
organisms	  to	  adapt.	  Studies	  investigating	  the	  evolution	  of	  mammalian	  genes	  infer	  a	  
gain	  of	  689	  new	  genes	  since	  the	  split	  from	  chimpanzees	  and	  a	  loss	  of	  only	  86	  genes	  
[262].	   Moreover,	   expansions	   in	   the	   human	   lineage	   for	   gene	   families	   with	   brain-­‐
specific	   functions	   had	   larger	   than	   expected	   changes,	   confirming	   the	   need	   for	   new	  
molecules	  in	  order	  for	  a	  more	  complex	  system	  to	  develop	  [262].	  
With	   a	   continued	   interest	   of	   understanding	   how	   protein	   families	   can	  
modulate	   key	   aspects	   of	   CNS	   development	   and	   function,	   we	   focused	   on	   another	  
protein	  family	  that	  also	  appeared	  late	  in	  evolution,	  are	  highly	  expressed	  in	  the	  brain	  
and	   most	   importantly,	   share	   structural	   similarities	   with	   Trks:	   the	   Slitrk	   family.	  
Orthologs	  of	  Slitrk	  genes	  are	  thought	  to	  be	  present	   in	   fish	  species	  but	  not	   in	   lower	  
organisms.	  However,	  a	   thorough	  examination	  of	  Slitrk	  orthologs	  across	  species	  has	  
not	  been	  done	  so	  far.	  Similar	  to	  Trks,	  Slitrks	  also	  contain	  extracellular	  LRR	  domains,	  
an	   NPXY	   domain	   in	   the	   cytoplasmic	   juxtamembrane	   region	   and	   putative	  
phosphorylated	   tyrosines	   at	   the	   C-­‐terminus.	  We	   selected	   the	   Slitrk5	  member	   as	   a	  
model	   to	   study	   the	   Slitrk	   family,	   considering	   that	   it	   contained	   all	   the	   domains	  
conserved	  in	  the	  family	  and	  its	  expression	  was	  one	  of	  the	  highest	  in	  the	  brain	  [118].	  
Interestingly	  we	  found	  that	  BDNF	  activated	  TrkB	  co-­‐localized	  with	  Slitrk5	   in	  cortical	  
neurons	   at	  higher	   ratios	   than	  with	  EEA1,	   suggesting	   that	   these	   two	  proteins	   share	  
the	   same	   endocytic	   compartment.	   Moreover,	   we	   found	   that	   over-­‐expression	   of	  
Slitrk5	  delayed	  BDNF-­‐induced	  degradation	  of	  TrkB	  in	  cortical	  neurons,	  discovering	  a	  
new	  potential	  mechanism	  to	  modulate	  TrkB	  endocytic	  trafficking.	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To	  further	  investigate	  the	  Slitrk5	  functions	  we	  developed	  a	  complete	  Slitrk5	  
KO	  mouse.	  Intriguingly,	  initial	  analysis	  of	  this	  mouse	  revealed	  some	  similarities	  with	  
the	   conditional	   BDNF	   null	   mouse	   such	   as	   striatal	   atrophy	   with	   reduced	   striatal	  
volume	   and	   a	   marked	   decrease	   in	   dendritic	   complexity	   of	   medium	   spiny	   neurons	  
[27],	   further	   strengthening	   a	   connection	   between	   these	   two	   protein	   families.	   A	  
crosstalk	   between	   Slitrks	   and	   neurotrophins	   was	   implied	   on	   the	   very	   first	   set	   of	  
studies	   that	   led	  to	  the	  discovery	  of	   the	  Slitrk	  protein	   family	   [8].	   In	   trying	  to	  dissect	  
the	  functions	  of	  Slitrks,	  these	  investigators	  used	  cultured	  PC12	  and	  Neuro2a	  cells	  (as	  
a	  model	   of	   neuronal	   cells),	   and	   quantified	   neurite	   number	   and	   length	   upon	   Slitrk	  
over-­‐expression.	  Interestingly,	  different	  results	  were	  obtained	  if	  the	  transfected	  cells	  
were	   treated	   with	   NGF	   or	   not.	   In	   the	   case	   of	   Slitrk1,	   it	   was	   observed	   that	   in	   the	  
absence	  of	  NGF,	  over-­‐expression	  of	  Slitrk1	  in	  PC12	  cells	  led	  to	  an	  increase	  of	  neurite	  
number	   per	   cell,	   as	   compared	  with	   cells	   transfected	  with	   control	   cDNA.	   However,	  
upon	  NGF	  treatment,	  which	  normally	  induces	  robust	  neurite	  sprouting	  in	  PC12	  cells,	  
the	  Slitrk1	  transfected	  cells	  had	  less	  neurites	  per	  cell	  on	  average,	  as	  compared	  with	  
the	  controls,	  suggesting	  that	  in	  this	  system	  Slitrk	  is	  antagonizing	  NGF	  signaling	  [8].	  
In	  comparison	  with	  our	  Slitrk5-­‐/-­‐	  mouse,	  the	  observations	  obtained	  with	  the	  
Slitrk6	  null	  mouse	  also	  advocates	  for	  a	  trophic	  function	  for	  Slitrks.	  Slitrk6	  expression	  
is	  tightly	  regulated	  and	  very	  high	  in	  the	  sensory	  epithelia	  of	  the	  inner	  ear.	  Analysis	  of	  
the	   development	   of	   the	   vestibular	   and	   auditory	   organs	   revealed	   pronounced	  
reduction	   in	   cochlear	   innervation,	   as	   well	   as	   loss	   of	   neurons	   in	   the	   spiral	   and	  
vestibular	   ganglia.	  Moreover,	   sensory	   epithelia	   from	   Slitrk6	   null	  mice	   had	   reduced	  
ability	   in	   promoting	   neurite	   outgrowth	   of	   spiral	   ganglion	   neurons.	   Interestingly,	   it	  
was	   found	   that	  expression	  of	  both	  BDNF	  and	  NT3	  mRNA,	  as	  well	  as	  TrkB	  and	  TrkC	  
protein,	  were	  decreased	  in	  the	  inner	  ear.	  Considering	  that	  these	  two	  neurotrophins	  
are	  key	   for	   the	  proper	  development	  of	   this	  organ,	   the	   results	  argue	   for	  a	  crosstalk	  
between	  the	  Slitrk	  and	  neurotrophin	  system	  [117].	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In	  addition,	   the	  Slitrks	  belong	  to	  a	   family	  of	  proteins	  that	  similarly	  to	  BDNF	  
are	  associated	  with	  psychiatric	  disorders	  in	  humans	  [9].	  Variants	  in	  Slitrk1	  gene	  have	  
been	  associated	  with	  Tourrete’s	  syndrome,	  trichotillomania	  and	  OCD.	  Re-­‐sequencing	  
of	   X-­‐chromosome	   genes	   found	   two	   missense	   variants	   in	   Slitrk2	   in	   patients	   with	  
schizophrenia	   and	   in	   their	   affected	   siblings	   [9].	  Our	   own	   studies	   describe	   how	   the	  
lack	   of	   Slitrk5	   expression	   in	   the	   mouse	   leads	   to	   OCD-­‐like	   phenotypes	   that	   were	  
ameliorated	  with	  selective	  serotonin	  re-­‐uptake	  inhibitors,	  the	  major	  pharmacological	  
treatment	   for	   human	   patients.	   Therefore	   the	   crosstalk	   between	   the	   Slitrk	   and	   the	  
neurotrophin	  families	  might	  go	  way	  beyond	  what	  our	  current	  knowledge	  allow	  us	  to	  
predict.	  
Based	  on	  the	  findings	  described	  in	  detail	  on	  chapter	  3,	  we	  found	  that	  Slitrk5	  
modulates	   brain	   morphology,	   interacts	   with	   TrkB	   and	   modulates	   its	   endocytic	  
trafficking;	   induces	   synapse	   formation	   in	   hippocampal	   neurons	   and	   is	   key	   for	   high	  
order	  cognitive	  functions	   in	  the	  sense	  that	   its	  absence	   leads	  to	  OCD-­‐like	  symptoms	  
and	  impaired	  spatial	  reference	  memory	  in	  the	  mouse.	  Figure	  2	  depicts	  three	  possible	  
scenarios	   that	   may	   explain	   the	   molecular	   functions	   of	   the	   Slitrk5	   protein	   as	   a	  
synaptogenic	   protein	   and	   TrkB	   partner.	   One	   hypothesis	   is	   that	   in	   a	   similar	  way	   to	  
other	  LRR	  containing	  proteins	  (see	  Table	  1	  Chapter	  1),	  Slitrk5	  acts	  mainly	  as	  a	  post-­‐
synaptic	   protein	   that	   induce	   synapse	   formation	   through	   interactions	   with	   a	   pre-­‐
synaptic	  protein	  of	  still	  unknown	  identity.	  In	  addition,	  the	  results	  obtained	  with	  the	  
Slitrk5-­‐/-­‐	  mouse,	  as	  well	  as	  previous	  data	  on	  Slitrk1	  and	  Slitrk6,	  suggest	  a	  trophic	  role	  
for	  this	  protein.	  In	  this	  scenario	  Slitrk5	  could	  act	  as	  a	  transmembrane	  receptor	  itself	  
that	   would	   be	   activated	   by	   a	   soluble	   ligand,	   leading	   to	   activation	   of	   downstream	  
signaling	  cascades	  that	  could	  overlap	  with	  the	  neurotrophin	  system.	  Alternatively	  or	  
in	   addition,	   Slitrk5	   can	   directly	   interact	   with	   Trk	   receptors	   and	   modulate	   Trk	  
mediated	  signaling.	  Given	   the	  similarities	  of	   the	  Slitrk5	  and	  BDNF	  null	  mice,	  where	  
both	  show	  morphological	  defects	  in	  the	  striatum,	  it	  would	  be	  interesting	  to	  address	  
if	   the	  neurotrophic	   system	   is	   compromised	   in	   the	  Slitrk5	  null	  mice.	   Perhaps	  Slitrk5	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acts	  as	  a	  positive	  modulator	  of	  TrkB	  function	  in	  the	  absence	  of	  which,	  this	  receptor	  
does	  not	  signal	  efficiently.	  P75,	  another	  neurotrophin	  receptor,	  has	  been	  shown	  to	  
interact	  with	  Trks	  and	  positively	  modulate	  their	  selectivity	  to	  BDNF	  and	  NGF.	  During	  
development	   of	   sympathetic	   neurons,	   differential	   expression	   of	   p75	   and	   TrkA	  
promotes	   cell	   competition.	   Selective	   cell	   survival	   is	   dependent	   on	   the	   regulated	  
expression	  of	  these	  receptors	  and	  their	  binding	  to	  different	  neurotrophins	  [263].	   In	  
the	  CNS	  however,	  p75	   is	  barely	  detectable	   in	  normal	  conditions,	   thus	   leading	  us	  to	  
speculate	  that,	  in	  the	  brain,	  Slitrk5	  may	  play	  a	  similar	  role	  as	  p75.	  Tight	  regulation	  of	  
RTK	   signaling	   is	   critical	   for	   the	   overall	   cell	   function;	   moreover,	   besides	   BDNF	   and	  
NT4,	  also	  NT3	   is	  expressed	   in	   the	  brain.	  Therefore,	   the	   idea	   that	  an	  analog	  of	  p75,	  
such	   as	   Slitrk5,	   would	   modulate	   the	   selectivity	   of	   TrkB	   for	   these	   neurotrophins,	  
adding	  another	  level	  of	  flexibility	  and	  regulation	  is	  interesting.	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Figure	  2:	  Model	  of	  Slitrk5	  function.	  Three	  hypotheses	  regarding	  the	  mechanisms	  of	  
Slitrk5	   action	   are	   displayed:	   synapse	   formation	   hypothesis;	   soluble	   ligand	   hypothesis	   and	  
transmembrane	   interactor	   hypothesis.	   Synapse	   formation	   hypothesis:	   Slitrk5	   can	   induce	  
synapse	   formation	   when	   expressed	   in	   COS7	   cells	   cultured	   with	   hippocampal	   neurons,	  
possibly	  by	  interacting	  with	  a	  pre-­‐synaptic	  partner	  of	  still	  unknown	  identity.	  Discovery	  of	  such	  
a	   protein	  would	   allow	   to	   a	   complete	   understanding	   of	   Slitrk5	   function.	   As	   an	   example,	   an	  
LRR-­‐containing	   protein	   with	   an	   established	   function	   role	   as	   a	   synaptogenic	   molecule:	  
LRRTM2,	   is	   shown.	   LRRTM2	   localizes	   to	   the	   post-­‐synaptic	   cell	   and	   binds	   both	   α	   and	   β	  
Neurexins	   (NRXN)	   through	   its	   LRR	   domains	   on	   the	   pre-­‐synaptic	   site.Soluble	   ligand	  
hypothesis:,	   Given	   the	   structural	   similarities	   with	   a	   transmembrane	   receptor,	   the	  
extracellular	  LRR	  domains	  and	  putative	  signaling	  motifs	   in	  the	  cytoplasmic	  domain,	   it	  would	  
be	   interesting	   to	   find	   if	   Slitrk5,	   in	  a	   similar	  way	  as	  Trk	   receptors,	   is	  activated	  by	  a	   secreted	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ligand.	   Binding	   of	   soluble	   ligand	   to	   Slitrk5	   would	   drive	   endocytosis	   and	   activation	   of	  
downstream	  signaling	  cascades.	  Slitrk2,	  3	  and	  5	  contain	  an	  NPXY	  motif	  at	  the	  juxtamembrane	  
region.	  Phosphorylated	  NPXY	  serves	  as	  docking	  site	  for	  phosphotyrosine	  bindig	  proteins	  such	  
as	   Shc	   that	   links	   activated	   receptors	   to	   intracellular	   signaling	   pathways.	   Transmembrane	  
interactor	  hypothesis:	  The	  phenotype	  of	  the	  Slitrk5-­‐/-­‐	  as	  well	  as	  previous	  data	  on	  Slitrk1	  and	  
Slitrk6,	  all	  converge	  to	  a	  hypothetical	  trophic	  role	  for	  the	  Slitrk	  family.	  One	  possible	  scenario	  
is	  that	  Trks	  and	  Slitrks	  act	  synergistically	  to	  achieve	  efficient	  downstream	  signaling	  in	  order	  to	  
maintain	  basic	  neuronal	  functions.	  	  
TM,	   transmembrane	   domain;	   Ig,	   immunoglobulin-­‐like	   domain;	   LRR,	   leucine	   rich	  
repeat;	  EGF,	  epidermal	  growth	  factor-­‐like	  domain;	  LamNT,	  laminin	  N-­‐terminal	  domain;	  LamG,	  
laminin	  G	  domain.	  
	  
In	   addition,	   we	   show	   that	   by	   manipulating	   Slitrk5	   levels,	   the	   surface	  
expression	   of	   GluA2	   subunit	   of	   AMPARs	  was	   drastically	   changed.	   The	   finding	   that	  
Slitrk5	   can	   modulate	   trafficking	   of	   probably	   the	   two	   most	   important	   plasticity	  
protein	   families	   in	   the	   brain	   (neurotrophin	   family	   and	   glutamate	   receptor	   family),	  
mediating	  both	  development	  and	  also	  higher	  order	  cognitive	  functions,	  strengthens	  
the	   importance	   of	   clearly	   delineating	   the	   molecular	   mechanisms	   of	   this	   protein	  
family	   [19,264].	   It	   is	   still	   unclear	   however	   how	   Slitrk5	   modulates	   both	   GluA2	   and	  
TrkB	  trafficking	  (figure	  3).	  Upon	  BDNF	  activation,	  TrkB	  is	  internalized	  to	  an	  endocytic	  
compartment	  where	   it	   co-­‐localizes	  and	   interacts	  with	  Slitrk5.	  This	   interaction	   leads	  
to	   differential	   TrkB	   trafficking	   reflected	   in	   slower	   degradation	   and	   inefficient	  
signaling.	  Considering	  that	  66%	  of	  endosomes	  containing	  TrkB	  co-­‐localize	  with	  Slitrk5	  
whereas	  only	  39%	  are	  also	  immunopositive	  to	  EEA1,	  its	  plausible	  to	  think	  that	  Slitrk5	  
redirects	   TrkB	   to	   an	   alternate	   endocytic	   compartment,	   less	   efficiently	   linked	   with	  
ubiquitin-­‐binding	  proteins	   (that	  promote	  degradation)	   as	  well	   as	   signaling	  proteins	  
(as	  observed	  by	  the	  reduces	  Akt	  and	  MAPK	  activation)	  (Figure	  3).	  On	  the	  other	  hand,	  
Slitrk5	  can	  reduce	  surface	  levels	  of	  GluA2.	  Our	  studies	  show	  that	  Slitrk5	  can	  interact	  
with	  Pick1,	  which	   is	  a	  key	   regulator	  of	  GluA2	   trafficking.	   Interestingly	  we	  observed	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that	  Pick1	  binds	  Slitrk5	  and	  GluA2	  through	  the	  same	  domain,	  suggesting	  that	  these	  
interactions	   may	   be	   mutually	   exclusive.	   Thus,	   Slitrk5	   may	   promote	   intracellular	  
stabilization	  of	  GluA2	  receptors	  by	  favoring	  GluA2	  interaction	  with	  ABP/GRIP	  versus	  
Pick1.	  We	  also	  observed	   that	   Slitrk5	   can	   interact	  with	  GluA2	   in	  heterologous	   cells,	  
hence,	  it	  could	  regulate	  the	  trafficking	  of	  this	  protein	  directly.	  Our	  results	  show	  that	  
Slitrk5	   does	   not	   alter	   AMPAR	   endocytosis;	   therefore,	   two	   additional	   pathways	  
remain:	   recycling	   and	   degradation.	   Slitrk5	   might	   prevent	   GluA2	   trafficking	   to	   the	  
recycling	   compartment	   or	   promote	   more	   efficient	   degradation	   through	   the	  




Figure	   3:	  Model	   of	   Slitrk5	   as	   a	  modulator	   of	   AMPARs	   and	   TrkB	   trafficking.	   TrkB	  
trafficking:	   upon	   BDNF	   stimulation	   TrkB	   is	   internalized	   to	   an	   intracellular	   endocytic	  
compartment	   that	   also	   contains	   Slitrk5.	   Interaction	   with	   Slitrk5	   within	   this	   compartment	  
alters	  TrkB	  trafficking	  by	  reducing	  receptor	  degradation,	  perhaps	  by	  stabilizing	  TrkB	  receptor.	  
The	  reduced	  BDNF-­‐induced	  Akt	  and	  MAPK	  signaling	  upon	  Slitrk5	  overexpression	  suggest	  that	  
this	   compartment	   is	   not	   efficiently	   linked	   to	   signaling	   proteins.	   AMPARs	   trafficking:	   Slitrk5	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overexpression	  leads	  to	  a	  decrease	  in	  surface	  GluA2,	  an	  effect	  that	  is	  potentially	  mediated	  by	  
Pick1.	   Slitrk5	   can	   interact	   with	   Pick1,	   which	   is	   known	   to	   induce	   GluA2	   cycling	   both	   from	  
surface	   as	   well	   as	   from	   intracellular	   membranes.	   Slitrk5	   may	   promote	   intracellular	  
stabilization	   of	  GluA2	   receptors	   by	   favoring	  GluA2	   interaction	  with	   ABP/GRIP	   versus	   Pick1.	  
Binding	   of	   Slitrk5	   to	   Pick1	   may	   prevent	   Pick1	   interaction	   with	   GluA2	   and	   thus	   favoring	  
receptor	  anchorage	  through	  scaffolding	  molecules	  (ABP/GRIP).	  On	  the	  other	  hand,	  Slitrk5	  can	  
interact	  with	  GluA2	   (in	   heterologous	   cells)	   and	   thus	   regulate	   the	   trafficking	   of	   this	   protein	  
directly.	   Slitrk5	   might	   prevent	   recycling	   of	   GluA2	   by	   impairing	   trafficking	   to	   the	   recycling	  
compartment	  or	  promote	  its	  degradation	  by	  enhancing	  sorting	  to	  the	  lysosome.	  
	  
TrkB	  and	  GluA2	  have	  not	  been	  found	  in	  the	  same	  compartments,	  therefore,	  
the	   differential	   expression	   of	   Slitrk5	   and	   the	   interaction	   with	   different	   partners	  
might	  regulate	  these	  proteins	  differently.	  The	  majority	  of	  the	  experiments	  described	  
in	   this	   thesis	   analyzing	   the	   crosstalk	   between	   TrkB	   and	   Slitrk5	   were	   done	   using	  
cultures	  DIV5-­‐6	  in	  vitro,	  whereas	  in	  the	  studies	  performed	  with	  Slitrk5	  and	  AMPARs	  
more	  mature	  cultures	  (DIV10-­‐15)	  were	  employed.	  In	  fact	  it	  was	  noted	  that,	  the	  more	  
mature	   the	  cultures,	   the	   larger	   impact	  Slitrk5	  expression	  had	   in	  decreasing	   surface	  
AMPARs.	   Perhaps	   the	   interaction	   of	   Slitrk5	   with	   TrkB	   and	   GluA2	   are	   temporally	  
regulated	  so	  that	  early	   in	  development	  Slitrk5	  would	  associate	  more	  with	  TrkB	  and	  
later,	  when	  synapses	  are	  being	  maintained	  and	  modulated	  by	  environmental	   cues,	  
Slitrk5	   would	   have	   a	   more	   prominent	   role	   in	   the	   glutamate	   receptor	   system.	  
Supporting	  this	  view	  is	  the	  analysis	  of	  the	  developmental	  expression	  of	  Slitrk5,	  TrkB,	  
GluA1	   and	   GluA2	   in	   the	   hippocampus	   (Figure	   10	   Chapter	   3).	   Slitrk5	   is	   highly	  
expressed	   at	   embryonic	   day	   17	   (E17),	   peaking	   post-­‐natally	   at	   P15.	   TrkB	   is	   also	  
expressed	  both	  pre	  and	  post-­‐natal	  and	  in	  parallel	  with	  Slitrk5	  it	  peaks	  at	  P15.	  GluA2	  
expression	   at	   E17	   was	   barely	   detectable,	   but	   interestingly,	   if	   followed	   the	   same	  
pattern	   as	   Slitrk5	   and	   TrkB,	   peaking	   at	   P15	   and	   stabilizing	   throughout	   adulthood.	  
Future	  studies	  will	  be	  necessary	  to	  further	  understand	  the	  mechanisms	  employed	  by	  
Slitrk5	  in	  regulating	  the	  trafficking	  of	  AMPAR	  and	  TrkB.	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The	   Slitrk	   family	   has	   six	   members	   and	   so	   far,	   few	   studies	   have	   been	  
performed	   on	   3	   members	   of	   this	   family.	   Little	   is	   known	   about	   the	   functions	   of	  
Slitrk2,	   Slitrk3	   and	   Slitrk4.	   Future	   studies	   addressing	   other	   members	   of	   the	   Slitrk	  
family	  will	  elucidate	  us	  regarding	  the	  main	  function	  these	  proteins	  are	  playing	  in	  the	  
brain.	  The	   fact	   that	   these	  genes	  show	  high	  conservancy	  across	  species	  strengthens	  
the	  idea	  that	  they	  are	  critical	  for	  proper	  overall	  function	  of	  the	  CNS.	  However,	  their	  
major	   function	   is	   still	   unknown.	   It	   is	   plausible	   to	   speculate	   that	   similarly	   to	   other	  
protein	   families	   such	   as	   the	   Neuroligin	   family	   and	   the	   LRRTM	   family,	   some	  
redundancy	  exists.	  Neuroligin	  proteins	  were	  the	  first	  shown	  to	  instruct	  pre-­‐synapse	  
formation	   when	   expressed	   at	   the	   surface	   of	   non-­‐neuronal	   cells,	   in	   contact	   with	  
neurons	  [233].	  The	  finding	  that	  the	  pre-­‐synaptic	  partner	  of	  neuroligin,	  the	  neurexins,	  
could	   instruct	   post-­‐synapse	   formation	   in	   neurons,	   complemented	   this	   set	   of	   cell	  
adhesion-­‐like	  molecules	  that	  bridge	  the	  two	  synaptic	  sites	  [265].	  Subsequent	  studies	  
revealed	  the	  prominent	  role	  neurexin-­‐neuroligin	  proteins	  play	  as	  central	  organizing	  
molecules	  for	  both	  inhibitory	  and	  excitatory	  synapse	  formation.	  However,	  despite	  all	  
the	   loss	   of	   function	   and	   gain	   of	   function	   studies	   illustrating	   a	   dramatic	   effect	   in	  
synapse	   formation,	   the	   in	   vivo	  validation	  of	   the	   relevance	  of	   this	  proteins	  was	   still	  
lacking	  mainly	  due	  to	  functional	  redundancy	  of	  this	  system	  [266].	  The	  generation	  of	  
a	  triple	  neuroligin	  knockout	  was	  necessary	  to	  obtain	  a	  clearly	  noticeable	  phenotype	  
[267].	   The	   fact	   that	   a	   single	   Slitrk	   gene	   knockout	   had	   such	   dramatic	   effects	   in	   the	  
morphology	   of	   CNS	   and	   behavior,	   suggests	   that	   in	   the	   Slitrk	   family,	   functional	  
redundancy	   is	   reduced.	   However,	   it	   will	   be	   very	   interesting	   to	   analyze	   a	  
Slitrk1/Slitrk5	   knockout,	   for	   example,	   and	   assess	   if	   the	   psychiatric	   phenotype	   is	  
exacerbated.	  Moreover,	  while	  our	  studies	   indicate	   that	  overexpression	  of	  Slitrk5	   in	  
COS7	   cells	   is	   sufficient	   for	   synapse	   formation,	   loss	   of	   function	   experiments	  will	   be	  
needed	  to	  address	  if	  it	  is	  absolutely	  necessary.	  Moreover,	  it	  is	  still	  unknown	  if	  Slitrk5	  
selectively	  induces	  excitatory	  synapses	  or	  if	  it	  could	  also	  be	  implicated	  in	  inhibitory,	  
GABAergic	  synapses.	  
Chapter	  4	  –	  General	  Discussion	  
	   168	  
Our	   studies	   point	   to	   a	   multitalented	   transmembrane	   protein	   capable	   of	  
interacting	  with	  the	  neurotrophin	  system	  through	  TrkB,	  inducing	  synapse	  formation	  
and	   modulating	   AMPAR	   trafficking	   (Figure	   2	   and	   Figure	   3).	   Clearly	   the	   finding	   of	  
more	  Slitrk5	  binding	  partners	  will	   contribute	   to	  our	  understanding	  of	   this	  protein’s	  
function.	  Moreover,	  it	  will	  be	  interesting	  to	  address	  if	  Slitrk5	  acts	  as	  a	  receptor	  to	  an	  
unidentified	   soluble	   ligand	  mediating	   specific	   signaling	   cascades	   affecting	  both	   the	  
glutamatergic	  and	  the	  neurotrophic	  system.	  
Thus,	   the	   findings	   described	   in	   this	   thesis	   highlight	   the	   importance	   of	  
meticulously	   investigating	   the	   molecular	   mechanisms	   underlying	   protein	   families	  
involved	   in	   CNS	   function	   and	   development.	   Considering	   the	   complexity	   of	   this	  
system,	   changes	   that	   at	   first	   sight	  might	   seem	   to	   induce	   a	   small	   effect,	   can	   have	  
significant	   consequences	   when	   integrated	   into	   this	   broader	   and	   elaborated	  
arrangement.	  Small	  changes	  in	  protein	  traffic	  can	  have	  extremely	  different	  outcomes	  
at	  the	  cellular	  level,	  not	  to	  mention	  at	  the	  scale	  of	  a	  whole	  system.	  The	  experiments	  
performed	   here,	   analyze	   discrete	   events	   occurring	   within	   a	   limited	   time-­‐scale,	  
whereas	   protein	   trafficking	   occurs	   continuously	   and	   is	   crucial	   for	   the	   cell’s	  
maintenance.	  Hence,	  even	  if	  a	  small	  fraction	  of	  a	  given	  set	  of	  proteins	  is	  mis-­‐sorted	  
in	   each	   round,	   these	   abnormalities	   accumulate	   and	   in	   the	   long	   range	   significantly	  
affect	   the	   cell’s	   function.	   In	   addition,	   this	   study	   strengthens	   the	   notion	   that	   a	  
complete	  understanding	  of	  the	  “brain’s	  proteome”	  is	  crucial	  to	  the	  identification	  and	  
development	  of	  new	  molecular	  targets	  in	  disease.	  Further	  studies	  with	  patients	  with	  
OCD	  or	  OCD-­‐spectrum	  disorders	  will	  possibly	  elucidate	  the	  exact	  role	  Slitrk5	  plays	  for	  
these	  disorders.	  With	  the	  advances	  of	  genetics	  and	  medicine	  we	  are	  entering	  an	  era	  
of	   “personalized	   medicine”	   where	   treatments	   are	   starting	   to	   be	   tailored	   to	   the	  
individual’s	  specific	  traits.	  Psychiatric	  disorders	  are	  multi-­‐symptomatic,	  complex	  and	  
can	   either	   be	   idiopathic	   or	   familial.	   Therefore,	   multiple	   combinations	   of	   genetic	  
variants,	   completely	   different	   sets	   of	   locus,	   or	   even	   environmental	   cues,	  might	   be	  
associated	   with	   the	   origin	   of	   a	   similar	   condition.	   As	   genetic	   research	   generates	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enormous	  amounts	  of	  new	  information,	  the	  basic	  cell	  biology	  studies	  will	  provide	  a	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